MUTATION_REMARK	MUTATION_SELECTIVITY	GENOMIC_MUTATION_ID	FUSION_ID	MUTATION_AA_SYNTAX	DISEASE	ACTIONABILITY_RANK	ACTIONABILITY_RANK_DESCRIPTION	DEVELOPMENT_STATUS	DRUG_COMBINATION	TESTING_REQUIRED	TRIAL_STATUS	TRIAL_ID	TRIAL_NAME	COMPLETION_STATUS	TRIAL_PRIMARY_COMPLETION_DATE	PATIENT_PRESCREENING	RESULTS_AVAILABILITY	PROGRESSION_REMARK	SOURCE_TYPE	SOURCE	TREATMENT_HISTORY	PATIENT_AGE	PRIMARY_OUTCOME_MEASURE	NUMBER_OF_PATIENTS	TREATED_NUMBER	CONTROL_NUMBER	CONTROL_TREATMENT	ORR_TREAT	ORR_CON	ORR_CI	ORR_PVAL	DOR_TREAT	DOR_CON	DOR_CI	DOR_PVAL	PFS_TREAT	PFS_CON	PFS_HR	PFS_CI	PFS_PVAL	TTP_TREAT	TTP_CON	TTP_HR	TTP_CI	TTP_PVAL	DCR_TREAT	DCR_CON	DCR_PVAL	OS_TREAT	OS_CON	OS_HR	OS_CI	OS_PVAL	OBJ_RR_TREAT	CR_COUNT	PR_COUNT	SD_COUNT	RFS_TREAT	RFS_CON	RFS_HR	RFS_CI	RFS_PVAL	BLOOD_RESPONSE	RESPONSE_VALUE	TIMEPOINT	TRIAL_OUTCOME	CLASSIFICATION_ID	LAST_UPDATED
(EGFR_Exon19del or EGFR_L858R or EGFR_T790M) and (CTNNB1_unspecified or PIK3CA_unspecified or RB1_unspecified or TP53_unspecified)	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Anlotinib,Sunvozertinib		Recruiting	NCT06348927	WUKONG-32	ECD	2025Oct31	Yes	No		4	NCT06348927	Untreated 		Progression free survival	52	52																																									No	COSO29915674	2024Oct17
(EGFR_Exon19del or EGFR_L858R or EGFR_T790M) and (CTNNB1_unspecified or PIK3CA_unspecified or RB1_unspecified or TP53_unspecified)	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Anlotinib,Sunvozertinib		Recruiting	NCT06355609	WUKONG-32-RW	ECD	2025Dec30	Yes	No		4	NCT06355609	Untreated 		Progression free survival	100	100																																									No	COSO29915674	2024Oct17
(EGFR_Exon19del or EGFR_L858R or EGFR_T790M) and MET_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Osimertinib,Savolitinib		Recruiting	NCT05261399	SAFFRON	ECD	2025Jun26	Yes	No		4	NCT05261399	Previously-treated		Progression free survival	324			Pemetrexed,Platinum-based chemotherapy																																							No	COSO29915674	2024Jul11
(EGFR_Exon19del or EGFR_L858R) and CD274_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Alflutinib		Unknown	NCT05255406		ECD	2023Dec31	Yes	No		4	NCT05255406			Progression free survival	62	62																																									No	COSO29915674	2025Jan08
(EGFR_Exon19del or EGFR_L858R) and CD274_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Bevacizumab,Cisplatin,Pemetrexed,Tislelizumab		Unknown	NCT05394233		ECD	2023Dec01	Expression confirmed	No		4	NCT05394233			Progression free survival	20	20																																									No	COSO29915674	2024Jul11
(EGFR_Exon19del or EGFR_L858R) and CD274_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Pemetrexed,Toripalimab		Completed	NCT03513666	PD-L1 +/-	PCD	2022Aug12	Expressed/not	Yes		1	34650034	Previously-treated		Overall Response Rate	40	21	19		61.9	36.8		0.204					7.6	5.8			0.424										21			0.052			20	15									No	COSO29915674	2025Jan08
(EGFR_Exon19del or EGFR_L858R) and MET_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Erlotinib,Telisotuzumab vedotin		Active, not recruiting	NCT02099058	Arm A	ECD	2024Nov16	Expression confirmed	Yes		1	36288547			Maximum tolerated dose/toxicity	28	28			32.1		15.9-52.4						5.9			2.8-							85.7									1	8	15									No	COSO29915674	2025Jan08
(EGFR_Exon19del or EGFR_L858R) and MET_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Capmatinib,Erlotinib		Terminated	NCT02468661		PCD	2017Nov15	Yes	Yes	Slow accrual	4	NCT02468661	Previously-treated		Maximum tolerated dose/toxicity	23	23		Cisplatin,Pemetrexed																																							No	COSO29915674	2022May03
(EGFR_Exon19del or EGFR_L858R) and MET_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Capmatinib,Nazartinib		Terminated	NCT02335944	Group 1 + Ph1b	PCD	2020Nov10	Comparison with wt	Yes		2	10.1016/j.annonc.2020.08.1598	Previously-treated		Overall Response Rate	66	23	43		43.5	27.9			6.3	9.3			7.7	5.4												18.8	17.2																No	COSO29915674	2025Jan08
(EGFR_Exon19del or EGFR_L858R) and TP53_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Almonertinib,Anlotinib		Not yet recruiting	NCT05778149		ECD	2025Mar31	Yes	No		4	NCT05778149	Untreated		Progression free survival	47	47																																									No	COSO29915674	2024Sep02
(EGFR_Exon19del or EGFR_L858R) and TP53_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Carboplatin,Osimertinib,Pemetrexed		Unknown	NCT04695925	TOP	ECD	2022Sep30	Yes	No		4	NCT04695925			Progression free survival	291			Osimertinib																																							No	COSO29915674	2024Jan04
(EGFR_Exon19del or EGFR_L858R) and TP53_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 4	Osimertinib		Recruiting	NCT05785208	TEMPLE-2	ECD	2024Feb28	Comparison with wt	No		4	NCT05785208			Progression free survival	122																																										No	COSO29915674	2023Jul12
(ESR1_unspecified or PGR_unspecified or (ESR1_unspecified and PGR_unspecified) (HR+)) and AKT_unspecified or EGFR_unspecified or ERBB2_unspecified or IGFR1_unspecified or PTEN_unspecified	Set				breast / carcinoma / hormone receptor-positive carcinoma	3	In trials	Phase 2	Goserelin,Letrozole,Linsitinib		Withdrawn	NCT01013506		PCD	2009Dec01	No	Yes	No patients recruited	4	NCT01013506			Time to progression, time to recurrence	0	0		Erlotinib,Goserelin,Letrozole,Linsitinib																																							No	COSO283920618	2024Sep13
AKT1_unspecified or BCL2_unspecified or EGFR_unspecified or MTOR_unspecified or HRAS_unspecified or KRAS_unspecified or NRAS_unspecified or TP53_unspecified	Set				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	Docetaxel,Everolimus		Terminated	NCT01313390		PCD	2011Apr01	No	Yes	Slow accrual	4	NCT01313390				4	4																																									No	COSO29324830	2022Oct28
AKT1_unspecified or BRAF_unspecified or EGFR_unspecified or ERBB2_unspecified or FGFR1_unspecified or KIT_unspecified or KRAS_unspecified or LKB1_unspecified or MET_unspecified or NF1_unspecified or NRAS_unspecified or PIK3CA_unspecified or PTEN_unspecified or RET_unspecified	Set				NS / other / neoplasm	3	In trials	Phase 2	Selumetinib,Vistusertib		Unknown	NCT02583542	TORCMEK	ECD	2020Mar01	No	Yes		2	10.1200/JCO.2017.35.15_suppl.2548			Disease control rate, Clinical benefit rate	23	23																														0	0	7									No	COSO31314888	2025Jan08
AKT1_unspecified or CSF1R_unspecified or EGFR_unspecified or FHIT_unspecified or MYC_unspecified or PDGFA_unspecified or PDGFRA_unspecifed or PDGFRB_unspecified or PIK3CA_unspecified or PTEN_unspecified or VHL_unspecified	Set				kidney / carcinoma / clear cell renal cell carcinoma	3	In trials	Phase 2	Dovitinib		Unknown	NCT01791387	DILIGENCE-1	ECD	2015Jun01	No	No		4	NCT01791387			Progression free survival	30	30																																									No	COSO29645555	2023Jan23
AKT1_unspecified or EGFR_unspecified or KRAS_unspecified or MTOR_unspecified or TP53_unspecified	Set				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	Docetaxel,Everolimus		Terminated	NCT01313390		PCD	2011Apr01	Yes	Yes	Slow accrual	4	NCT01313390			Response rate	4	4																																									No	COSO29324830	2023Jan23
ALK_fusions or BRAF_V600E or EGFR _Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I or NTRK1_fusions or NTRK2_fusions or NTRK3_fusions  or MET_Exon14del or RET_fusions or ROS1_fusions	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	SKB264		Recruiting	NCT06074588	MK-2870-004	ECD	2027May10	Yes	No		4	NCT06074588	Previously-treated		OS, PFS	556			Docetaxel or Pemetrexed																																							No	COSO29915674	2024Jan04
ALK_fusions or EGFR_unspecified	Set				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Carboplatin,Lenvatinib,Pembrolizumab,Pemetrexed		Unknown	NCT04989322		ECD	2024Aug01	Yes	Yes		2	10.1200/JCO.2024.42.23_suppl.198			Overall Response Rate	15	15			40								11.9																														No	COSO29915674	2025Jan08
ALK_fusions or EGFR_unspecified	Set				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Atezolizumab,Bevacizumab,Carboplatin,Paclitaxel		Active, not recruiting	NCT03991403		PCD	2023Mar11	Yes	Yes		1	37861993			Progression free survival	228	154	74	Chemotherapy	69.5	41.9		<0.001					8.48	5.62	.62	0.45-0.86	0.004									20.63	20.27	1.01	0.69-1.46	0.975													Yes	COSO29915674	2025Jan08
ALK_fusions or EGFR_unspecified	Set				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Atezolizumab,Bevacizumab,Carboplatin,Paclitaxel or Pemetrexed		Completed	NCT04194203	IMpower151	PCD	2023Feb02	Expression confirmed	Yes		3	https://www.onclive.com/view/impower151-misses-primary-pfs-end-point-with-frontline-atezolizumab-plus-bevacizumab-chemo-in-nsclc			Progression free survival	163	163		Bevacizumab,Carboplatin,Paclitaxel or Pemetrexed,Placebo									8.5	8.3	.86	0.55-1.19																											No	COSO29915674	2025Jan08
ALK_fusions or EGFR_unspecified (and CD274_unspecified)	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Atezolizumab,Bevacizumab,Carboplatin,Paclitaxel		Active, not recruiting	NCT03991403	PD-L1 >= 1%	PCD	2023Mar11	Yes	Yes		1	37861993			Progression free survival				Chemotherapy											.47																												No	COSO29915674	2025Jan08
ALK_fusions or EGFR_unspecified (and CD274_unspecified)	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Atezolizumab,Bevacizumab,Carboplatin,Paclitaxel		Active, not recruiting	NCT03991403	PD-L1 >= 50%	PCD	2023Mar11	Yes	Yes		1	37861993			Progression free survival				Chemotherapy											.24																												No	COSO29915674	2025Jan08
ALK_fusions or EGFR_unspecified (and CD274_unspecified)	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Atezolizumab,Bevacizumab,Carboplatin,Paclitaxel		Active, not recruiting	NCT03991403	PD-L1 >= 10%	PCD	2023Mar11	Yes	Yes		1	37861993			Progression free survival				Chemotherapy											.41																												No	COSO29915674	2025Jan08
ALK_unspecified and CD274_unspecified and EGFR_unspecified and ROS1_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	NK510		Recruiting	NCT06097962		ECD	2024Jul01	Expression confirmed	No		4	NCT06097962	Previously-treated		Maximum tolerated dose/toxicity	9	9																																									No	COSO29915674	2023Nov06
ALK_unspecified or EGFR_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	DV281		Completed	NCT03326752		PCD	2019Sep19	No	Yes	Manageable toxicity	2	10.1158/1538-7445.AM2019-CT224			Maximum tolerated dose/toxicity	22	22																																									No	COSO29915674	2025Jan08
ALK_unspecified or EGFR_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	PF-07934040		Recruiting	NCT06447662		ECD	2027Jun08	No	No		4	NCT06447662	Previously-treated		Overall Response Rate	330	330																																									No	COSO29915674	2024Oct17
ALK_unspecified or EGFR_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	ITIL-168		Withdrawn	NCT05393635	DELTA-2 Cohort 3	PCD	2022Dec08	No	Yes	Changed business priorities	4	NCT05393635			Maximum tolerated dose/toxicity	0	0																																									No	COSO29915674	2024Aug15
ALK_unspecified or EGFR_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	CCL21 dendritic cell adenovirus vaccine,Pembrolizumab		Active, not recruiting	NCT03546361		PCD	2024Jan11	No	No		4	NCT03546361			Overall Response Rate	24	24																																									No	COSO29915674	2024Aug01
ALK_unspecified or EGFR_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Radiotherapy,Tyrosine kinase inhibitor		Recruiting	NCT05236946		ECD	2024Jul01	Yes	No		4	NCT05236946			Progression free survival	190			Tyrosine kinase inhibitor																																							No	COSO29915674	2022Apr27
ALK_unspecified or EGFR_unspecified or ERBB2_unspecified or ROS1_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	CD40L-augmented TILs,Cyclophosphamide,Fludarabine,Interleukin-2,Nivolumab		Recruiting	NCT05681780		ECD	2025Jan01	Yes	No		4	NCT05681780			Maximum tolerated dose/toxicity	20	20																																									No	COSO29915674	2025Jan08
ALK_unspecified or EGFR_unspecified or MET_Exon14 or NTRK1_fusions or NTRK2_fusions or NTRK3_fusions	Set				lung / carcinoma / adenocarcinoma	3	In trials	Phase 2	Carboplatin,Dimesna,Pemetrexed		Recruiting	NCT05456256	HARMONIC	ECD	2025Dec01	Yes	No		4	NCT05456256			OS, PFS	90			Carboplatin,Pemetrexed																																							No	COSO29914826	2025Jan08
ALK_unspecified or EGFR_unspecified or ROS1_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Observational	Pemetrexed		Recruiting	NCT06399926		ECD	2025Jun30	Yes	No		4	NCT06399926	Previously-treated		Overall Response Rate	64	64																																									No	COSO29915674	2024May30
ALK_unspecified or EGFR_unspecified or ROS1_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Observational	Pemetrexed		Recruiting	NCT06399926		ECD	2025Jun30	Yes	No		4	NCT06399926	Previously-treated		Overall Response Rate	64	64																																									No	COSO29915674	2024Jul03
ALK_unspecified or EGFR_unspecified or ROS1_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Atezolizumab,Bevacizumab,Carboplatin,Pemetrexed		Recruiting	NCT04042558		PCD	2021Oct22	Yes	Yes	ORR 3m 58.2 v 46.5	1	36801605			Overall Response Rate	149	71	78	Atezolizumab,Carboplatin,Cisplatin,Cyclophosphamide,Doxorubicin hydrochloride,Etoposide,Pemetrexed,Stem cell transplantation,Topotecan,Vindesine sulphate									7.3	7.2												17.2	16.8																No	COSO29915674	2023Sep13
ALK_unspecified or EGFR_unspecified or ROS1_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Carboplatin,Cetuximab or Placebo,Gemcitabine,SIM1803-1A,SNK01		Unknown	NCT04872634	SNK_ASTER	ECD	2023May26	Yes	Yes		2	10.1200/JCO.2023.41.16_suppl.9057	Previously-treated		Maximum tolerated dose/toxicity	12	12			25								4.7										100																				No	COSO29915674	2025Jan08
ALK_unspecified or EGFR_unspecified or ROS1_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Stereotactic body radiation therapy		Completed	NCT02314364		PCD	2021Nov10	Yes	Yes	SAE 0%	4	NCT02314364			Disease free survival, relapse free survival, regression free survival, recurrence free survival	27	27											14.7			8.3-46.4										70.8			41.8-														No	COSO29915674	2024Aug14
ANGPT1_unspecified or ANGPT2_unspecified or KDR_unspecfied (VEGFR2_unspecfied) or TEK_unspecified or VEGFA_unspecified	Set				ovary / carcinoma / mixed carcinoma	3	In trials	Phase 2	Fosbretabulin,Pazopanib		Terminated	NCT02055690	PAZOFOS	PCD	2017Nov24	Expression confirmed	Yes	Toxicity issues	4	NCT02055690			Maximum tolerated dose/toxicity	21			Pazopanib																																							No	COSO30135797	2024Dec20
BCL2L11_unspecified and EGFR_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Gefitinib,Vorinostat		Unknown	NCT02151721	VICTORY-J 	ECD	2018Feb20	Yes	Yes		1	31782583	Previously-treated		Maximum tolerated dose/toxicity	12	12											5.2										83.3			22.4								10									No	COSO29915674	2022Dec13
BCL2L11_unspecified and EGFR_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Retrospective/Meta-analysis	Bevacizumab,EGFR-TKI		Unknown					Yes	Yes		2	10.1200/PO.20.00404	Untreated		Unknown	33	18	15	EGFR-TKI	94.4	40		>0.001					11.12	7.87			>0.001									30.9	25.4			0.06													No	COSO29915674	2021May21
BCL2_unspecified and EGFR_unspecified	Set				lung / carcinoma / adenocarcinoma	3	In trials	Phase 1	Icotinib		Completed	NCT02044328	ICAPE	PCD	2018Jan01	Comparison with wt	Yes		1	36355317			Disease free survival, relapse free survival, regression free survival, recurrence free survival																																				41.7			0.75				No	COSO29914826	2024Aug14
BRAF_unspecified and EGFR_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Erlotinib,Gemcitabine,Platinum-based chemotherapy		Recruiting	NCT02098954		ECD	2024Dec01	Yes	No		4	NCT02098954	Previously-treated		Progression free survival	40	40																																									No	COSO29915674	2024Jan04
BRAF_unspecified or EGFR_unspecified or NRAS_unspecified or KRAS_unspecified	Set				large intestine / carcinoma / adenocarcinoma	3	In trials	Unknown	Fluorouracil,Fruquintinib,Irinotecan,Oxaliplatin,Tislelizumab		Recruiting	NCT06199232	Group B	ECD	2026Jan23	Yes	No		4	NCT06199232	Previously-treated		Progression free survival	47	47																																									No	COSO28864826	2024Mar05
CCND1_unspecified or CD274_unspecified or CD4_unspecified or CDKN2A_unspecified or EGFR_unspecified or FGF19_unspecified or FGF3_unspecified or FGF4_unspecified or MDM2_unspecified or MDM4_unspecified or PDCD1_unspecified or TP53_unspecified	Set				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	Cisplatin or Nedaplatin,Nab-paclitaxel,Toripalimab		Recruiting	NCT05860335		ECD	2025Jun01	No	No		4	NCT05860335	Untreated		PFS, ORR	30	30																																									No	COSO29324830	2024Apr25
CCND1_unspecified or EGFR_unspecified	Set				central nervous system / glioma / NS	3	In trials	Phase 1	Erlotinib,Fluorouracil,Oxaliplatin		Completed	NCT01561014		PCD	2009Mar01	No	No		4	NCT01561014			Maximum tolerated dose/toxicity	9	9																																									No	COSO28245257	2023Feb03
CD274_unspecified and (ALK_unspecified or EGFR_unspecified)	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Cetuximab,Durvalumab,Intensity modulated radiation therapy		Active, not recruiting	NCT02087423	ATLANTIC Cohort 1	PCD	2016Jun03	Expressed/not	Yes		4	NCT02087423			Overall Response Rate	102	74	28		12.2	3.6																				13.3	9.9																No	COSO29915674	2025Jan08
CD274_unspecified and (EGFR_Exon19del or EGFR_L858R)	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Carboplatin,Pemetrexed,Toripalimab		Not yet recruiting	NCT05962021		ECD	2026Jun30	No	No		4	NCT05962021			Complete response, Pathological complete response	126	126																																									No	COSO29915674	2024Apr25
CD274_unspecified and (EGFR_Exon19del or EGFR_L858R)	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Carboplatin,Nab-paclitaxel,Toripalimab		Not yet recruiting	NCT05962021		ECD	2026Jun30	No	No		4	NCT05962021			Complete response, Pathological complete response	126	126																																									No	COSO29915674	2024Apr25
CD274_unspecified and EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 	Set	COSV51765161,COSV51767322,COSV51801258,COSV51804843,COSV51766344,COSV51768106		p.G719?,p.L858R,p.L861Q,p.S768I	lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Atezolizumab,Bevacizumab,Carboplatin,Pemetrexed		Active, not recruiting	NCT04147351	 PD-L1 ? 1% v PD-L1 < 1% 	ECD	2024Dec31	Yes	Yes		2	10.1016/j.annonc.2022.02.021			Overall Response Rate								0.003																																			Yes	COSO29915674	2025Jan08
CD274_unspecified and EGFR_Exon21*	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Osimertinib,Pembrolizumab,Pemetrexed,Platinum-based chemotherapy		Not yet recruiting	NCT06142617	PD-L1 (22C3) IHC TPS?1%	ECD	2027Nov30	Expression confirmed	No		4	NCT06142617			Progression free survival	37	37																																									No	COSO29915674	2024Mar27
CD274_unspecified and EGFR_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Atezolizumab,Bevacizumab		Completed	NCT04426825		PCD	2022Jan19	Expression confirmed	Yes	SAE 40%	2	10.1016/j.annonc.2022.07.1158			Progression free survival	19	19			15.8								2.8										68.4										3	10									No	COSO29915674	2025Jan08
CD274_unspecified and EGFR_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Almonertinib,Envafolimab		Not yet recruiting	NCT05534113		ECD	2025Jun01	Yes	No		4	NCT05534113			Progression free survival	38	38																																									No	COSO29915674	2024Sep02
CD274_unspecified and EGFR_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Toripalimab		Recruiting	NCT06269211	TOPLINE (PD-L1 TPS ? 1%)	ECD	2027Jan31	Expression confirmed	No		4	NCT06269211	Untreated		Major pathologic response	29	29																																									No	COSO29915674	2025Jan08
CD274_unspecified and EGFR_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Unknown	Carboplatin or Cisplatin,Pemetrexed,Tislelizumab		Recruiting	NCT05527808		ECD	2025Jun30	Expression confirmed	No		4	NCT05527808			Major pathologic response	28	28																																									No	COSO29915674	2023Mar20
CEACAM5_unspecified and EGFR_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	M9140		Not yet recruiting	NCT06710132		ECD	2029Jan31	Yes	No		4	NCT06710132	Previously-treated			250	250																																									No	COSO29915674	2024Dec11
CSF1R_unspecified or FGFR1_unspecified or FGFR2_unspecified or FGFR3_unspecified or FLT3_unspecified or KIT_unspecified or PDGFRA_unspecified or PDGFRB_unspecified or RET_unspecified or VEGFR1_unspecified or VEGFR2_unspecified or VEGFR3_unspecified or VHL_unspecified	Set				NS / other / neoplasm	3	In trials	Phase 2	Sunitinib		Recruiting	NCT03297606	CAPTUR group 9	ECD	2026Jan31	No	No		4	NCT03297606			Overall Response Rate	720	720																																									No	COSO31314888	2023Apr04
EGFR-SEPT14_fusion	Fusion				central nervous system / glioma / astrocytoma Grade IV	4	Pre clinical drug/Case studies	Case study	Afatinib		Active, not recruiting	NCT06385483	MATCH - Subprotocol A Responder	PCD	2022Dec06	Yes	Yes		2	10.1200/PO.23.00725			Overall Response Rate	1	1			100																											1											No	COSO36715232	2025Jan08
EGFR_A859T and ERBB2_G776L	Multigene	COSV51833668		p.A859T,p.G776L	lung / carcinoma / adenocarcinoma	4	Pre clinical drug/Case studies	Case study	Afatinib		Completed	NCT00730925		PCD	2012Jan01	Yes	Yes		1	22325357			Overall Response Rate	1	1																4								14.0							1										No	COSO29914826	2025Jan08
EGFR_C797	Colocated	COSV51766493,COSV51766509,COSV51818388,COSV51832145		p.C797G,p.C797S,p.C797Y	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	BLU-701		Terminated	NCT05153408	HARMONY	PCD	2022Dec09	Yes	No		4	NCT05153408			Overall Response Rate	20	20																																									No	COSO29915674	2023Aug31
EGFR_C797	Colocated	COSV51766493,COSV51766509,COSV51818388,COSV51832145		p.C797G,p.C797S,p.C797Y	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	STX-241		Recruiting	NCT06567015		ECD	2027Nov20	Yes	No		4	NCT06567015	Previously-treated		MTD, ORR, Toxicity	171	171																																									No	COSO29915674	2025Jan08
EGFR_C797	Colocated	COSV51766493,COSV51766509,COSV51818388,COSV51832145		p.C797G,p.C797S,p.C797Y	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	TRX-221		Recruiting	NCT06186076		ECD	2027Jun30	Yes	No		4	NCT06186076	Previously-treated		Maximum tolerated dose/toxicity	115	115																																									No	COSO29915674	2024Jul11
EGFR_C797	Colocated	COSV51766493,COSV51766509,COSV51818388,COSV51832145		p.C797G,p.C797S,p.C797Y	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	WJ13404		Recruiting	NCT05662670		ECD	2025Sep01	Yes	No		4	NCT05662670			Overall Response Rate	162	162																																									No	COSO29915674	2023Sep27
EGFR_C797 or EGFR_T790M	Cluster	COSV51765492,COSV51766493,COSV51766509,COSV51818388,COSV51832145		p.C797G,p.C797S,p.C797Y,p.T790M	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	JIN-A02		Recruiting	NCT05394831		ECD	2024Jul31	Yes	No		4	NCT05394831			Maximum tolerated dose/toxicity	150	150																																									No	COSO29915674	2023Apr04
EGFR_C797S	Point	COSV51766493,COSV51766509		p.C797S	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	QLH11811		Recruiting	NCT05555212	Cohort 4	ECD	2024Dec31	Yes	No		4	NCT05555212	Previously-treated		Overall Response Rate	72	72																																									No	COSO29915674	2023Sep25
EGFR_C797S	Point	COSV51766493,COSV51766509		p.C797S	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	HS-10504		Not yet recruiting	NCT06461156	Dose expansion	ECD	2026Dec31	Yes	No		4	NCT06461156			Maximum tolerated dose/toxicity	230	230																																									No	COSO29915674	2024Oct21
EGFR_C797S	Point	COSV51766493,COSV51766509		p.C797S	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	WSD0922-FU		Recruiting	NCT06631989		ECD	2026Jun30	Yes	No		4	NCT06631989			Overall Response Rate	100	100																																									No	COSO29915674	2024Dec11
EGFR_C797S	Point	COSV51766493,COSV51766509		p.C797S	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	BBT-207		Recruiting	NCT05920135		ECD	2026Aug01	Yes	No		4	NCT05920135			Overall Response Rate	92	92																																									No	COSO29915674	2024Dec12
EGFR_C797S	Point	COSV51766493,COSV51766509		p.C797S	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	TAS3351		Recruiting	NCT05765734		ECD	2027Dec01	Yes	No		4	NCT05765734				200	200																																									No	COSO29915674	2023Sep26
EGFR_C797S	Point	COSV51766493,COSV51766509		p.C797S	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	HS-10375		Recruiting	NCT05435248		ECD	2025Mar31	No	No		4	NCT05435248			Overall Response Rate	354	354																																									No	COSO29915674	2023Sep25
EGFR_C797S and EGFR_T790M 	Multigene	COSV51765492,COSV51766493,COSV51766509		p.C797S,p.T790M	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	BLU-945		Active, not recruiting	NCT04862780	Group 1	ECD	2025Jan31	Yes	No		4	NCT04862780	Previously-treated		Overall Response Rate	190	190																																									No	COSO29915674	2024Apr17
EGFR_C797S and EGFR_no_T790M	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	BLU-945		Active, not recruiting	NCT04862780	Group 3	ECD	2025Jan31	Yes	No		4	NCT04862780	Previously-treated		Overall Response Rate	190	190																																									No	COSO29915674	2024Apr17
EGFR_C797S or EGFR_E709_T70delInsD or EGFR_G719 or EGFR_G724S or EGFR_L718 or EGFR_L747P or EGFR_L747S or EGFR_L792H or EGFR_S768I or EGFR_T854I or EGFR_V769L	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Afatinib		Recruiting	NCT06062823		ECD	2026Oct01	Yes	No		4	NCT06062823	Untreated		Overall Response Rate	35	35																																									No	COSO29915674	2024Jul11
EGFR_D770_N771insSVD	Point			p.D770_N771insSVD	salivary gland / carcinoma / NS	4	Pre clinical drug/Case studies	Case study	Osimertinib		Active, not recruiting	NCT06303167	MATCH-Subprotocol E -  Responder 	PCD	2023Feb26	Yes	Yes		1	38591867	Previously-treated		Overall Response Rate	1	1			100																																						No	COSO68594862	2025Jan08
EGFR_E690K	Point			p.E690K	endometrium / carcinoma / NS	4	Pre clinical drug/Case studies	Case study	Lapatinib		Completed	NCT00096447	NCI-2012-02631 	PCD	2011Mar01	Yes	Yes		1	22885469	Previously-treated		Progression free survival	1	1																															1										No	COSO29024862	2025Jan08
EGFR_E709 or EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I	Set	COSV51765161,COSV51767322,COSV51801258,COSV51804843,COSV51766344,COSV51768106		p.G719?,p.L858R,p.L861Q,p.S768I	lung / carcinoma / non small cell carcinoma	3	In trials	Observational	Osimertinib		Recruiting	NCT06538038		ECD	2028Aug01	Yes	No		4	NCT06538038			Progression free survival	538	538		Chemotherapy,Osimertinib																																							No	COSO29915674	2024Oct21
EGFR_E709A/G/K or EGFR_E884K or EGFR_G719A/C/S or EGFR_L858R or EGFR_L861Q or EGFR_L833V or EGFR_S768I	Cluster				NS / neoplasm / NS	3	In trials	Observational	Erlotinib		Recruiting	NCT05525858	KOSMOSII	ECD	2026Sep01	Yes	No		4	NCT05525858			Disease control rate, Clinical benefit rate	1000	1000																																									No	COSO31315444	2024Oct17
EGFR_E709K/A	Colocated	COSV51767260,COSV51772956		p.E709A,p.E709K	lung / carcinoma / non small cell carcinoma	4	Pre clinical drug/Case studies	Case study	Afatinib		Unknown					Yes	Yes		1	26354527	Previously-treated		Unknown	4																	12.2																									No	COSO29915674	2021May18
EGFR_E709_T710delinsD	Point	COSV51779132		p.E709_T710delinsD	lung / carcinoma / non small cell carcinoma	4	Pre clinical drug/Case studies	Case study	Afatinib		Unknown					Yes	Yes		1	28625646			Unknown	1																																1										No	COSO29915674	2021May18
EGFR_E709_T710delinsD	Point	COSV51779132		p.E709_T710delinsD	lung / carcinoma / non small cell carcinoma	4	Pre clinical drug/Case studies	Case study	Gefitinib		Unknown					Yes	Yes	Lack of efficacy	1	27785061			Unknown	5																																										No	COSO29915674	2024Jan30
EGFR_E709_T710delinsD	Point	COSV51779132		p.E709_T710delinsD	lung / carcinoma / non small cell carcinoma	4	Pre clinical drug/Case studies	Case study	Erlotinib		Unknown					Yes	Yes	Lack of efficacy	1	27785061			Unknown	5																																										No	COSO29915674	2024Jan30
EGFR_Exon18	Exon				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Neratinib		Terminated	NCT01953926	SUMMIT	PCD	2023Jan02	Yes	Yes		2	10.1200/JCO.2021.39.15_suppl.9068			Overall Response Rate	10	10			40		12-74		7.5		4.0-		9.1			3.7-										17.9			5.7-			0	4										No	COSO29915674	2025Jan08
EGFR_Exon18	Exon				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Neratinib		Not yet recruiting	NCT06029816		ECD	2024Dec30	Yes	No		4	NCT06029816	Previously-treated		Overall Response Rate	42	42																																									No	COSO29915674	2023Nov09
EGFR_Exon19del	Cluster				NS / other / neoplasm	3	In trials	Phase 2	Afatinib		Completed	NCT01466660		PCD	2016Apr08	Yes	Yes		1	28426106	Untreated		PFS, TTP, OS	186	93	93	Gefitinib																						30.7	26.4	.83	0.58-1.17	0.2841													No	COSO31314888	2025Jan08
EGFR_Exon19del	Cluster				NS / other / neoplasm	3	In trials	Phase 2	Carboplatin,Nab-paclitaxel,Toripalimab		Not yet recruiting	NCT05962021		ECD	2026Jun30	No	No		4	NCT05962021			Complete response, Pathological complete response	126	126																																									No	COSO31314888	2024Apr25
EGFR_Exon19del	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Case study	Pimitespib		Completed	NCT02965885		PCD	2019May03	Yes	Yes		1	30679388			Overall Response Rate	1	1																															1										No	COSO29915674	2025Jan08
EGFR_Exon19del	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Amivantamab,Lazertinib		Active, not recruiting	NCT02609776	CHRYSALIS cohort E	PCD	2024Jan31	Yes	Yes		1	37710001	Previously-treated		Overall Response Rate	30	30			33		17-53		9.6		5.6-		4.9			3.7-9.5							64																				No	COSO29915674	2025Jan08
EGFR_Exon19del	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Gefitinib,Pemetrexed		Completed	NCT01469000		PCD	2015Apr01	Yes	Yes		1	27507876	Untreated		Progression free survival	105	65	40	Gefitinib									17.1	11.1	.67		0.078																54	3									No	COSO29915674	2025Jan08
EGFR_Exon19del	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Carboplatin,Pemetrexed,Toripalimab		Not yet recruiting	NCT05962021		ECD	2026Jun30	No	No		4	NCT05962021			Complete response, Pathological complete response	126	126																																									No	COSO29915674	2024Apr25
EGFR_Exon19del	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Apatinib,Camrelizumab		Completed	NCT03083041		PCD	2022Apr22	Comparison with wt	Yes		1	35832447	Previously-treated		Overall Response Rate	22	22			13.6																																						No	COSO29915674	2025Jan08
EGFR_Exon19del	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Bevacizumab,Osimertinib		Recruiting	NCT05104281		ECD	2023Dec31	Yes	Yes		1	37016906	Untreated		Progression free survival	17	17											20			14.56-25.44																											No	COSO29915674	2025Jan08
EGFR_Exon19del and EGFR_G724S	Cluster				lung / carcinoma / non small cell carcinoma	4	Pre clinical drug/Case studies	Case study	Pimitespib		Completed	NCT02965885		PCD	2019May03	Yes	Yes		1	35979997	Previously-treated		Overall Response Rate	1	1											9																														No	COSO29915674	2025Jan08
EGFR_Exon19del and EGFR_T790M	Cluster	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Crizotinib,Dacomitinib		Completed	NCT01121575		PCD	2014Feb01	Yes	Yes		1	26899759			Maximum tolerated dose/toxicity	1	1																															1										No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Erlotinib		Unknown	NCT03382795		ECD	2023Mar31	Yes	Yes		2	10.1016/S1556-0864(23)00278-2	Previously-treated		Overall Response Rate	29	29											3.5													9.0																	No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Osimertinib		Active, not recruiting	NCT04233021	ORBITAL	PCD	2023Mar15	Yes	No		4	NCT04233021			Overall Response Rate	57	57																																									No	COSO29915674	2023Aug31
EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Gefitinib		Unknown	NCT03382795		ECD	2023Mar31	Yes	Yes		2	10.1016/S1556-0864(23)00278-2	Previously-treated		Overall Response Rate	34	34											1.8													8.3																	No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Osimertinib		Completed	NCT02529995	AURAChinaPK 80mg cohort	PCD	2016Jan28	Yes	Yes		1	29239002	Previously-treated		Maximum tolerated dose/toxicity	16	16			75.0		47.6-92.7																																				No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Fruquintinib,Genolimzumab		Unknown	NCT03976856	Gxplore-015	ECD	2021Dec01	Yes	No		4	NCT03976856			Maximum tolerated dose/toxicity	42	42																																									No	COSO29915674	2023Apr04
EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Osimertinib,Rifampicin		Completed	NCT02197247		PCD	2015Jul09	Yes	Yes	SAE 17.65% 	4	NCT02197247	Previously-treated		Maximum tolerated dose/toxicity	41	41																																									No	COSO29915674	2024Dec20
EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Itraconazole,Osimertinib		Completed	NCT02157883		PCD	2015Apr03	Yes	Yes	SAE 23%	1	29381826	Previously-treated		Absorption rate	39	39																																									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Osimertinib		Completed	NCT02529995	AURAChinaPK 40mg cohort	PCD	2016Jan28	Yes	Yes		1	29239002			Maximum tolerated dose/toxicity	15	15			47		21.3-73.4																																				No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Gefitinib		Terminated	NCT02025218	NVALT 16	PCD	2017Jan01	Yes	No		4	NCT02025218	Previously-treated		Disease control rate, Clinical benefit rate	21	21																																									No	COSO29915674	2021Aug03
EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Gefitinib,Vinorelbine		Unknown	NCT02319577	GENOA	ECD	2015Jun01	Yes	Yes	Lack of efficacy, PFS 6m 48 vs 66% p=0.24	3	https://www.jto.org/article/S1556-0864(19)32471-2/pdf			Progression free survival	23	21		Gefitinib	47	55		0.76					6.2	9.5			0.17									18.2				0.12													No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Gefitinib,Tepotinib 		Completed	NCT01982955	INSIGHT	PCD	2017Dec12	Yes	Yes		1	36971777	Previously-treated		Progression free survival	55	31	24	Chemotherapy	45.2	33.3			7	4.6			10.15	4.37	.47	0.21?1.03							83.9	70.8		17.25	19.5	.67	0.34?1.32														No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Atezolizumab,Bevacizumab,Carboplatin,Pemetrexed		Active, not recruiting	NCT04147351		ECD	2024Dec31	Yes	Yes		2	10.1016/j.annonc.2022.02.021			Overall Response Rate	19	19			42.1								10.2										100																				No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Erlotinib,Luminespib		Completed	NCT01259089		PCD	2013Jun04	Yes	Yes	Primary outcome not met, Response not correlated with T790M status	1	25870087			MTD, ORR, Toxicity	25																																4										No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Erlotinib,Radiotherapy		Unknown	NCT03074864	TREND	ECD	2019Jun30	Yes	No		4	NCT03074864			Overall Response Rate	90	90																																									No	COSO29915674	2022May03
EGFR_Exon19del or EGFR_Exon19ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_S768I 	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Gefitinib,Stereotactic body radiation therapy		Terminated	NCT02893332	Sindas	PCD	2020Aug30	Yes	Yes	IRB recommended termination	4	NCT02893332	Untreated		Progression free survival	200	200																																									No	COSO29915674	2024Oct23
EGFR_Exon19del or EGFR_Exon20ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Afatinib,Cetuximab		Completed	NCT01090011		PCD	2013Jan01	Yes	Yes		1	29110849	Previously-treated		Maximum tolerated dose/toxicity	36	36											2.9																				4										No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_Exon20ins or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Cetuximab,Osimertinib,Tucatinib		Not yet recruiting	NCT06067776		ECD	2025Jan01	Yes	No		4	NCT06067776			Maximum tolerated dose/toxicity	36	36																																									No	COSO29915674	2023Nov09
EGFR_Exon19del or EGFR_G719 or EGFR_L858R	Cluster	COSV51765161,COSV51767322,COSV51801258,COSV51804843		p.G719X,p.L858R	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Lazertinib		Unknown	NCT03046992		ECD	2022Sep01	Yes	Yes		2	10.1016/j.jtho.2022.07.707	Previously-treated		Overall Response Rate	43	43			69.8		56.0-83.5		23.5				24.6			12.2-30.2							86.0									6	24										No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_G719 or EGFR_L858R	Cluster	COSV51765161,COSV51767322,COSV51801258,COSV51804843		p.G719X,p.L858R	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Osimertinib,Stereotactic body radiation therapy		Not yet recruiting	NCT05998993	CULTRO	ECD	2026Nov01	Yes	No		4	NCT05998993			Progression free survival	35	35																																									No	COSO29915674	2024Jul31
EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861G or EGFR_S768I or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Unknown	Osimertinib,Stereotactic radiotherapy		Recruiting	NCT05033691		ECD	2024Dec31	Yes	No		4	NCT05033691			Progression free survival	162	162																																									No	COSO29915674	2021Nov15
EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Afatinib,Pembrolizumab		Completed	NCT02364609		PCD	2018Apr26	Yes	Yes	MTD established 	4	NCT02364609	Previously-treated		Maximum tolerated dose/toxicity	6	6																																									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Patritumab deruxtecan		Recruiting	NCT03260491		ECD	2026Mar31	Yes	Yes		2	10.1200/JCO.2021.39.15_suppl.9007	Previously-treated		Overall Response Rate	57	57			39		26.0-52.4		6.9		3.1-		8.2			4.4-8.3							72									1	21	19									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Gefitinib,Tremelimumab		Completed	NCT02040064		PCD	2016Mar01	Yes	Yes	Toxicity issues	1	34953624	Previously-treated		Maximum tolerated dose/toxicity	27	27											2.2			1.8-4.2																		19									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Navitoclax,Osimertinib		Completed	NCT02520778		PCD	2022Oct26	Yes	Yes		1	33376097	Previously-treated		Maximum tolerated dose/toxicity	27	27											7.6			1.9-12.6																1	10	12									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Icotinib		Recruiting	NCT05536505		ECD	2025Oct01	Yes	No		4	NCT05536505			Disease free survival, relapse free survival, regression free survival, recurrence free survival	180	180																																									No	COSO29915674	2022Sep27
EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Carboplatin,Lazertinib,Pemetrexed		Not yet recruiting	NCT05477615		ECD	2023Jun01	Yes	No		4	NCT05477615			Overall Response Rate	28	28																																									No	COSO29915674	2024Dec18
EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Atezolizumab,Rociletinib		Terminated	NCT02630186		PCD	2017Sep05	Yes	Yes	Changed business priorities	4	NCT02630186			Overall Response Rate	3	3																																									No	COSO29915674	2022May03
EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Lazertinib		Unknown	NCT05326425		ECD	2024Jun30	Yes	Yes	IORR 57.9%	2	10.1200/JCO.2023.41.16_suppl.9054			Intracranial ORR, CNS ORR	38	38																																									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Dasatinib,Osimertinib		Terminated	NCT02954523		PCD	2018Aug01	Yes	Yes	Slow accrual	1	34568058	Untreated		Progression free survival	10	10			90								19.4													36.1							9										No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Afatinib,Cyclophosphamide,EGF-PTI		Completed	NCT03623750	EPICAL	PCD	2020Mar26	Yes	Yes		2	10.1016/j.jtho.2021.08.117			Maximum tolerated dose/toxicity	23	23			78.3		53.6-92.5						17.4			13.22-							95.7																				No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Unknown	Alflutinib		Unknown	NCT03127449		ECD	2020Jun01	Yes	Yes		1	33077354	Previously-treated		Overall Response Rate	116	116			76.7																																						No	COSO29915674	2024Apr23
EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or S768I	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Datopotamab Deruxtecan		Recruiting	NCT06417814	TROPION-Lung15	ECD	2026Jun11	Yes	No		4	NCT06417814	Previously-treated		Progression free survival	630			Carboplatin or Cisplatin,Pemetrexed																																							No	COSO29915674	2025Jan21
EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_L861Q or S768I	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Datopotamab Deruxtecan,Osimertinib		Recruiting	NCT06417814	TROPION-Lung15	ECD	2026Jun11	Yes	No		4	NCT06417814	Previously-treated		Progression free survival	630			Carboplatin or Cisplatin,Pemetrexed																																							No	COSO29915674	2025Jan21
EGFR_Exon19del or EGFR_G719 or EGFR_L858R or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Osimertinib		Active, not recruiting	NCT03433469		PCD	2023Jan31	Yes	Yes	MpaR 15%, PaR 48%, Primary outcome not met	2	10.1200/JCO.2023.41.16_suppl.85			Major pathologic response	27	27																					100										14	12									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved FDA	Afatinib	Required	Completed	NCT00949650	LUX-Lung 3	PCD	2012Feb09	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf	Untreated		Progression free survival	345	230	115	Chemotherapy	50.4	19.11							11.1	6.9	.58	0.43-0.78	p<0.001									28.2	28.2	.88	0.66-1.17	0.39													Yes	COSO29915674	2023Jan17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved FDA	Osimertinib,Platinum-based chemotherapy	Required	Active, not recruiting	NCT03521154	LAURA	PCD	2024Jan05	Yes	Yes	Primary outcome met	7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s033lbl.pdf			Progression free survival	216	143	73	Platinum-based chemotherapy	54	26							39.1	5.6	.16	0.10-0.24	<0.001																										Yes	COSO29915674	2024Oct09
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved FDA	Amivantamab,Lazertinib	Required	Active, not recruiting	NCT04487080	MARIPOSA	PCD	2023Aug11	Yes	Yes	IORR 68 v 69%	7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s005lbl.pdf	Untreated		Progression free survival	858	429	429	Osimertinib,Placebo	78	73			25.8	16.7			23.7	16.6	.7	0.58-0.85	<0.0002																										Yes	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved FDA	Amivantamab,Carboplatin,Pemetrexed	Required	Active, not recruiting	NCT04988295	MARIPOSA-2	PCD	2023Jul10	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s004lbl.pdf			Progression free survival	394	263	131	Carboplatin,Pemetrexed	53	29		<0.0001	6.9	5.6			6.3	4.2	.48	0.36-0.64	<0.0001											.73	0.54-0.99														Yes	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved FDA	Erlotinib,Ramucirumab	Required	Active, not recruiting	NCT02411448	RELAY	PCD	2019Jan23	Yes	Yes	Primary outcome met	7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf	Untreated		Progression free survival	449	224	225	Erlotinib	76	75							19.4	12.4	.591	0.46-0.76	<0.0001						95.1	95.6	1.0																		Yes	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved FDA	Osimertinib	Required	Active, not recruiting	NCT02511106	ADAURA	PCD	2022Apr11	Yes	Yes	OS 5y 88 v 78% HR 0.49 95%CI 0.34-0.70 p<0.001	1	36720083			Disease free survival, relapse free survival, regression free survival, recurrence free survival	682	339	343	Placebo																															65.8	28.1	.27	0.21-0.34					No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved FDA	Osimertinib	Required	Active, not recruiting	NCT02296125	FLAURA	PCD	2017Jun19	Yes	Yes		1	29151359	Untreated		Progression free survival	556	279	277	Gefitinib					17.2	8.5	7.3-9.8		18.9	10.2	.46	0.37-0.57	p<0.001									83	71																Yes	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved FDA	Dacomitinib	Required	Completed	NCT01774721	ARCHER 1050 	PCD	2016Jul29	Yes	Yes		1	29864379	Untreated		Progression free survival	452	227	225	Gefitinib									14.7	9.2	.59	0.47-0.74	p<0.0001									34.1	26.8	.76	0.582-0.993	p=0.044													Yes	COSO29915674	2022May03
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved FDA	Gefitinib	Required	Completed	NCT01203917	IFUM EURTAC (Study 1)	PCD	2012Aug01	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf	Untreated		Overall Response Rate	106	106			50.0	41-59			6		5.1-11.1																																No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved FDA	Gefitinib	Required	Completed	NCT00322452	IPASS (Study 2)	PCD	2008Apr01	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/206995s004lbl.pdf	Untreated		Progression free survival	186	88	98	Chemotherapy	67.0	41	31-51		9.6	5.5			10.9	7.4	.54	0.38-0.79																											No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved FDA	Erlotinib	Required	Completed	NCT00446225	EURTAC (Study 1)	PCD	2009Dec01	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf	Untreated		Progression free survival	174	86	88	Chemotherapy	65	16							10.4	5.2	.34	0.23-0.49	p<0.001									22.9	19.5	.93	0.64-1.35														Yes	COSO29915674	2023Apr04
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved FDA	Erlotinib	Required	Completed	NCT00036647	BR.21 (Study 4)	PCD	2004Jan30	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf	Previously-treated		Not defined	731	488	243	Placebo	8.9	0.9							2.3	1.8	.59	0.5-0.7	p<0.001									6.7	4.7	.73	0.61-0.86	<0.001													No	COSO29915674	2023Jan17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved FDA	Erlotinib	Required	Completed	NCT00556712	SATURN (Study 3)	PCD	2010Nov01	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf	Previously-treated		Progression free survival	889	438	451	Placebo									2.8	2.6	.71	0.62-0.82	p<0.0001									12.0	11	.81	0.7-0.95	0.0088													Yes	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Case study	Erlotinib		Unknown					Yes	Yes		1	15329413			Unknown	7	7																															7										No	COSO29915674	2021May18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Case study	Gefitinib		Unknown					Yes	Yes		1	15329413			Unknown	4	4																															4										No	COSO29915674	2021May18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Case study	Gefitinib		Unknown					Yes	Yes		1	15118073			Unknown	4	4																															4										No	COSO29915674	2021May18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Observational	Alflutinib		Recruiting	NCT06352502		ECD	2024Sep30	Yes	No		4	NCT06352502			IPFS, IORR, IDCR	30	30																																									No	COSO29915674	2024Jun12
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Observational	Chemotherapy,Osimertinib		Recruiting	NCT06376084	FOREFRONT	ECD	2028Feb28	Yes	No		4	NCT06376084			Progression free survival	700	700																																									No	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Out of trials human study	Pemetrexed		Unknown					Comparison with wt	Yes		1	21642865			Unknown	80	43	37		4.7	16.2												1.4	2.9																								No	COSO29915674	2021May18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Osimertinib		Completed	NCT02228369	BLOOM	PCD	2017Aug19	Yes	Yes		1	31809241	Previously-treated		Maximum tolerated dose/toxicity	41	41			41		26-58		8.3		5.6-16.5		8.6			5.4-13.7										11.0			8-18				17	17									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Osimertinib,Tamnorzatinib		Active, not recruiting	NCT06525246		ECD	2025Oct31	Yes	No		4	NCT06525246			Maximum tolerated dose/toxicity	78	78																																									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	BPI-1178,Osimertinib		Recruiting	NCT06362980		ECD	2025Apr01	Yes	No		4	NCT06362980	Previously-treated		Maximum tolerated dose/toxicity	20	20																																									No	COSO29915674	2024Jul11
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	YL202		Recruiting	NCT05653752		ECD	2025Dec01	Yes	No		4	NCT05653752			Maximum tolerated dose/toxicity	80	80																																									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	QLH11811		Recruiting	NCT05555212	Cohort 1	ECD	2024Dec31	Yes	No		4	NCT05555212	Previously-treated		Overall Response Rate	72	72																																									No	COSO29915674	2023Sep25
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Osimertinib,VIC-1911		Recruiting	NCT05489731	Cohort 2 - Osimertinib resistant cohort	ECD	2024Feb24	Yes	Yes	PFS 6m 38.5%	2	10.1200/JCO.2024.42.16_suppl.8077	Previously-treated		Maximum tolerated dose/toxicity	13	3			0																		53.8											7									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Osimertinib,VIC-1911		Recruiting	NCT05489731	Cohort 2 - Osimertinib naive cohort	ECD	2024Feb24	No	Yes	PFS 6m 70.0%	2	10.1200/JCO.2024.42.16_suppl.8077			Maximum tolerated dose/toxicity	10	10			50																		80										5	3									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Almonertinib,Gentuximab		Unknown	NCT05223595		ECD	2023Sep30	Yes	No		4	NCT05223595			Maximum tolerated dose/toxicity	42	42																																									No	COSO29915674	2024Sep02
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Osimertinib,Triptolide		Recruiting	NCT05166616		ECD	2026Oct28	Yes	No		4	NCT05166616			Maximum tolerated dose/toxicity	30	30																																									No	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Camrelizumab,Carboplatin,Pemetrexed		Unknown	NCT04970043		ECD	2024Jul30	Yes	No		4	NCT04970043			Progression free survival	58	58																																									No	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Osimertinib,Tegavivint		Recruiting	NCT04780568		ECD	2025Jul31	Yes	No		4	NCT04780568	Untreated		Maximum tolerated dose/toxicity	24	24																																									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Osimertinib,Temozolomide		Completed	NCT04541407		PCD	2022Apr25	Yes	Yes	Slow accrual	4	NCT04541407			Maximum tolerated dose/toxicity	1	1																																									No	COSO29915674	2024Oct23
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Anlotinib,Erlotinib		Unknown	NCT03628521		ECD	2019Dec31	Yes	Yes		1	35958322	Untreated		Overall Response Rate	30	30			92.9								20.53										96.4										26										No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Nazartinib,Ribociclib		Active, not recruiting	NCT03333343		ECD	2025Apr21	Yes	No		4	NCT03333343			Overall Response Rate	105	105																																									No	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Naporafenib,Nazartinib		Active, not recruiting	NCT03333343		ECD	2025Apr21	Yes	No		4	NCT03333343			Overall Response Rate	105	105																																									No	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Nazartinib,Trametinib		Completed	NCT03516214	EATON	PCD	2022Sep30	Yes	Yes		2	10.1158/1538-7445.AM2020-CT255			Maximum tolerated dose/toxicity	2	2																																1									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Nazartinib,Trametinib		Active, not recruiting	NCT03333343		ECD	2025Apr21	Yes	No		4	NCT03333343			Overall Response Rate	105	105																																									No	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Osimertinib,Savolitinib		Active, not recruiting	NCT02143466	TATTON	PCD	2020Mar04	Yes	Yes		1	32139298	Previously-treated		Maximum tolerated dose/toxicity	7	7			86		42-100																										24										No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	AV-412		Terminated	NCT00381654		PCD	2009Dec01	Yes	Yes	Primary outcome not met	4	NCT00381654	Previously-treated		Maximum tolerated dose/toxicity	27	27																																									No	COSO29915674	2023Sep22
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Osimertinib,Selumetinib		Active, not recruiting	NCT02143466	TATTON	PCD	2020Mar04	Yes	Yes		1	32139298	Previously-treated		Maximum tolerated dose/toxicity	7	7			14		0-58																																				No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Durvalumab,Osimertinib		Active, not recruiting	NCT02143466	TATTON	PCD	2020Mar04	Yes	Yes		1	32139298	Previously-treated		Maximum tolerated dose/toxicity	8	8			38		9-76																										9	9									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Bevacizumab,Osimertinib		Not yet recruiting	NCT06557096		ECD	2027Jun01	Yes	No		4	NCT06557096	Previously-treated		Overall survival	100	100																																									No	COSO29915674	2024Oct21
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Gefitinib,Nazartinib		Active, not recruiting	NCT03333343		ECD	2025Apr21	Yes	No		4	NCT03333343			Overall Response Rate	105	105																																									No	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Capmatinib,Nazartinib		Active, not recruiting	NCT03333343		ECD	2025Apr21	Yes	No		4	NCT03333343			Overall Response Rate	105	105																																									No	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Gefitinib,Savolitinib		Completed	NCT02374645		PCD	2018Feb18	Yes	Yes		2	10.1200/JCO.2016.34.15_suppl.e20559 	Previously-treated		Maximum tolerated dose/toxicity	11	11																															2										No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Zorifertinib		Completed	NCT02228369	BLOOM	PCD	2017Aug19	Yes	Yes	Promising activity 	1	29056570	Previously-treated		Maximum tolerated dose/toxicity	67	67																																									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	DS-1205c,Gefitinib		Terminated	NCT03599518		PCD	2020Apr22	Yes	Yes		1	36621830	Previously-treated		Maximum tolerated dose/toxicity	20	20			0																											0	0	5									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Afatinib,Xentuzumab		Completed	NCT02191891		PCD	2018Apr18	Yes	Yes		1	34590052	Previously-treated		MTD, ORR, Toxicity	26								3.5		0.8-12.9		2.8			1.7-3.6							73										1	18									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Osimertinib,Sapanisertib		Active, not recruiting	NCT02503722		ECD	2025May13	Yes	No		4	NCT02503722			Maximum tolerated dose/toxicity	36	36																																									No	COSO29915674	2024Jul11
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Afatinib		Completed	NCT01466660	LUX-Lung 7	PCD	2016Apr08	Yes	Yes		1	28426106	Untreated		PFS, TTP, OS	319	160	159	Gefitinib	72.5	56.0	1.32-3.40	0.0018					11	10.9	.74	0.57-0.95	p=0.0178	13.7	5.5	.75	0.60-0.94	p=0.0136				27.9	24.5	.86	0.66-1.12	0.2580													Yes	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Carboplatin,Pemetrexed,Sintilimab		Not yet recruiting	NCT06688656		ECD	2026Mar31	Yes	No		4	NCT06688656	Untreated		Major pathologic response	30	30																																									No	COSO29915674	2024Dec11
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	ABSK043,Alflutinib		Recruiting	NCT06668103		ECD	2027Dec30	Yes	No		4	NCT06668103	Untreated		Progression free survival	54	54																																									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	EGFR-TKI,Stereotactic radiotherapy		Recruiting	NCT06020066		ECD	2028Aug10	Yes	No		4	NCT06020066			Progression free survival	202	202																																									No	COSO29915674	2023Nov08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Amivantamab,Cetrelimab		Recruiting	NCT05908734		ECD	2025Jun30	Yes	No		4	NCT05908734			Overall Response Rate	75	75																																									No	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	BL-B01D1,Osimertinib		Recruiting	NCT05880706		ECD	2025Jul01	Yes	No		4	NCT05880706			Overall Response Rate	114	114																																									No	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Amivantamab,Osimertinib		Active, not recruiting	NCT05801029	OSTARA	ECD	2028Apr30	Yes	No		4	NCT05801029	Untreated		Progression free survival	60	60																																									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib,SKB264		Recruiting	NCT05816252	Cohort 7	ECD	2025Dec01	Yes	No		4	NCT05816252			Overall Response Rate	498	498																																									No	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Ametinib,Bevacizumab		Recruiting	NCT05754736		ECD	2023Dec01	Yes	No		4	NCT05754736			PFS, ORR	50	50																																									No	COSO29915674	2023Mar20
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Amivantamab,Bevacizumab,Lazertinib		Recruiting	NCT05601973	AMAZE-lung	ECD	2026Mar30	Yes	No		4	NCT05601973	Previously-treated		Overall Response Rate	60	60																																									No	COSO29915674	2024Dec18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Erlotinib,R-(-)-gossypol acetic acid		Terminated	NCT00988169		PCD	2010May01	Yes	Yes		4	NCT00988169			Overall Response Rate	5	5																															1	3									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Bafisontamab,Osimertinib		Not yet recruiting	NCT05498389	Group 1	ECD	2024Jul01	Yes	No		4	NCT05498389	Previously-treated		Overall Response Rate	115	115																																									No	COSO29915674	2023Sep25
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Carboplatin,Lazertinib,Pemetrexed		Not yet recruiting	NCT05786430	LUCAS	ECD	2024Dec01	Yes	No		4	NCT05786430			Progression free survival	87	87																																									No	COSO29915674	2024Dec18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Carboplatin,Lazertinib,Pemetrexed		Not yet recruiting	NCT06268210	NeoLazer	ECD	2026Jun01	Yes	No		4	NCT06268210	Untreated		Pathologic Response	160	160		Lazertinib																																							No	COSO29915674	2024Dec18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Carboplatin,Lazertinib,Pemetrexed		Not yet recruiting	NCT06020989		ECD	2024Sep01	Yes	No		4	NCT06020989	Previously-treated		Progression free survival	129			Lazertinib																																							No	COSO29915674	2024Dec18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Alflutinib,Bevacizumab,Carboplatin,Pemetrexed		Recruiting	NCT05334277	FOCUS-C Group B3	ECD	2025Feb28	Yes	No		4	NCT05334277	Untreated		Progression free survival	280	280																																									No	COSO29915674	2024Apr23
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Alflutinib,Carboplatin,Pemetrexed		Recruiting	NCT05334277	FOCUS-C Group B2	ECD	2025Feb28	Yes	No		4	NCT05334277	Untreated		Progression free survival	280	280																																									No	COSO29915674	2024Apr23
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Alflutinib,Chemotherapy		Recruiting	NCT06339242		ECD	2025Jul01	Yes	No		4	NCT06339242	Previously-treated		PFS, ORR	30	30																																									No	COSO29915674	2024Jul03
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Lazertinib,Stereotactic body radiation therapy		Not yet recruiting	NCT05167851		ECD	2025Dec01	Yes	No		4	NCT05167851			Progression free survival	68			Lazertinib																																							No	COSO29915674	2024Dec18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	BLU-701,Carboplatin,Pemetrexed		Terminated	NCT05153408	HARMONY	PCD	2022Dec09	Yes	No		4	NCT05153408			Overall Response Rate	20	20																																									No	COSO29915674	2023Aug31
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	BLU-701,Osimertinib		Terminated	NCT05153408	HARMONY	PCD	2022Dec09	Yes	No		4	NCT05153408			Overall Response Rate	20	20																																									No	COSO29915674	2023Aug31
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	BLU-701		Terminated	NCT05153408	HARMONY	PCD	2022Dec09	Yes	No		4	NCT05153408			Overall Response Rate	20	20																																									No	COSO29915674	2023Aug31
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Carboplatin,Cisplatin,Icotinib,Pemetrexed		Not yet recruiting	NCT05132985		ECD	2024Jul01	Yes	No		4	NCT05132985			Major pathologic response	45	45																																									No	COSO29915674	2022Jan28
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Carboplatin,Cisplatin,Icotinib,Pemetrexed		Recruiting	NCT05104788		ECD	2024Mar01	Yes	No		4	NCT05104788			Major pathologic response	27	27																																									No	COSO29915674	2021Nov16
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib,Radiotherapy		Completed	NCT04764214		PCD	2023Mar31	Yes	Yes	OS 2y 88.8% 	2	10.1016/j.esmoop.2024.102593			Progression free survival	46	46											29.9			21.0-38.8																											No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Carboplatin,Lenvatinib,Pembrolizumab,Pemetrexed		Active, not recruiting	NCT05258279		PCD	2023Oct31	Yes	No		4	NCT05258279			Overall Response Rate	30	30																																									No	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	LY3295668,Osimertinib		Active, not recruiting	NCT05017025		ECD	2025Jun30	Yes	No		4	NCT05017025			Maximum tolerated dose/toxicity	32	32																																									No	COSO29915674	2024Jan04
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Amivantamab,Carboplatin,Lazertinib,Pemetrexed		Recruiting	NCT05498428	PALOMA-2 Cohort 3	ECD	2025Oct31	Yes	No		4	NCT05498428	Untreated		Overall Response Rate	390	390																																									No	COSO29915674	2024Dec18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Amivantamab,Carboplatin,Lazertinib,Pemetrexed		Recruiting	NCT05299125	AMIGO-1	ECD	2026Oct01	Yes	No		4	NCT05299125	Untreated		Progression free survival	49	49																																									No	COSO29915674	2024Dec18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Cisplatin,Osimertinib,Pemetrexed		Recruiting	NCT05011487		PCD	2023Sep01	Yes	No		4	NCT05011487			Lymph node clearance rate	30	30																																									No	COSO29915674	2024Apr17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Befotertinib,Icotinib		Active, not recruiting	NCT05007938		ECD	2024Dec31	Yes	No		4	NCT05007938			Overall Response Rate	30	30																																									No	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Keynatinib		Recruiting	NCT04824079		ECD	2025Apr22	Yes	No		4	NCT04824079	Previously-treated		Overall Response Rate	30	30																																									No	COSO29915674	2024Jan04
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Afatinib,Cisplatin,Pemetrexed,Radiotherapy		Active, not recruiting	NCT01553942	ASCENT	ECD	2024Dec01	Yes	Yes		2	10.1016/j.jtho.2021.01.072			Response rate	19	19			58		33-80						34.6			16.9-66.1										69.1			29.4-														No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Almonertinib,Microwave ablation		Not yet recruiting	NCT04755738		ECD	2023Mar31	Yes	No		4	NCT04755738			Progression free survival	234			Almonertinib																																							No	COSO29915674	2024Sep02
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Lenvatinib,Pembrolizumab		Unknown	NCT05078931		ECD	2022Oct01	Yes	No		4	NCT05078931			Progression free survival	35	35																																									No	COSO29915674	2024Jul11
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib,Pemetrexed,Platinum-based chemotherapy		Recruiting	NCT05281406	PACE-LUNG	ECD	2023Nov01	Yes	No		4	NCT05281406			Progression free survival	50	50																																									No	COSO29915674	2022May17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Amivantamab,Lazertinib		Recruiting	NCT05498428	PALOMA-2 Cohort 1	ECD	2025Oct31	Yes	No		4	NCT05498428	Untreated		Overall Response Rate	390	390																																									No	COSO29915674	2024Dec18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Amivantamab,Lazertinib		Recruiting	NCT06667076	COPERNICUS	ECD	2029May23	Yes	No		4	NCT06667076	Previously-treated		Progression free survival	365			Amivantamab,Carboplatin,Pemetrexed																																							No	COSO29915674	2024Dec18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Atezolizumab,Bevacizumab		Terminated	NCT04099836		PCD	2022Nov13	Yes	Yes	Slow accrual	4	NCT04099836	Previously-treated		Overall Response Rate	7	7																																									No	COSO29915674	2023Sep15
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Ascorbic acid,Tyrosine kinase inhibitor		Unknown	NCT03799094		ECD	2020Dec31	Yes	No		4	NCT03799094			Progression free survival	150	150																																									No	COSO29915674	2023Apr04
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Anlotinib,Gefitinib		Unknown	NCT04358562		ECD	2022May01	Yes	No		4	NCT04358562			Progression free survival	240	240																																									No	COSO29915674	2022Nov28
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Durvalumab,Tremelimumab		Active, not recruiting	NCT03994393	ILLUMINATE	ECD	2023Jun30	Yes	No		4	NCT03994393			Overall Response Rate	100	100																																									No	COSO29915674	2023Aug31
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	ZN-e4		Completed	NCT03446417		PCD	2022Jan17	Yes	No		4	NCT03446417			Maximum tolerated dose/toxicity	34	34																																									No	COSO29915674	2023Apr04
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Chemotherapy,Icotinib		Unknown	NCT03396185		ECD	2022Feb01	Yes	No		4	NCT03396185	Untreated		Disease free survival, relapse free survival, regression free survival, recurrence free survival	30	30																																									No	COSO29915674	2023Apr04
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Cisplatin,Icotinib,Pemetrexed		Completed	NCT03544814	Concurrent v sequential	PCD	2017Jun01	Yes	Yes		1	32747190			Progression free survival	99	49	50	Cisplatin,Icotinib,Pemetrexed									7.7	5.7	.66	0.44-1.00	0.026									20.0	14.7	.52	0.32-0.85	0.038													Yes	COSO29915674	2023Apr27
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Pemetrexed,Toripalimab		Completed	NCT03513666		PCD	2022Aug12	Yes	Yes		1	34650034	Previously-treated		Overall Response Rate	40	40			50		33.8-66.2		7		4.8-8.4		7										87.5			23.5			18.0-				20	15									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib,Stereotactic radiotherapy		Active, not recruiting	NCT03769103	LUOSICNS	ECD	2025Apr01	Yes	No		4	NCT03769103			Progression free survival	40	40																																									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Anlotinib,Icotinib		Completed	NCT03736837	ALTER-L004	PCD	2021Jan01	Yes	Yes	SAE 1.7%	1	37543587	Untreated		Progression free survival	57	57			68.5				13.5		10.0-17.1		15.1			12.6-17.6							98.2			30.0			25.5-34.5			1	23	9									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Anlotinib,Tyrosine kinase inhibitor		Unknown	NCT03720873		ECD	2021Jun01	Yes	Yes		2	10.1200/JCO.2021.39.15_suppl.9030			Progression free survival	60	60			78.3								13			10.7-15.3							100																				No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Patritumab deruxtecan		Active, not recruiting	NCT04619004	HERTHENA-Lung01	PCD	2022Nov21	Yes	Yes	IORR 33%	1	37689979	Previously-treated		Overall Response Rate	30	30																																									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Patritumab deruxtecan		Active, not recruiting	NCT04619004	HERTHENA-Lung01	PCD	2022Nov21	Yes	Yes	Promising activity 	1	37689979	Previously-treated		Overall Response Rate	225	225			29.8		23.9-36.2		6.4				5.5													11.9																	No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Carboplatin,Icotinib,Pemetrexed		Unknown	NCT02737774		PCD	2019Oct25	Yes	No		4	NCT02737774			Progression free survival	60	60																																									No	COSO29915674	2022Nov28
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Carboplatin,Icotinib,Pemetrexed		Unknown	NCT03151161		ECD	2018Dec31	Yes	No		4	NCT03151161			Clinical activity	118	118																																									No	COSO29915674	2022May03
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Icotinib,Stereotactic body radiation therapy		Unknown	NCT03153358		ECD	2017Nov02	Yes	Yes		3	https://www.redjournal.org/article/S0360-3016(20)32755-3/pdf			Progression free survival	31	31											24.6			17.6-31.6										43.9			31.1-57.8														No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Pemetrexed		Not yet recruiting	NCT06296745		ECD	2026Jan20	Yes	No		4	NCT06296745	Previously-treated		Response rate	36	36																																									No	COSO29915674	2024Apr30
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Bevacizumab,Gefitinib		Unknown					Yes	Yes		1	25695221	Untreated		Unknown	42	42			73.8								14.4			10.1-19.2																2	29										No	COSO29915674	2021May18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Bevacizumab,Gefitinib		Unknown	NCT02930954		ECD	2018Dec01	Yes	No		4	NCT02930954	Untreated		Progression free survival	180	180																																									No	COSO29915674	2021May18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib,Selumetinib		Active, not recruiting	NCT03392246		ECD	2025Jun30	Yes	No		4	NCT03392246	Untreated		Best overall response	25	25																																									No	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Gefitinib,Thalidomide		Unknown	NCT03341494		ECD	2019Nov01	Yes	No		4	NCT03341494			Progression free survival	128	128																																									No	COSO29915674	2022May03
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Cyclophosphamide,Fludarabine,Interleukin-2,Tumour infiltrating lymphocytes,Vemurafenib		Unknown	NCT00801385		ECD	2009Jun01	Comparison with wt	Yes		1	26898607			Response rate	23	8	15		62.5	6.7							11	2.93									87.5	46.7		26.1	9.17																No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Atezolizumab,Bevacizumab,Carboplatin,Pemetrexed		Terminated	NCT04512430	Neo-DIANA	PCD	2024Jul19	Yes	Yes	Slow accrual	4	NCT04512430			Major pathologic response	4	4																																									No	COSO29915674	2024Oct23
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Cisplatin,Pemetrexed		Unknown	NCT03050437		ECD	2017Feb01	Yes	No		4	NCT03050437	Previously-treated		Progression free survival	96	96																																									No	COSO29915674	2021May18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib,Ramucirumab		Active, not recruiting	NCT03909334	RAMOSE	ECD	2025Sep01	Yes	Yes		3	https://www.onclive.com/view/dr-le-on-the-efficacy-of-osimertinib-plus-ramucirumab-in-egfr-mutant-mnsclc			Progression free survival	139	93	46	Osimertinib					14.2				24.8	15.6	.55	0.32-0.93	0.026																										Yes	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Aspirin,Osimertinib		Not yet recruiting	NCT06018688		ECD	2026Mar01	Yes	No		4	NCT06018688	Untreated		Major pathologic response	44	44																																									No	COSO29915674	2024Jan04
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Fruquintinib,Gefitinib		Completed	NCT02976116		PCD	2019Jun28	Yes	Yes	SAE 18.0%	1	33718026	Untreated		Overall Response Rate	50	50			73.5		58.9-85.1						14.7										98.0																				No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Almonertinib		Withdrawn	NCT06227897	AERESA	ECD	2026Apr01	Yes	No		4	NCT06227897			Disease free survival, relapse free survival, regression free survival, recurrence free survival	0	0																																									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Almonertinib		Recruiting	NCT05810350		ECD	2024Dec31	Yes	No		4	NCT05810350			Progression free survival	40	40																																									No	COSO29915674	2024Sep02
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Almonertinib		Recruiting	NCT04922138	APPOINT	ECD	2024Apr15	Yes	No		4	NCT04922138	Untreated		Disease free survival, relapse free survival, regression free survival, recurrence free survival	104	104																																									No	COSO29915674	2024Sep02
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Almonertinib		Recruiting	NCT04354961	ARISE	ECD	2023Dec31	Yes	Yes	Slow accrual rate	2	10.1016/j.jtho.2023.09.1271	Untreated		Progression free survival	12	12		Carboplatin,Paclitaxel	58.3								6.2										83.3										7										No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Alflutinib		Recruiting	NCT05334277	FOCUS-C Group B1	ECD	2025Feb28	Yes	No		4	NCT05334277	Untreated		Progression free survival	280	280																																									No	COSO29915674	2024Apr23
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Alflutinib		Recruiting	NCT05165355	ATHEM	ECD	2024Nov01	Yes	No		4	NCT05165355	Previously-treated		Disease free survival, relapse free survival, regression free survival, recurrence free survival	90	90																																									No	COSO29915674	2024Apr23
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Alflutinib		Unknown	NCT05079022		ECD	2023Mar01	Yes	No		4	NCT05079022			Clearance of ctDNA	50	50																																									No	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Alflutinib		Not yet recruiting	NCT04965831	FRONT	ECD	2023Mar01	Yes	No		4	NCT04965831			Overall Response Rate	40	40																																									No	COSO29915674	2024Apr23
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Alflutinib		Recruiting	NCT05379803		ECD	2024Dec31	Yes	No		4	NCT05379803			Progression free survival	40	40																																									No	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Alflutinib		Unknown	NCT04982900	TERMGGO	ECD	2022Aug01	Yes	No		4	NCT04982900			Response rate	138			Placebo																																							No	COSO29915674	2024Apr23
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib,Trastuzumab-emtansine		Terminated	NCT03784599	TRAEMOS	PCD	2021May17	Yes	Yes		2	10.1016/j.jtho.2021.08.116	Previously-treated		Maximum tolerated dose/toxicity	23	23			13								2.8			2.3-3.3							43																				No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Gefitinib,Nazartinib		Active, not recruiting	NCT03292133		PCD	2023Dec31	Yes	No		4	NCT03292133	Untreated		Progression free survival	11	11																																									No	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Capmatinib,Nazartinib		Terminated	NCT02335944	Group 3	PCD	2020Nov10	Yes	Yes		2	10.1016/j.annonc.2020.08.1598	Previously-treated		Overall Response Rate	47	47			61.7		46.4-75.5		11.6		6.6-14.3		11			7.6-13.8										15.9																	No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Capmatinib,Nazartinib		Terminated	NCT02335944	Group 1	PCD	2020Nov10	Yes	Yes		2	10.1016/j.annonc.2020.08.1598	Previously-treated		Overall Response Rate	52	52			28.8		17.1-43.1		6.3		3.7-10.8		5.6			3.7-7.4										18.8			14.9-21.7														No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Erlotinib,Linsitinib		Completed					Yes	Yes	Lack of efficacy	1	27686971	Untreated		Unknown	88	88		Erlotinib																																							No	COSO29915674	2024Jan30
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Gefitinib,Osimertinib		Active, not recruiting	NCT03122717		ECD	2025Apr01	Yes	Yes		2	10.1200/JCO.2020.38.15_suppl.9507	Untreated		Maximum tolerated dose/toxicity	27	27			85.2		67.5-94.1																																				No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Gefitinib,Olaparib		Completed	NCT01513174	GOAL	PCD	2016Jul01	Yes	Yes	Lack of efficacy	2	10.1200/JCO.2018.36.15_suppl.9012 	Untreated		Maximum tolerated dose/toxicity	186	186		Gefitinib																																							No	COSO29915674	2024Jan30
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Berberine,Gefitinib		Unknown	NCT03486496	Geber	ECD	2019Jun01	Yes	No		4	NCT03486496			Progression free survival	50																																										No	COSO29915674	2022May03
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Bevacizumab,Erlotinib		Unknown	NCT03126799	AvaTa	PCD	2021Dec31	Yes	Yes		2	10.1200/JCO.2022.40.16_suppl.9107			Progression free survival	127	64	63	Erlotinib	85.9	83.9		0.746					17.5	12.4	.74	0.51-1.08	0.119																										No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Bevacizumab,Erlotinib		Completed	NCT01532089		PCD	2018Feb13	Yes	Yes		4	NCT01532089			Progression free survival	88	43	45	Erlotinib									17.9	13.5	.81	0.5-1.31	0.39									32.4	50.6	1.41	0.71-2.81	0.33													No	COSO29915674	2022May03
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Gefitinib,Tegafur-gimeracil-oteracil potassium		Unknown	NCT03457337		ECD	2020Oct31	Yes	No		4	NCT03457337	Untreated		Progression free survival	200	200		Gefitinib																																							No	COSO29915674	2022May03
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib,Telaglenastat		Active, not recruiting	NCT03831932		ECD	2025Jun01	Yes	No		4	NCT03831932	Previously-treated		Overall Response Rate	28	28																																									No	COSO29915674	2024Jul11
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Ficlatuzumab,Gefitinib		Completed	NCT01039948		PCD	2013Aug01	Yes	Yes	Lack of efficacy	1	27448761	Untreated		Overall Response Rate	188	94	94	Gefitinib																																							No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Poziotinib		Terminated	NCT01819428		PCD	2015Nov01	Yes	Yes	Slow accrual	4	NCT01819428	Untreated		Overall Response Rate	22	22																																									No	COSO29915674	2022Aug17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Neratinib		Completed	NCT00266877		PCD	2009Jan01	Comparison with wt	Yes		1	20479403	Previously-treated		Overall Response Rate	139	91	48		54.0	25.0			14	7.7																																	No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Lapatinib		Terminated	NCT00073008	EGF20014	PCD	2008Jul01	Yes	Yes	Lack of efficacy	1	20215545			Overall Response Rate	131	131																																									No	COSO29915674	2024Jan30
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Lazertinib		Unknown	NCT03046992	Centrally Confirmed mutations	ECD	2022Sep01	Yes	Yes		2	10.1016/j.jtho.2022.07.707	Previously-treated		Overall Response Rate	35	35			77.1		63.2 to 91.1		23.5				24.9										94.3									6	21										No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Lazertinib		Active, not recruiting	NCT05463224		ECD	2025Mar31	Yes	No		4	NCT05463224			Progression free survival	150	150																																									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Lazertinib		Recruiting	NCT06156527		ECD	2026Sep05	Yes	No		4	NCT06156527			Progression free survival	120	120		Bevacizumab,Lazertinib																																							No	COSO29915674	2024Dec18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Olmutinib		Completed	NCT02444819		PCD	2017Aug01	No	No		4	NCT02444819	Untreated		Overall Response Rate	33	33																																									No	COSO29915674	2021May18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Nazartinib		Completed	NCT02108964		PCD	2018Mar22	Yes	Yes		3	https://oncologypro.esmo.org/meeting-resources/esmo-2018-congress/Phase-II-results-for-single-agent-nazartinib-EGF816-in-adult-patients-pts-with-treatment-naive-EGFR-mutant-non-small-cell-lung-cancer-NSCLC	Untreated		Overall Response Rate	45	45			64		49-78																93									1	28										No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Tesevatinib		Completed	NCT02616393	Cohort C	PCD	2018Apr03	Yes	Yes		4	NCT02616393	Previously-treated		Overall Response Rate	3	3											8.7			4.65-14.34		8.06			7.42-8.70																						No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Tesevatinib		Completed	NCT02616393	Cohort B	PCD	2018Apr03	Yes	Yes		4	NCT02616393	Previously-treated		Overall Response Rate	20	20											2.51			1.58-3.96		1.88			1.39-8.28																						No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Tesevatinib		Completed	NCT02616393	Cohort A	PCD	2018Apr03	Yes	Yes		4	NCT02616393	Previously-treated		Overall Response Rate	13	13											2.14			0.96-6.33		4.95			0.96-6.33												6										No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Tesevatinib		Completed	NCT00522145		PCD	2009Oct01	No	Yes		1	22011666	Previously-treated		Response rate	41	41			3																																						No	COSO29915674	2024Jul17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Tesevatinib		Completed	NCT00364780		PCD	2010May01	Yes	Yes		1	22722787	Untreated		Response rate	51	14	37										9.3	3.6												22.5	18.4		13.6-19.6	0.05													No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Recruiting	NCT06206850	Neo-Bio-ADAURA	ECD	2029Jan01	Yes	No		4	NCT06206850	Previously-treated		Overall survival	20	20																																									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Completed	NCT04563871	BLOSSOM	PCD	2023Oct25	Yes	Yes		2	10.1200/JCO.2024.42.16_suppl.8582			Overall survival	73	73			51.6																		81.3			15.0																	No	COSO29915674	2024Jun26
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Withdrawn	NCT04591002		PCD	2020Oct07	Yes	No	No patients recruited	4	NCT04591002			Clinical activity	0	0																																									No	COSO29915674	2024Apr26
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Active, not recruiting	NCT03769103	LUOSICNS	ECD	2025Apr01	Yes	No		4	NCT03769103			Progression free survival	40	40																																									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Active, not recruiting	NCT03586453		ECD	2026Feb28	Yes	No		4	NCT03586453			Biomarker discovery	30	30																																									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Dacomitinib		Active, not recruiting	NCT04027647		ECD	2026Mar31	Yes	Yes	IRR 67%, PFS 12m 42%	2	10.1016/j.annonc.2022.10.400			Progression free survival	24	24			67																																						No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Icotinib		Not yet recruiting	NCT05514314		ECD	2024Sep30	Yes	No		4	NCT05514314			Disease free survival, relapse free survival, regression free survival, recurrence free survival	90	90																																									No	COSO29915674	2022Sep27
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Icotinib		Unknown	NCT03346811	CHALLENGE	ECD	2019May10	Yes	Yes		1	35862035			Overall Response Rate	116	116			52.6		43.1-61.9						10.3			8,3-12.2							84.5			23.2			17.7-28.0														No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Icotinib		Unknown	NCT03349203		ECD	2022Feb01	Yes	No		4	NCT03349203			Overall Response Rate	60	60																																									No	COSO29915674	2024Jan04
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Icotinib		Unknown	NCT03749213		ECD	2022Feb01	Yes	No		4	NCT03749213			Overall Response Rate	36	36																																									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Gefitinib		Unknown	NCT03399669		ECD	2018Jun30	Yes	Yes		1	30268476	Previously-treated		Progression free survival	49	49											27.7			21.6-33.9																											No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Gefitinib		Withdrawn	NCT02347839	NEGOTIATE	ECD	2025Jan01	Yes	No		4	NCT02347839			Resection rate, surgery rate	0	0																																									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Gefitinib		Completed	NCT01933347	CTONG1304	PCD	2017Apr10	Yes	Yes	SAE 16.28%	1	30950859	Previously-treated		Disease control rate, Clinical benefit rate	43	43			4.7		0.78-13.06						4.4			3.2-4.8							69.8			10.3			5.8-15.4														No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Afatinib		Completed	JRCT031180136	NEJ027	PCD	2019Dec23	Yes	Yes		2	10.1186/s12885-021-07861-1	Untreated	Geriatric	Overall Response Rate	37	37			75.7		58.8-88.2						14.2			9.5-19.0										35.2			35.2-														No	COSO29915674	2022Feb15
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Erlotinib		Completed	NCT01024413		PCD	2015Jun01	Yes	Yes	Primary outcome not met	1	28103612			Progression free survival	256	128	128	Gefitinib									13	10.4	.81	0.62-1.05	0.11									22.9	20.1	.84	0.63-1.13	0.25													No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Almonertinib,HS-20117		Not yet recruiting	NCT06417008		ECD	2026Jun01	Yes	No		4	NCT06417008	Untreated 		PFS, ORR	1080			Almonertinib																																							No	COSO29915674	2024Sep02
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Datopotamab Deruxtecan,Osimertinib		Recruiting	NCT06350097	TROPION-Lung14	ECD	2028Mar21	Yes	No		4	NCT06350097	Untreated 		Progression free survival	582																																										No	COSO29915674	2025Jan21
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Carboplatin or Cisplatin,Osimertinib		Active, not recruiting	NCT04035486	FLAURA2	PCD	2023Apr03	Yes	Yes	SAE 38 v 19%	1	37937763			Progression free survival	557	279	278	Osimertinib	83	76			24	15.3			25.5	16.7	.62	0.49-0.79	<0.001																										Yes	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Almonertinib,Stereotactic body radiation therapy		Recruiting	NCT05800223		ECD	2027Dec01	Yes	No		4	NCT05800223	Untreated		Progression free survival	300			Almonertinib																																							No	COSO29915674	2024Sep02
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Almonertinib,Radiotherapy		Recruiting	NCT05768490	Early v Delayed Brain Radiotherapy	ECD	2028Dec31	Yes	No		4	NCT05768490			Overall survival	232			Almonertinib,Radiotherapy																																							No	COSO29915674	2024Sep02
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Amivantamab,Carboplatin,Lazertinib,Pemetrexed		Active, not recruiting	NCT04988295	MARIPOSA-2	PCD	2023Jul10	Yes	Yes		2	10.1016/j.annonc.2023.10.117			Progression free survival	526	263	263	Carboplatin,Pemetrexed	63	36		<0.001	9.4	5.6			8.3	4.2	.44	0.35-0.56	<0.001																										Yes	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	EGFR-TKI,JY025		Unknown	NCT04874844		ECD	2022Mar30	Yes	No		4	NCT04874844	Untreated		Progression free survival	420	420																																									No	COSO29915674	2023Aug31
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Almonertinib,Chemotherapy		Active, not recruiting	NCT04923906		PCD	2024Jun18	Yes	No		4	NCT04923906	Untreated		Progression free survival	624			Chemotherapy,Placebo																																							No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Gefitinib or Erlotinib,Niacinamaide		Unknown	NCT02416739		ECD	2020Mar01	Yes	Yes		1	38593249			Progression free survival	110	55	55	Gefitinib,Placebo									12.7	10.9			0.2									31.0	29.4			0.2													No	COSO29915674	2024May15
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Lazertinib,Placebo		Active, not recruiting	NCT04487080	MARIPOSA	PCD	2023Aug11	Yes	No		4	NCT04487080	Untreated		Progression free survival	1074	1074																																									No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Amivantamab,Lazertinib		Active, not recruiting	NCT05388669	PALOMA-3 - subcutaneous v intravenous group	PCD	2024Jan03	Yes	Yes		1	38857463	Previously-treated		PFS, ORR	418	206	212	Amivantamab,Lazertinib	30	33							6.1	4.3														.62	0.42-0.92	0.02													No	COSO29915674	2024Dec18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Almonertinib,Carboplatin,Pemetrexed		Unknown	NCT04500717	ACROSS2	ECD	2022Oct01	Yes	No		4	NCT04500717			Progression free survival	460			Almonertinib																																							No	COSO29915674	2024Sep02
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Almonertinib,Carboplatin,Pemetrexed		Unknown	NCT04500704	ACROSS1	ECD	2021Dec01	Yes	No		4	NCT04500704			Progression free survival	166			Almonertinib																																							No	COSO29915674	2024Sep02
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Icotinib,Stereotactic radiotherapy		Unknown	NCT04058704	SMART	ECD	2022Dec31	Yes	No		4	NCT04058704			Overall survival	296			Icotinib																																							No	COSO29915674	2023Apr04
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Anlotinib,Gefitinib		Unknown	NCT04028778	FL-ALTER	ECD	2020Dec01	Yes	Yes		2	10.1016/j.annonc.2022.10.352			Progression free survival	315	157	158	Gefitinib,Placebo	76.13	64.52			12.48	9.46		0.0003	14.75	11.2	.64		0.0035																										Yes	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Befotertinib		Recruiting	NCT06041776		ECD	2028Apr30	Yes	No		4	NCT06041776			Disease free survival, relapse free survival, regression free survival, recurrence free survival	570			Icotinib																																							No	COSO29915674	2023Nov09
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Patritumab deruxtecan		Active, not recruiting	NCT05338970	HERTHENA-Lung02	PCD	2024May31	Yes	No		4	NCT05338970	Previously-treated		Progression free survival	586			Pemetrexed,Platinum-based chemotherapy																																							No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Chemotherapy,Erlotinib	Required	Completed	NCT00883779	FASTACT-2	PCD	2014Dec01	Yes	Yes		1	23782814	Untreated		Progression free survival	97	49	48	Chemotherapy	84	15							16.8	6.9	.25	0.16-0.39	p<0.0001									31.4	20.6	.48	0.27-0.84	0.0092													Yes	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Gefitinib,Yiqi-yangyin-jiedu Decoction		Unknown	NCT02929693	SHUTCM	ECD	2019Jun01	Yes	No		4	NCT02929693			Progression free survival	198			Placebo																																							No	COSO29915674	2022May03
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Apatinib,Gefitinib		Unknown	NCT02824458		ECD	2023Dec01	Yes	Yes		1	34033974	Untreated		Progression free survival	313	157	156	Gefitinib,Placebo									13.7	10.2	.71	0.0189																											No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Bevacizumab,Osimertinib		Recruiting	NCT05104281		ECD	2023Dec31	Yes	Yes		1	37016906	Untreated		Progression free survival	52	52			75.0								17			11.46-22.54							96.2																				No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Naquotinib		Terminated	NCT02588261	SOLAR	PCD	2017Dec21	Yes	Yes	IDMC recommendation	4	NCT02588261	Untreated		Progression free survival	530	267	263	Erlotinib	33.0	47.9		1.0					9.26	9.59																													No	COSO29915674	2023Sep28
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Almonertinib		Recruiting	NCT06674343		ECD	2026Dec31	Yes	No		4	NCT06674343			Progression free survival	144	144																																									No	COSO29915674	2024Dec11
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Almonertinib		Recruiting	NCT04951635	POLESTAR	ECD	2024Jul15	Yes	Yes		2	10.1016/j.jtho.2024.09.021	Previously-treated		Progression free survival	142	92	50	Placebo									30.4	3.8	.2	0.11-0.35	<0.0001																										Yes	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Almonertinib		Unknown	NCT03849768		PCD	2021Jan15	Yes	Yes	SAE 22.0 v 21.4	1	35580297	Untreated		Progression free survival	429	214	215	Gefitinib	73.8	72.1		0.6939	18.1	8.3	0.28-0.51	<0.0001	19.3	9.9	.46	0.36-0.60	<0.0001						93.0	96.7	0.0884																		Yes	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Alflutinib		Active, not recruiting	NCT04143607		PCD	2024Mar31	Yes	No		4	NCT04143607			Progression free survival	337			Gefitinib																																							No	COSO29915674	2024Jul11
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Alflutinib		Unknown	NCT03787992	FLAG	ECD	2021Jun01	Yes	Yes		1	35662408	Untreated		Progression free survival	357	178	179	Gefitinib									20.8	11.1	.44	0.34-0.58	<0.0001																										Yes	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Zorifertinib		Completed	NCT03653546	EVEREST	PCD	2022Jul12	Yes	Yes		2	10.1200/JCO.2023.41.16_suppl.9001	Previously-treated		Progression free survival	439	220	219	Gefitinib	68.6	58.4		0.027	8.2	6.8		0.0997	9.6	6.9	.719	0.580-0.893	0.0024																										Yes	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Abivertinib		Unknown	NCT03856697		ECD	2022Mar01	Yes	No		4	NCT03856697	Untreated		Progression free survival	406			Gefitinib																																							No	COSO29915674	2024Apr17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Bevacizumab,Erlotinib		Active, not recruiting	NCT02633189	BEVERLY	ECD	2023Dec01	Yes	Yes		1	35659580	Untreated		Progression free survival	159	80	79	Erlotinib									15.4	9.6	.6	0.42-0.85	0.0039									33.3	22.8	1.38		0.132													Yes	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Bevacizumab,Erlotinib		Unknown	NCT02759614	Artemis	PCD	2018Jun01	Yes	Yes		2	10.1093/annonc/mdz260.002	Untreated		Progression free survival	311	157	154	Erlotinib	86.3	84.7		0.74					18	11.3	.55	0.41-0.75	<0.001																										Yes	COSO29915674	2024May20
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Afatinib,Cetuximab		Active, not recruiting	NCT02438722	SWOG S1403	PCD	2018Sep25	Yes	Yes	OS 2y 67 vs 70%	2	10.1093/annonc/mdy425.022	Untreated		OS, PFS	168	83	85	Afatinib	67	74							11.9	13.4	1.01	0.72-1.43	0.94																										No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Cisplatin,Gefitinib,Pemetrexed		Unknown	NCT02518802		ECD	2018Jan01	Yes	No		4	NCT02518802			Disease free survival, relapse free survival, regression free survival, recurrence free survival	220			Cisplatin,Pemetrexed																																							No	COSO29915674	2021May18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Cisplatin,Gefitinib,Pemetrexed		Unknown	NCT03381066		ECD	2022Dec01	Yes	No		4	NCT03381066			Disease free survival, relapse free survival, regression free survival, recurrence free survival	225			Cisplatin,Vinorelbine																																							No	COSO29915674	2023Apr04
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Olmutinib		Unknown		ELUXA3			Yes	No		5	https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-launches-ambitious-eluxa-trial-program-broadly-investigate	Untreated		Unknown																																											No	COSO29915674	2021May18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Nazartinib		Withdrawn	NCT03529084		ECD	2020Aug13	Yes	Yes	Changed business priorities	4	NCT03529084	Untreated		Progression free survival	0	0																																									No	COSO29915674	2024Jul17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Tesevatinib		Terminated	NCT01487174		PCD	2013Jul25	No	Yes	Slow accrual	4	NCT01487174	Previously-treated		Overall survival	8	8																																									No	COSO29915674	2022Nov29
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Osimertinib		Active, not recruiting	NCT04351555	NeoADAURA	PCD	2024Oct15	Yes	No		4	NCT04351555			Major pathologic response	358			Pemetrexed,Platinum-based chemotherapy																																							No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Osimertinib		Not yet recruiting	NCT06323148		ECD	2026Mar31	Yes	No		4	NCT06323148			Disease free survival, relapse free survival, regression free survival, recurrence free survival	226	226		Placebo																																							No	COSO29915674	2024Apr30
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Osimertinib		Active, not recruiting	NCT05120349	ADAURA2	ECD	2027Aug02	Yes	No		4	NCT05120349			Disease free survival, relapse free survival, regression free survival, recurrence free survival	385			Placebo																																							No	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Icotinib		Unknown	NCT02448797	EVIDENCE	ECD	2022Jun30	Yes	Yes		1	34280355			Disease free survival, relapse free survival, regression free survival, recurrence free survival	283	151	132																																47	22.1	.36	0.24?0.55	<0.0001				Yes	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Icotinib		Completed	NCT01040780	ICOGEN	PCD	2010Mar01	No	Yes		1	23948351	Previously-treated		Progression free survival	395	199	196	Gefitinib									4.6	3.4	.84	0.67-1.05	p=0.13																										No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Gefitinib		Unknown	UMIN000006252	IMPACT			Yes	Yes		2	10.1200/JCO.21.01729			Disease free survival, relapse free survival, regression free survival, recurrence free survival	232	116	116	Cisplatin,Vinorelbine																								1.03	0.65-1.65	0.89					35.9	25.1	.92	0.67-1.28	0.63				No	COSO29915674	2022Feb14
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Erlotinib		Completed	NCT00556712	SATURN	PCD	2010Nov01	Expression confirmed	Yes		1	20493771	Previously-treated		Progression free survival	618	307	311	Placebo									2.8	2.6	.69	0.58-0.82	p<0.0001																										Yes	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 4	Dacomitinib		Completed	NCT04511533		PCD	2022Oct15	Yes	Yes		4	NCT04511533			Maximum tolerated dose/toxicity	101	101			50.5				11.1		8.3-16.6																																No	COSO29915674	2024Apr24
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Unknown	Apatinib,Erlotinib		Unknown	NCT03634059		ECD	2019Aug15	Yes	No		4	NCT03634059	Untreated		Progression free survival	80	80																																									No	COSO29915674	2022May03
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Unknown	Osimertinib,Pemetrexed		Recruiting	NCT06304441	Group A v Group B	ECD	2025Mar01	No	No		4	NCT06304441			Response rate	100	100		Osimertinib																																							No	COSO29915674	2024Apr30
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Unknown	Almonertinib,Stereotactic body radiation therapy		Recruiting	NCT06481566		ECD	2026Jan01	Yes	No		4	NCT06481566			Progression free survival	30	30																																									No	COSO29915674	2024Oct21
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Unknown	Apatinib,Icotinib		Unknown	NCT03634059		ECD	2019Aug15	Yes	No		4	NCT03634059	Untreated		Progression free survival	80	80																																									No	COSO29915674	2022May03
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Unknown	Anlotinib,Gefitinib,Icotinib		Unknown	NCT03766490		ECD	2019Dec20	Yes	No		4	NCT03766490	Previously-treated		Progression free survival	66	66																																									No	COSO29915674	2022May03
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Unknown	Gefitinib,Radiotherapy		Not yet recruiting	NCT03381430	GRAY	ECD	2023Mar01	Yes	No		4	NCT03381430			Disease free survival, relapse free survival, regression free survival, recurrence free survival	50	50																																									No	COSO29915674	2021May18
EGFR_Exon19del or EGFR_L858R	Cluster				lung / carcinoma / squamous cell carcinoma	3	In trials	Approved FDA	Afatinib	Not required	Completed	NCT01523587	LUX-Lung 8	PCD	2013Oct21	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf	Previously-treated		Progression free survival	795	398	397	Erlotinib	3	2							2.4	1.9	.82	0.68-0.998	0.0427									7.9	6.8	.81	0.69-0.95	0.008													Yes	COSO29914830	2024Oct09
EGFR_Exon19del or EGFR_L858R and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Lazertinib,Tepotinib 		Not yet recruiting	NCT06106802		ECD	2029Sep30	Yes	No		4	NCT06106802			Overall Response Rate	47	47																																									No	COSO29915674	2024Dec18
EGFR_Exon19del or EGFR_L858R and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Osimertinib,Telisotuzumab vedotin		Withdrawn	NCT06093503		ECD	2028Apr11	Yes	No		4	NCT06093503	Previously-treated		Progression free survival	0			Carboplatin,Cisplatin,Pemetrexed																																							No	COSO29915674	2024Jul11
EGFR_Exon19del or EGFR_L858R and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Almonertinib,HS-10241		Not yet recruiting	NCT06110663		ECD	2024Dec30	Yes	No		4	NCT06110663			Progression free survival	314			Carboplatin or Cisplatin,Pemetrexed																																							No	COSO29915674	2024Sep02
EGFR_Exon19del or EGFR_L858R and MET_unspecified	Multigene				stomach / carcinoma / adenocarcinoma	3	In trials	Phase 2	Chemotherapy,Serplulimab,Trastuzumab		Recruiting	NCT05975749		ECD	2026Jan01	Expression confirmed	No		4	NCT05975749			Disease free survival, relapse free survival, regression free survival, recurrence free survival	114			Chemotherapy																																							No	COSO36004826	2024Jul04
EGFR_Exon19del or EGFR_L858R or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Observational	Alflutinib		Not yet recruiting	NCT06117644		ECD	2025Nov01	Yes	No		4	NCT06117644			Overall Response Rate	30	30																																									No	COSO29915674	2024Apr23
EGFR_Exon19del or EGFR_L858R or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Almonertinib		Recruiting	NCT05826483		ECD	2024Dec28	Yes	No		4	NCT05826483	Untreated		Overall Response Rate	20	20																																									No	COSO29915674	2024Sep02
EGFR_Exon19del or EGFR_L858R or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Alflutinib		Recruiting	NCT06394674		ECD	2025Jun01	Yes	No		4	NCT06394674	Previously-treated		Overall Response Rate	84	84																																									No	COSO29915674	2024Jun12
EGFR_Exon19del or EGFR_L858R or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Cisplatin or Carboplatin,Osimertinib,Pemetrexed or Paclitaxel,Radiotherapy		Recruiting	NCT06194448	NEOLA	ECD	2027Apr28	Yes	No		4	NCT06194448	Previously-treated		Progression free survival	70	70																																									No	COSO29915674	2024Jul11
EGFR_Exon19del or EGFR_L858R or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Pemetrexed,Platinum-based chemotherapy,Sunvozertinib		Recruiting	NCT06195189	WU-KONG36	ECD	2025Dec01	Yes	No		4	NCT06195189	Previously-treated		Overall Response Rate	40	40																																									No	COSO29915674	2024Apr30
EGFR_Exon19del or EGFR_L858R or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Anlotinib,Sunvozertinib		Not yet recruiting	NCT06182761	WUKONG-9	ECD	2026Jan01	Yes	No		4	NCT06182761	Previously-treated		Overall Response Rate	45	45																																									No	COSO29915674	2024Apr30
EGFR_Exon19del or EGFR_L858R or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Almonertinib,Chemotherapy		Unknown	NCT04952168		ECD	2022Jun02	Yes	No		4	NCT04952168			Overall survival	26	26																																									No	COSO29915674	2024Sep02
EGFR_Exon19del or EGFR_L858R or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Almonertinib,Chemotherapy		Unknown	NCT04905550		ECD	2024Mar01	Yes	No		4	NCT04905550			Progression free survival	50	50																																									No	COSO29915674	2024Oct17
EGFR_Exon19del or EGFR_L858R or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Local Consolidation Therapy,Osimertinib		Active, not recruiting	NCT03410043		ECD	2025Jun01	Yes	Yes	Manageable toxicity	2	10.1016/S1556-0864(23)00256-3	Untreated		Progression free survival	122	59	63	Osimertinib																																							No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Afatinib,Cetuximab		Active, not recruiting	NCT02438722	SWOG S1403	PCD	2018Sep25	Yes	Yes	OS 2y 67 vs 70%	2	10.1093/annonc/mdy425.022	Untreated		OS, PFS	168	83	85	Afatinib	67	74							11.9	13.4	1.01	0.72-1.43	0.94																										No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Almonertinib		Active, not recruiting	NCT04687241		PCD	2024Jul08	Yes	No		4	NCT04687241	Untreated		Disease free survival, relapse free survival, regression free survival, recurrence free survival	192			Almonertinib,Placebo																																							No	COSO29915674	2025Jan08
EGFR_Exon19del or EGFR_L858R or ESR1_unspecified or PGR_unspecified or (ESR1_unspecified and PGR_unspecified) (HR+)	Set				NS / other / neoplasm	3	In trials	Phase 1	YL202		Recruiting	NCT05653752		ECD	2025Dec01	Yes	Yes	PFS 6m 61.6%	2	10.1200/JCO.2024.42.16_suppl.3034			Maximum tolerated dose/toxicity	46	46			37				8.4														93.5									1	16	26									No	COSO31314888	2025Jan08
EGFR_Exon19del or Exon20ins or EGFR_G719 or EGFR_L858R or EGFR_L861 or EGFR_S768I or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Bintrafusp alfa,Carboplatin,Cisplatin,Pemetrexed		Terminated	NCT04971187		PCD	2022Feb21	Yes	Yes	PI requested termination 	4	NCT04971187	Previously-treated		Progression free survival	3	3																																									No	COSO29915674	2022Dec02
EGFR_Exon19del or Exon20ins or EGFR_G719 or EGFR_L858R or EGFR_L861 or EGFR_S768I or EGFR_T790M	Cluster				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Almonertinib,Carboplatin,Nab-paclitaxel		Recruiting	NCT06300424	NEOVADE	ECD	2026Mar01	Yes	No		4	NCT06300424			Major pathologic response	32	32																																									No	COSO29915674	2024Sep02
EGFR_Exon2-7del (EGFRvIII)	Exon				central nervous system / glioma / NS	3	In trials	Phase 1	BRiTE		Not yet recruiting	NCT04903795		ECD	2026Dec01	Yes	No		4	NCT04903795			Maximum tolerated dose/toxicity	18	18																																									No	COSO28245257	2024Jul11
EGFR_Exon2-7del (EGFRvIII)	Exon				central nervous system / glioma / NS	3	In trials	Phase 1	BRiTE,CAR T-cell therapy		Not yet recruiting	NCT04903795		ECD	2026Dec01	Yes	No		4	NCT04903795			Maximum tolerated dose/toxicity	18	18																																									No	COSO28245257	2024Aug01
EGFR_Exon20ins or ERBB2_Exon20ins	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Mobocertinib		Active, not recruiting	NCT02716116	Expansion Cohort 3	ECD	2025Mar28	Yes	No		4	NCT02716116			Overall Response Rate	395	395																																									No	COSO29915674	2025Jan08
EGFR_Exon20ins or ERBB2_Exon20ins	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	STX-721		Recruiting	NCT06043817		ECD	2027Jun01	Yes	No		4	NCT06043817			Overall Response Rate	120	120																																									No	COSO29915674	2023Nov09
EGFR_Exon_19ins	Exon				lung / carcinoma / non small cell carcinoma	4	Pre clinical drug/Case studies	Case study	Gefitinib		Unknown					Yes	Yes		1	29483495			Unknown	1	1																															1										No	COSO29915674	2021May18
EGFR_Exon_19ins or EGFR_G719A or EGFR_G719C or EGFR_G719D or EGFR_G719S or EGFR_L861Q or EGFR_S786I	Set	COSV51766344,COSV51766606,COSV51788343,COSV51767289,COSV51769339,COSV51779524		p.G719A,p.G719C,p.G719D,p.G719S,p.L861Q	NS / other / neoplasm	3	In trials	Phase 2	Osimertinib		Active, not recruiting	NCT06303167	MATCH-Subprotocol E	PCD	2023Feb26	Yes	Yes	PFS 6m 16.7%, Osimertinib well-tolerated, Primary outcome not met 	1	38591867			Overall Response Rate	13	13			15.4		2.8-41.0																																				No	COSO31314888	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved FDA	Amivantamab,Carboplatin,Pemetrexed	Required	Active, not recruiting	NCT04538664	PAPILLON	PCD	2023May03	Yes	Yes	SAE 37 v 31%	7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s003lbl.pdf	Untreated		Progression free survival	308	153	155	Carboplatin,Pemetrexed	67	36			10.1	5.6			11.4	6.7	.4	0.30-0.53	<0.0001																										Yes	COSO29915674	2024Mar07
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved FDA	Amivantamab	Not required	Active, not recruiting	NCT02609776		PCD	2024Jan31	Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761210s003lbl.pdf	Previously-treated		Overall Response Rate	81	81			40		29-51		11.1		6.9-																					3	29										No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved other	Sunvozertinib	Not required	Active, not recruiting	NCT05712902	WO-KONH6	PCD	2022Oct17	Yes	Yes		5	https://www.dizalpharma.com/news/detail?id=59			Overall Response Rate	97	97			60.8		50.4-70.6	<0.0001															87.6																				Yes	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved other	Sunvozertinib	Required	Unknown		WU-KONG6			Yes	Yes		3	https://www.precisionmedicineonline.com/regulatory-news-fda-approvals/dizal-egfr-inhibitor-nets-approval-china-nsclc-patients-egfr-exon-20?utm_source=Sailthru&utm_medium=email&utm_campaign=PON%20Daily%20Wednesday%202023-08-23&utm_term=PON%20Weekly	Previously-treated		Overall Response Rate	97	97			60.8																																						No	COSO29915674	2024May29
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Case study	Erlotinib		Unknown					Yes	Yes		1	24353160			Unknown	3																																2	1									No	COSO29915674	2021May18
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Case study	Icotinib		Unknown					Yes	Yes		3	https://www.jto.org/article/S1556-0864(17)32886-1/fulltext			Unknown	18				33.3	0							9	1.2			p<0.001						100	16.2																			No	COSO29915674	2021May18
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Alflutinib		Unknown	NCT04858958	FAVOUR1 treatment-naive	ECD	2023Mar01	Yes	Yes		2	10.1016/j.jtho.2023.09.033	Untreated		Overall Response Rate	30	30			69		49.2-84.7						10.7										96.6										7	3									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	ABSK112		Recruiting	NCT06225804		ECD	2027Mar01	Yes	No		4	NCT06225804			Maximum tolerated dose/toxicity	164	164																																									No	COSO29915674	2024Apr30
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	BEBT-109		Completed	NCT06001671		PCD	2023Mar01	Yes	No		4	NCT06001671	Previously-treated		Maximum tolerated dose/toxicity	23	23																																									No	COSO29915674	2024Dec11
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	HS-20117		Not yet recruiting	NCT05940116		ECD	2025Jul30	Yes	No		4	NCT05940116			Overall Response Rate	322	322																																									No	COSO29915674	2023Sep25
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Andamertinib		Active, not recruiting	NCT05347628		PCD	2023Apr04	Yes	Yes	Manageable toxicity	2	10.1158/1538-7445.AM2023-CT102			Maximum tolerated dose/toxicity	26	26			57.7																		100																				No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Andamertinib		Recruiting	NCT06046495		ECD	2028Feb09	Yes	No		4	NCT06046495			Maximum tolerated dose/toxicity	81	81																																									No	COSO29915674	2024Oct17
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	BLU-451		Active, not recruiting	NCT05241873		PCD	2024Jul31	Yes	Yes	Promising activity 	2	10.1200/JCO.2023.41.16_suppl.9064	Previously-treated		Overall Response Rate	19	19																																									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Bevacizumab,Chemotherapy,Pembrolizumab		Recruiting	NCT05751187		ECD	2026Mar30	Yes	No		4	NCT05751187			Overall Response Rate	54	54																																									No	COSO29915674	2023Aug31
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Becotatug		Unknown	NCT04448379		ECD	2021Dec31	Yes	Yes		1	37308490			Maximum tolerated dose/toxicity	121	121			36.4		27.8-45.6						8.2			6.8-9.5							95.0																				No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Sunvozertinib		Unknown					Yes	Yes		1	35404393			Overall Response Rate	56	56			37.5																																						No	COSO29915674	2024Apr25
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Necitumumab,Osimertinib		Active, not recruiting	NCT02496663		ECD	2025Jun30	Yes	Yes		2	10.1200/JCO.2022.40.16_suppl.901	Previously-treated		Maximum tolerated dose/toxicity	18	18											6.9			4.1-11.4																	4										No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Alflutinib		Unknown	NCT04858958	FAVOUR1 240mg/day	ECD	2023Mar01	Yes	Yes		2	10.1016/j.jtho.2023.09.033	Previously-treated		Overall Response Rate	24	24			50.0		28.2-71.8						7										95.5																				No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Alflutinib		Unknown	NCT04858958	FAVOUR1 160mg/day	ECD	2023Mar01	Yes	Yes		2	10.1016/j.jtho.2023.09.033	Previously-treated		Overall Response Rate	25	25			40.9		20.7-63.7						5.8										90.9																				No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Alflutinib		Withdrawn	NCT04958967	FAVOUR1	ECD	2022May01	Yes	Yes	No patients recruited	4	NCT04958967			Overall Response Rate	0	0																																									No	COSO29915674	2024Apr29
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Afatinib		Completed	NCT02369484	NICHE	PCD	2017Sep15	Yes	Yes		1	30825613			Disease control rate, Clinical benefit rate	13	13			7.7								3.67			1.38-8.17							53.8			12.93							1	6									No	COSO29915674	2024May14
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	BEBT-109,Carboplatin or Cisplatin,Pemetrexed		Not yet recruiting	NCT06514027	Cohort 1	ECD	2027Jun01	Yes	No		4	NCT06514027			MTD, ORR, Toxicity	30	30																																									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	BEBT-109		Recruiting	NCT06706713		ECD	2025Dec31	Yes	No		4	NCT06706713	Previously-treated		PFS, ORR	200	200																																									No	COSO29915674	2025Jan07
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	BEBT-109		Not yet recruiting	NCT06514027	Cohort 2	ECD	2027Jun01	Yes	No		4	NCT06514027			MTD, ORR, Toxicity	30	30																																									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	YK-029A		Recruiting	NCT05767866		ECD	2023Dec30	Yes	Yes		1	37776953	Untreated		Overall Response Rate	26	26			73.1		52.21-88.43		7.5		3.75-		9.3			5.85-							92.3																				No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	YK-029A		Recruiting	NCT05767866		ECD	2023Dec30	Yes	No		4	NCT05767866	Previously-treated		Overall Response Rate	160	160																																									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	HS-10376		Recruiting	NCT05435274		ECD	2024Oct07	Yes	No		4	NCT05435274			Overall Response Rate	380	380																																									No	COSO29915674	2023Sep25
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Andamertinib		Recruiting	NCT06015503	Kannon	ECD	2024Oct30	Yes	No		4	NCT06015503			Overall Response Rate	157	157																																									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Becotatug,Osimertinib		Unknown	NCT05132777	BECOME	ECD	2023Sep30	Yes	Yes	IORR 43% 95%CI 28-59	2	10.1016/j.esmoop.2024.102724	Previously-treated		Overall Response Rate	112	112			50		40-60																80																				No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Carboplatin,Mobocertinib,Pemetrexed		Active, not recruiting	NCT02716116		ECD	2025Mar28	Yes	No		4	NCT02716116			Overall Response Rate	395	395																																									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Poziotinib,Ramucirumab		Withdrawn	NCT05045404		PCD	2023Feb02	Yes	Yes	Lack of funding	4	NCT05045404			Progression free survival	0	0																																									No	COSO29915674	2023May03
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	MCLA-129		Recruiting	NCT04930432	Cohort B - 2000mg  - Prior PBCT	ECD	2028Apr30	Yes	Yes		2	10.1200/JCO.2024.42.16_suppl.8604	Previously-treated		Overall Response Rate	7	7			57.1		18.4-90.1																100																				No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	MCLA-129		Recruiting	NCT04930432	Cohort B - 1500mg - Prior PBCT	ECD	2028Apr30	Yes	Yes		2	10.1200/JCO.2024.42.16_suppl.8604	Previously-treated		Overall Response Rate	38	38			28.9		15.4-45.9		6.9														81.6																				No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	MCLA-129		Recruiting	NCT04930432	Cohort B - 2000mg 	ECD	2028Apr30	Yes	Yes		2	10.1200/JCO.2024.42.16_suppl.8604			Overall Response Rate	9	9			55.6		21.2-86.3																88.9																				No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	MCLA-129		Recruiting	NCT04930432	Cohort B - 1500mg 	ECD	2028Apr30	Expression confirmed	Yes		2	10.1200/JCO.2024.42.16_suppl.8604			Overall Response Rate	63	63			28.6		17.9-41.3		7.2		4.2-												84.1																				No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Amivantamab,Carboplatin,Pemetrexed		Recruiting	NCT05498428	PALOMA-2 Cohort 2	ECD	2025Oct31	Yes	No		4	NCT05498428	Untreated		Overall Response Rate	390	390																																									No	COSO29915674	2024Jul11
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Pyrotinib		Unknown	ChiCTR1800020262				Yes	Yes		1	35101045				62	62			17.7		9.2-29.5																																				No	COSO29915674	2022Sep21
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Pyrotinib		Unknown	NCT04063462	PEER20	ECD	2021Apr01	Yes	No		4	NCT04063462	Previously-treated		Overall Response Rate	60	60																																									No	COSO29915674	2022May19
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Tarloxotinib		Terminated	NCT03805841	RAIN cohort A	PCD	2021Apr09	Yes	Yes		4	NCT03805841			Overall Response Rate	11	11																					55											6									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Zipalertinib		Active, not recruiting	NCT05967689	REZILIENT2 Cohort B	ECD	2025Jun30	Yes	No		4	NCT05967689	Untreated		Overall Response Rate	160	160																																									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Zipalertinib		Active, not recruiting	NCT05967689	REZILIENT2 Cohort A	ECD	2025Jun30	Yes	No		4	NCT05967689	Previously-treated		Overall Response Rate	160	160																																									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Zipalertinib		Active, not recruiting	NCT04036682		ECD	2024Dec01	Yes	Yes		2	10.1200/JCO.2021.39.15_suppl.9077	Previously-treated		Overall Response Rate	25	25			40																												10	14									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Sunvozertinib		Recruiting	NCT06563999		ECD	2027Nov01	Yes	No		4	NCT06563999	Untreated 		Resection rate, surgery rate	120	120																																									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Sunvozertinib		Active, not recruiting	NCT03974022	WU-KONG1b	PCD	2024Jul29	Yes	Yes	Primary outcome met	2	10.1200/JCO.2024.42.16_suppl.8513	Previously-treated		Overall Response Rate					54.3																		90.8																				Yes	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Sunvozertinib		Unknown					Yes	Yes		2	10.1200/JCO.2023.41.16_suppl.9073	Untreated		Overall Response Rate	26	26			73.1																																						No	COSO29915674	2024Apr25
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Sunvozertinib		Active, not recruiting	NCT03974022	WU-KONG1	PCD	2024Jul29	Yes	Yes		2	10.1200/JCO.2023.41.16_suppl.9073	Untreated		Overall Response Rate	26	26			73.1																																						No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Mobocertinib	Required	Active, not recruiting	NCT02716116		ECD	2025Mar28	Yes	Yes		1	33632775	Previously-treated		Overall Response Rate	28	28			43		24-63		14		5.0-		7.3			4.4-15.6																											No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Mobocertinib		Active, not recruiting	NCT02716116	Expansion Cohort 2	ECD	2025Mar28	Yes	No		4	NCT02716116			Overall Response Rate	395	395																																									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Mobocertinib		Active, not recruiting	NCT02716116		ECD	2025Mar28	Yes	Yes	Withdrawn due to failed confirmatory trial NCT04129502	7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf			Overall Response Rate	114	114			28		20-37		17.5		7.4-20.3																																No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Mobocertinib		Withdrawn	NCT04576208		ECD	2022Jul31	Yes	Yes	Changed business priorities	4	NCT04576208			Maximum tolerated dose/toxicity	0	0																																									No	COSO29915674	2023May02
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Anlotinib,Sintilimab		Completed	NCT04790409		PCD	2023Sep13	Yes	Yes		1	37723837			Progression free survival	12	12			41.7								4.3																														No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Pirotinib		Unknown	NCT03574402	CTONG1702 Arm 9	ECD	2022Dec30	Yes	No		4	NCT03574402			Overall Response Rate	400	400																																									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Luminespib		Completed	NCT01922583		PCD	2017Feb01	Yes	No		4	NCT01922583	Previously-treated		Overall Response Rate	31	31																																									No	COSO29915674	2021Oct08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Alflutinib		Recruiting	NCT06192849		ECD	2026Dec01	Yes	No		4	NCT06192849			Disease free survival, relapse free survival, regression free survival, recurrence free survival	20	20																																									No	COSO29915674	2024Apr30
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Alflutinib		Recruiting	NCT05466149		ECD	2024Apr01	Yes	No		4	NCT05466149			Overall Response Rate	100	100																																									No	COSO29915674	2024Apr23
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Afatinib,Cetuximab		Completed	NCT03727724	AFACET	PCD	2022Sep06	Yes	Yes	Primary outcome met	2	10.1200/JCO.2021.39.15_suppl.9112			Disease control rate, Clinical benefit rate	37	37			47								5.5																				8	7									Yes	COSO29915674	2024Jan04
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Erlotinib,Onalespib lactate		Active, not recruiting	NCT02535338	Cohort B	PCD	2021Sep03	Yes	Yes		1	34140248	Previously-treated		Maximum tolerated dose/toxicity	10	10			0								5.4										40																				No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Poziotinib		Terminated	NCT03318939	ZENITH20-C3	PCD	2023Apr03	Yes	Yes	IORR 8.3%	2	10.1200/JCO.2021.39.15_suppl.909	Untreated			12	12																																									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Poziotinib		Terminated	NCT03318939	ZENITH20-C3	PCD	2023Apr03	Yes	Yes		3	10.1016/j.annonc.2021.01.051	Untreated		Overall Response Rate	79	79			27.8		18.4-39.1		6.5				7.2										86.1																				No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Poziotinib		Terminated	NCT04402008	SPI-POZ-104	PCD	2023Feb15	Yes	Yes	Changed business priorities	4	NCT04402008			Overall Response Rate	19	19																																									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Poziotinib		Terminated	NCT04044170		PCD	2020Apr13	Yes	No		4	NCT04044170			Overall Response Rate	5	5																																									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Poziotinib		Active, not recruiting	NCT03066206	2016-0783	ECD	2025Dec31	Yes	Yes		1	35820397			Overall Response Rate	42	42			31		19.1-46.0																76.0										13	19									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Recruiting	NCT03191149		ECD	2025Jun30	Yes	No		4	NCT03191149	Previously-treated		Overall Response Rate	46	46																																									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Completed	NCT03414814		PCD	2021Aug03	Yes	Yes		2	10.1093/annonc/mdz260.051	Previously-treated		Overall Response Rate	3	3			0																													3									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Poziotinib		Suspended	NCT05378763	PINNACLE	ECD	2027Dec25	Yes	No		4	NCT05378763			Progression free survival	268			Docetaxel																																							No	COSO29915674	2023Apr04
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Carboplatin or Cisplatin,Pemetrexed,Zipalertinib		Recruiting	NCT05973773	REZILIENT3	ECD	2026Jul27	Yes	No		4	NCT05973773			Progression free survival	272	272																																									No	COSO29915674	2024Jul11
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	YK-029A		Not yet recruiting	NCT05767892		ECD	2025Jul30	Yes	No		4	NCT05767892	Untreated		Progression free survival	350			Carboplatin or Cisplatin,Pemetrexed																																							No	COSO29915674	2023Sep26
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Becotatug,Osimertinib		Not yet recruiting	NCT06380348		ECD	2027Mar26	Yes	No		4	NCT06380348	Untreated 		Progression free survival	398	398		Cisplatin,Pemetrexed																																							No	COSO29915674	2024Nov13
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Pyrotinib		Active, not recruiting	NCT04447118	PYRAMID-1	ECD	2023Jun30	Yes	No		4	NCT04447118	Previously-treated		Progression free survival	151			Docetaxel																																							No	COSO29915674	2023Apr04
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Sunvozertinib		Recruiting	NCT05668988		ECD	2026Feb28	Yes	No		4	NCT05668988	Untreated		Progression free survival	320			Platinum-based chemotherapy																																							No	COSO29915674	2024Apr25
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Mobocertinib		Active, not recruiting	NCT04129502	EXCLAIM-2	ECD	2024Dec30	Yes	Yes	Primary outcome not met	5	https://www.takeda.com/newsroom/newsreleases/2023/Takeda-Provides-Update-on-EXKIVITY-mobocertinib/			Progression free survival	354			Carboplatin,Pemetrexed																																							No	COSO29915674	2024Jul11
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Entrectinib		Active, not recruiting	NCT03178552	B-FAST Cohort F	ECD	2028Aug03	Yes	No		4	NCT03178552			Overall Response Rate	700	700																																									No	COSO29915674	2025Jan08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Alflutinib		Recruiting	NCT05607550		ECD	2025Aug15	Yes	No		4	NCT05607550	Untreated		Progression free survival	375			Platinum-based chemotherapy																																							No	COSO29915674	2024Apr23
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 4	Osimertinib		Unknown	NCT05513664		ECD	2023Jun01	Yes	No		4	NCT05513664			Overall Response Rate	80	80																																									No	COSO29915674	2024Jul11
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Retrospective/Meta-analysis	Poziotinib		Unknown					Yes	Yes		1	36343036			Overall Response Rate	126	126			27		19-35																72																				No	COSO29915674	2023Sep08
EGFR_Exon_20ins	Exon				lung / carcinoma / non small cell carcinoma	1	Marketed drug	Unknown	Sunvozertinib		Recruiting	NCT05559645	WU-KONG15	ECD	2025Dec31	Yes	Yes	Promising activity 	2	10.1200/JCO.2023.41.16_suppl.9073	Previously-treated		Progression free survival	26	26			 73.1																											14											No	COSO29915674	2025Jan08
EGFR_Exon_20ins and ERBB2_unspecified 	Multigene				NS / other / neoplasm	3	In trials	Phase 2	YH42946		Recruiting	NCT06616766		ECD	2028Mar15	Yes	No		4	NCT06616766			MTD, ORR, Toxicity	161	161																																									No	COSO31314888	2025Jan08
EGFR_G719	Colocated	COSV51766606,COSV51788343,COSV51767289,COSV51769339,COSV51779524		p.G719A,p.G719C,p.G719D,p.G719S,p.G719V	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved FDA	Afatinib	Required	Unknown		Afatinib FDA			Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf			Not defined	8	8			75				17.3																																		No	COSO29915674	2023Jan23
EGFR_G719	Colocated	COSV51766606,COSV51788343,COSV51767289,COSV51769339,COSV51779524		p.G719A,p.G719C,p.G719D,p.G719S,p.G719V	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Case study	Gefitinib		Unknown					Yes	Yes		1	28184913			Unknown					50																										50												No	COSO29915674	2024Jul31
EGFR_G719	Colocated	COSV51766606,COSV51788343,COSV51767289,COSV51769339,COSV51779524		p.G719A,p.G719C,p.G719D,p.G719S,p.G719V	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Case study	Gefitinib		Unknown					Yes	Yes		1	15118073			Unknown	1	1																															1										No	COSO29915674	2021May18
EGFR_G719	Colocated	COSV51766606,COSV51788343,COSV51767289,COSV51769339,COSV51779524		p.G719A,p.G719C,p.G719D,p.G719S,p.G719V	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Unknown	NCT03424759		PCD	2017Dec31	Yes	Yes		1	31825714			Overall Response Rate	19	19			53		28-77						8.2			6.2-10.2																											No	COSO29915674	2025Jan08
EGFR_G719	Colocated	COSV51766606,COSV51788343,COSV51767289,COSV51769339,COSV51779524		p.G719A,p.G719C,p.G719D,p.G719S,p.G719V	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Neratinib		Completed	NCT00266877		PCD	2009Jan01	Yes	Yes		1	20479403			Overall Response Rate	4	4																															3										No	COSO29915674	2025Jan08
EGFR_G719	Colocated	COSV51766606,COSV51788343,COSV51767289,COSV51769339,COSV51779524		p.G719A,p.G719C,p.G719D,p.G719S,p.G719V	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Afatinib		Completed					Yes	Yes		1	26051236			Unknown	18	18			77.8																																						No	COSO29915674	2021May18
EGFR_G719	Colocated	COSV51766606,COSV51788343,COSV51767289,COSV51769339,COSV51779524		p.G719A,p.G719C,p.G719D,p.G719S,p.G719V	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Retrospective/Meta-analysis	Afatinib		Unknown					Yes	Yes		1	34540680				82	82			52.4								11.3			5.6-17.0																											No	COSO29915674	2021Nov23
EGFR_G719 or EGFR_L861Q or EGFR_S768I	Cluster	COSV51766344,COSV51766606,COSV51788343,COSV51767289,COSV51768106,COSV51769339,COSV51779524		p.G719A,p.G719C,p.G719D,p.G719S,p.G719V,p.L861Q,p.S768I	NS / other / neoplasm	3	In trials	Phase 2	Afatinib		Active, not recruiting	NCT06385483	MATCH - Subprotocol A	PCD	2022Dec06	Yes	Yes	PFS 6m 15%, Primaary outcome not met 	2	10.1200/PO.23.00725	Previously-treated		Overall Response Rate	17	17			11.8																					9						1	1	3									No	COSO31314888	2025Jan08
EGFR_G719 or EGFR_L861Q or EGFR_S768I	Cluster	COSV51766344,COSV51766606,COSV51788343,COSV51767289,COSV51768106,COSV51769339,COSV51779524		p.G719A,p.G719C,p.G719D,p.G719S,p.G719V,p.L861Q,p.S768I	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Osimertinib		Completed	NCT03434418		PCD	2022Oct12	Yes	Yes		2	10.1016/j.esmoop.2023.101183	Untreated		Overall Response Rate	17	17			47		23-72						10.5			5.0-15.2										13.8			7.3-29.2				8	8									No	COSO29915674	2023Apr27
EGFR_G719 or EGFR_L861Q or EGFR_S768I	Cluster	COSV51766344,COSV51766606,COSV51788343,COSV51767289,COSV51768106,COSV51769339,COSV51779524		p.G719A,p.G719C,p.G719D,p.G719S,p.G719V,p.L861Q,p.S768I	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	YK-029A		Recruiting	NCT05767866		ECD	2023Dec30	Yes	No		4	NCT05767866	Previously-treated		Overall Response Rate	160	160																																									No	COSO29915674	2025Jan08
EGFR_G719 or EGFR_L861Q or EGFR_S768I	Cluster	COSV51766344,COSV51766606,COSV51788343,COSV51767289,COSV51768106,COSV51769339,COSV51779524		p.G719A,p.G719C,p.G719D,p.G719S,p.G719V,p.L861Q,p.S768I	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Afatinib,Bevacizumab		Recruiting	NCT05267288		ECD	2024Dec01	Yes	No		4	NCT05267288			Progression free survival	30	30																																									No	COSO29915674	2023Apr04
EGFR_G719 or EGFR_L861Q or EGFR_S768I	Cluster	COSV51766344,COSV51766606,COSV51788343,COSV51767289,COSV51768106,COSV51769339,COSV51779524		p.G719A,p.G719C,p.G719D,p.G719S,p.G719V,p.L861Q,p.S768I	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Sutetinib		Recruiting	NCT05168566		ECD	2024Aug01	Yes	No		4	NCT05168566			Overall Response Rate	99	99																																									No	COSO29915674	2023Apr04
EGFR_G719 or EGFR_L861Q or EGFR_S768I	Cluster	COSV51766344,COSV51766606,COSV51788343,COSV51767289,COSV51768106,COSV51769339,COSV51779524		p.G719A,p.G719C,p.G719D,p.G719S,p.G719V,p.L861Q,p.S768I	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Osimertinib,Pemetrexed,Platinum-based chemotherapy		Terminated	NCT05215951	MINOVA	PCD	2023Mar09	Yes	Yes	Slow accrual	4	NCT05215951			Overall Response Rate	5	5																																									No	COSO29915674	2023Sep18
EGFR_G719 or EGFR_L861Q or EGFR_S768I	Cluster	COSV51766344,COSV51766606,COSV51788343,COSV51767289,COSV51768106,COSV51769339,COSV51779524		p.G719A,p.G719C,p.G719D,p.G719S,p.G719V,p.L861Q,p.S768I	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Alflutinib		Recruiting	NCT05548348		ECD	2023Dec31	Yes	No		4	NCT05548348			Overall Response Rate	30	30																																									No	COSO29915674	2024Apr23
EGFR_G719 or EGFR_L861Q or EGFR_S768I	Cluster	COSV51766344,COSV51766606,COSV51788343,COSV51767289,COSV51768106,COSV51769339,COSV51779524		p.G719A,p.G719C,p.G719D,p.G719S,p.G719V,p.L861Q,p.S768I	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Osimertinib		Active, not recruiting	NCT05546866		ECD	2029Jun30	Yes	No		4	NCT05546866			Disease free survival, relapse free survival, regression free survival, recurrence free survival	51	51																																									No	COSO29915674	2024Oct17
EGFR_G719 or EGFR_L861Q or EGFR_S768I	Cluster	COSV51766344,COSV51766606,COSV51788343,COSV51767289,COSV51768106,COSV51769339,COSV51779524		p.G719A,p.G719C,p.G719D,p.G719S,p.G719V,p.L861Q,p.S768I	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Osimertinib		Unknown	NCT03424759		PCD	2017Dec31	Yes	Yes	OS 18m 56% 95%CI 39-73	1	31825714			Overall Response Rate	36	36			50		33-67		11.2		7.7-14.7		8.2			5.9-10.5							89										18	14									No	COSO29915674	2025Jan08
EGFR_G719 or EGFR_L861Q or EGFR_S768I	Cluster	COSV51766344,COSV51766606,COSV51788343,COSV51767289,COSV51768106,COSV51769339,COSV51779524		p.G719A,p.G719C,p.G719D,p.G719S,p.G719V,p.L861Q,p.S768I	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Almonertinib		Unknown	NCT04951648		ECD	2023Oct04	Yes	No		4	NCT04951648	Untreated		Progression free survival	220			Chemotherapy																																							No	COSO29915674	2024Oct17
EGFR_G719 or EGFR_L861Q or EGFR_S768I	Cluster	COSV51766344,COSV51766606,COSV51788343,COSV51767289,COSV51768106,COSV51769339,COSV51779524		p.G719A,p.G719C,p.G719D,p.G719S,p.G719V,p.L861Q,p.S768I	lung / carcinoma / non small cell carcinoma	3	In trials	Retrospective/Meta-analysis	Osimertinib		Unknown					Yes	Yes		1	35832438			Overall Response Rate	21	21			47.6				7.9				5.5										85.7																				No	COSO29915674	2023Apr28
EGFR_G719X or EGFR_L861Q or EGFR_S768I	Set	COSV51766344,COSV51768106		p.G719X,p.L861Q,p.S768I	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Befotertinib,Icotinib		Recruiting	NCT06517953	IcomBine	ECD	2026Jul30	Yes	No		4	NCT06517953			Overall Response Rate	23	23																																									No	COSO29915674	2024Oct21
EGFR_Glu746_Ala750_deletion	Point	COSV51765066,COSV51765119,COSV51788765		p.E746_A750del	NS / carcinoma / adenocarcinoma	4	Pre clinical drug/Case studies	Case study	Afatinib		Active, not recruiting	NCT06385483	MATCH - Subprotocol A Responder	PCD	2022Dec06	Yes	Yes		2	10.1200/PO.23.00725			Overall Response Rate	1	1			100																												1										No	COSO31314826	2025Jan08
EGFR_L833V and EGFR_H835L	Multigene	COSV51773059,COSV51777782		p.H835L,p.L833V	lung / carcinoma / adenocarcinoma	4	Pre clinical drug/Case studies	Case study	Almonertinib		Unknown					Yes	Yes		1	37719840				1	1											18													29							1										No	COSO29914826	2024Sep02
EGFR_L858R	Point	COSV51765161,COSV51767322,COSV51801258,COSV51804843		p.L858R	NS / other / neoplasm	3	In trials	Phase 2	Carboplatin,Nab-paclitaxel,Toripalimab		Not yet recruiting	NCT05962021		ECD	2026Jun30	No	No		4	NCT05962021			Complete response, Pathological complete response	126	126																																									No	COSO31314888	2024Apr25
EGFR_L858R	Point	COSV51765161,COSV51767322,COSV51801258,COSV51804843		p.L858R	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Amivantamab,Lazertinib		Active, not recruiting	NCT02609776	CHRYSALIS cohort E	PCD	2024Jan31	Yes	Yes		1	37710001	Previously-treated		Overall Response Rate	14	14			43		18-71		9.6		5.6-		4.9			3.7-9.5							64																				No	COSO29915674	2025Jan08
EGFR_L858R	Point	COSV51765161,COSV51767322,COSV51801258,COSV51804843		p.L858R	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	CFT8919		Not yet recruiting	NCT06641609		ECD	2025Dec09	Yes	No		4	NCT06641609			Overall Response Rate	166	166																																									No	COSO29915674	2024Dec11
EGFR_L858R	Point	COSV51765161,COSV51767322,COSV51801258,COSV51804843		p.L858R	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Afatinib		Completed	NCT01466660		PCD	2016Apr08	Yes	Yes		1	28426106	Untreated		PFS, TTP, OS	133	67	66	Gefitinib																						25	21.2	.91	0.62-1.36	0.6585													No	COSO29915674	2025Jan08
EGFR_L858R	Point	COSV51765161,COSV51767322,COSV51801258,COSV51804843		p.L858R	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Anlotinib,Dacomitinib		Recruiting	NCT05271916		ECD	2025Jan01	Yes	No		4	NCT05271916			Progression free survival	140	140																																									No	COSO29915674	2023Aug31
EGFR_L858R	Point	COSV51765161,COSV51767322,COSV51801258,COSV51804843		p.L858R	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Alflutinib,Anlotinib		Unknown	NCT04895930	FOCUS-A	ECD	2023Nov30	Yes	Yes		3	https://oncologypro.esmo.org/meeting-resources/european-lung-cancer-congress-2024/furmonertinib-combined-with-anlotinib-as-the-first-line-treatment-in-patients-with-egfr-exon-21-leu858arg-mutation-results-from-focus-a-study	Untreated		Overall Response Rate	22	22			95.45		77.2-99.9																100										21	1									No	COSO29915674	2025Jan08
EGFR_L858R	Point	COSV51765161,COSV51767322,COSV51801258,COSV51804843		p.L858R	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Carboplatin,Pemetrexed,Toripalimab		Not yet recruiting	NCT05962021		ECD	2026Jun30	No	No		4	NCT05962021			Complete response, Pathological complete response	126	126																																									No	COSO29915674	2024Apr25
EGFR_L858R	Point	COSV51765161,COSV51767322,COSV51801258,COSV51804843		p.L858R	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Apatinib,Camrelizumab		Completed	NCT03083041		PCD	2022Apr22	Comparison with wt	Yes		1	35832447	Previously-treated		Overall Response Rate	14	14			21.4																																						No	COSO29915674	2025Jan08
EGFR_L858R	Point	COSV51765161,COSV51767322,COSV51801258,COSV51804843		p.L858R	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Gefitinib,Pemetrexed		Completed	NCT01469000		PCD	2015Apr01	Yes	Yes		1	27507876	Untreated		Progression free survival	75	52	23	Gefitinib									12.6	10.9	.58		0.054																39	11									No	COSO29915674	2025Jan08
EGFR_L858R	Point	COSV51765161,COSV51767322,COSV51801258,COSV51804843		p.L858R	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Bevacizumab,Osimertinib		Not yet recruiting	NCT04988607		ECD	2024Nov01	Yes	No		4	NCT04988607	Untreated		Progression free survival	90			Osimertinib																																							No	COSO29915674	2021Aug24
EGFR_L858R	Point	COSV51765161,COSV51767322,COSV51801258,COSV51804843		p.L858R	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Bevacizumab,Osimertinib		Recruiting	NCT05104281		ECD	2023Dec31	Yes	Yes		1	37016906	Untreated		Progression free survival	35	35											17			13.28-20.72																											No	COSO29915674	2025Jan08
EGFR_L858R	Point	COSV51765161,COSV51767322,COSV51801258,COSV51804843		p.L858R	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Bevacizumab,Icotinib		Unknown	NCT05263947		ECD	2023Oct30	Yes	Yes		2	10.1200/JCO.2023.41.16_suppl.e21020	Previously-treated		Progression free survival	30	30			66.7								14.8										96.7										20	9									No	COSO29915674	2025Jan08
EGFR_L858R	Point	COSV51765161,COSV51767322,COSV51801258,COSV51804843		p.L858R	lung / carcinoma / non small cell carcinoma	3	In trials	Unknown	Almonertinib,Anlotinib		Recruiting	NCT06102928		ECD	2026Oct30	Yes	No		4	NCT06102928			Progression free survival	30	30																																									No	COSO29915674	2024Sep02
EGFR_L858R_Exon19del and (TP53_Exon4 or TP53_Exon7)	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Gefitinib or Erlotinib		Completed	NCT01024413		PCD	2015Jun01	Yes	Yes		1	33317922			Progression free survival													9.4													15.8																	No	COSO29915674	2025Jan08
EGFR_L858R_Exon19del and EGFR_no_T790M and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Gumarontinib,Osimertinib		Unknown	NCT04338243		ECD	2020Dec31	Yes	Yes		2	10.1016/j.annonc.2022.10.334	Previously-treated		Overall Response Rate	19	19			73.7		48.8-90.9		6.2		3.3-		7			4.1-13.8										15.1			9.5-														No	COSO29915674	2025Jan08
EGFR_L858R_Exon19del and EGFR_no_T790M and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Gumarontinib,Osimertinib		Unknown	NCT04338243		ECD	2020Dec31	Expression confirmed	Yes		2	10.1016/j.annonc.2022.10.334			Overall Response Rate	30	30			60		40.6-77.3		5.8				6.9			3.9-8.9										16.9			11.1-														No	COSO29915674	2025Jan08
EGFR_L858R_Exon19del and EGFR_no_T790M and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Capmatinib,Osimertinib		Terminated	NCT04816214	GEOMETRY-E	PCD	2022Dec27	Yes	Yes	Changed business priorities	4	NCT04816214	Previously-treated		Progression free survival	6			Pemetrexed,Platinum-based chemotherapy																																							No	COSO29915674	2023Sep15
EGFR_L858R_Exon19del and TP53_not_Exon4 and TP53_not_Exon7	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Gefitinib or Erlotinib		Completed	NCT01024413		PCD	2015Jun01	Yes	Yes		1	33317922			Progression free survival													11													20.0																	No	COSO29915674	2025Jan08
EGFR_L861Q	Point	COSV51766344		p.L861Q	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved FDA	Afatinib	Required	Unknown		Afatinib FDA			Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf			Not defined	12	12			58.3				9.7																																		No	COSO29915674	2023Jan23
EGFR_L861Q	Point	COSV51766344		p.L861Q	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Unknown	NCT03424759		PCD	2017Dec31	Yes	Yes		1	31825714			Overall Response Rate	9	9			78		44-100						15.2			1.3-29.1																	7										No	COSO29915674	2025Jan08
EGFR_L861Q	Point	COSV51766344		p.L861Q	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Neratinib		Not yet recruiting	NCT06029816		ECD	2024Dec30	Yes	No		4	NCT06029816	Previously-treated		Overall Response Rate	42	42																																									No	COSO29915674	2023Nov09
EGFR_L861Q	Point	COSV51766344		p.L861Q	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Afatinib		Completed					Yes	Yes		1	26051236			Unknown	16	16			56.3																																						No	COSO29915674	2021May18
EGFR_S768I	Point	COSV51768106		p.S768I	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved FDA	Afatinib	Required	Unknown		Afatinib FDA			Yes	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201292s017lbl.pdf			Not defined	1	1			100				37.3																																		No	COSO29915674	2023Jan23
EGFR_S768I	Point	COSV51768106		p.S768I	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Unknown	NCT03424759		PCD	2017Dec31	Yes	Yes		1	31825714			Overall Response Rate	8	8			38		0-81						12.3			0-28.8																	3										No	COSO29915674	2025Jan08
EGFR_S768I	Point	COSV51768106		p.S768I	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Neratinib		Not yet recruiting	NCT06029816		ECD	2024Dec30	Yes	No		4	NCT06029816	Previously-treated		Overall Response Rate	42	42																																									No	COSO29915674	2023Nov09
EGFR_S768I	Point	COSV51768106		p.S768I	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Afatinib		Completed					Yes	Yes		1	26051236			Unknown	8	8			100																																						No	COSO29915674	2021May18
EGFR_S768I or EGFR_V769L	Cluster	COSV51768106,COSV51811749		p.S768I,p.V769L	lung / carcinoma / non small cell carcinoma	4	Pre clinical drug/Case studies	Case study	Gefitinib		Unknown					Yes	Yes		1	17045698			Unknown	1	1																															1										No	COSO29915674	2021May18
EGFR_S768T and EGFR_G719C 	Multigene	COSV51766606,COSV51788343		p.G719C	NS / carcinoma / neuroendocrine carcinoma	4	Pre clinical drug/Case studies	Case study	Osimertinib		Active, not recruiting	NCT06303167	MATCH-Subprotocol E - Responder 	PCD	2023Feb26	Yes	Yes		1	38591867	Previously-treated		Overall Response Rate	1	1			100																																						No	COSO313110373	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Approved FDA	Osimertinib	Required	Completed	NCT02151981	AURA3	PCD	2016Apr15	Yes	Yes		1	32861806	Untreated		Progression free survival	315	279	36	Chemotherapy									10.1	4.4	.3	0.23?0.4	< 0.001									26.8	22.5	.87	0.67-1.12	0.277													Yes	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Case study	Afatinib		Completed	NCT00711594	LUX-Lung 4	PCD	2013Nov01	Yes	Yes		1	22071596	Previously-treated		Unknown	1	1																																1									No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Out of trials human study	Afatinib		Unknown					Comparison with wt	Yes		1	24035188			Unknown	34	21	13		5	38							3.2	4.6			0.33																										No	COSO29915674	2022May11
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Osimertinib,Sapanisertib		Completed	NCT04479306		PCD	2023Jul27	Yes	Yes		2	10.1200/JCO.2022.40.16_suppl.9105	Previously-treated		Maximum tolerated dose/toxicity	16	16			12.5		1.6-38.3						4.6										68.7																				No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	FHND-9041		Completed	NCT06521034	Arm 1	PCD	2021May17	Yes	No		4	NCT06521034	Previously-treated		Absorption rate	124	124																																									No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	QLH11811		Recruiting	NCT05555212	Cohort 3	ECD	2024Dec31	Yes	No		4	NCT05555212	Previously-treated		Overall Response Rate	72	72																																									No	COSO29915674	2023Sep25
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Alisertib,Osimertinib		Completed	NCT04479306		PCD	2023Jul27	Yes	Yes		2	10.1200/JCO.2022.40.16_suppl.9105	Previously-treated		Maximum tolerated dose/toxicity	20	20			5		0.1-24.9						1.9										5																				No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Rilertinib		Unknown	NCT03618043		ECD	2019Dec01	Yes	No		4	NCT03618043			Maximum tolerated dose/toxicity	14	14																																									No	COSO29915674	2024Nov26
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Rilertinib		Unknown	NCT03603262		ECD	2019Dec01	Yes	Yes	SAE 20.0%	1	36813747	Previously-treated		Maximum tolerated dose/toxicity	20	20			40		19.12-63.95																70.0																				No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Befotertinib		Completed	NCT03452150	100mg	PCD	2020Aug28	Yes	Yes		1	35274722	Previously-treated		Maximum tolerated dose/toxicity	33	33											9.6			6.9-																	15	16									No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Avitinib maleate		Completed	NCT03053219		PCD	2018Jul01	Yes	No		4	NCT03053219			Overall Response Rate	7	7																																									No	COSO29915674	2021May18
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Osimertinib,Savolitinib		Active, not recruiting	NCT02143466	TATTON	PCD	2020Mar04	Yes	Yes		1	32139298	Previously-treated		Maximum tolerated dose/toxicity	8	8			25		3-65																																				No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Osimertinib,Selumetinib		Active, not recruiting	NCT02143466	TATTON	PCD	2020Mar04	Yes	Yes		1	32139298	Previously-treated		Maximum tolerated dose/toxicity	23	23			57		34-77																																				No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Afatinib,Ruxolitinib		Completed	NCT02145637		PCD	2017Nov09	Yes	Yes		1	31319994	Previously-treated		Maximum tolerated dose/toxicity	20	20			25								4.9										100										5	15									No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Durvalumab,Osimertinib		Active, not recruiting	NCT02143466	TATTON	PCD	2020Mar04	Yes	Yes		1	32139298	Previously-treated		Maximum tolerated dose/toxicity	13	13			54		25-81																										7	2									No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Nazartinib,Nivolumab		Terminated	NCT02323126		PCD	2019Sep23	Yes	Yes	SAE 77.8%	2	10.1016/j.jtho.2021.01.1060	Previously-treated		Progression free survival	18	18			38.9								63.4										94.4			55.6																	No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Osimertinib,Ramucirumab		Completed	NCT02789345	JVDL Cohort A	PCD	2017Oct19	Yes	Yes		1	33046516	Previously-treated		Maximum tolerated dose/toxicity	25	25			76				13.4		9.6-21.2		11			5.5-19.3																											No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Necitumumab,Osimertinib		Active, not recruiting	NCT02496663		ECD	2025Jun30	Yes	Yes		2	10.1200/JCO.2022.40.16_suppl.901	Previously-treated		Maximum tolerated dose/toxicity	18	18											3.9			2.4-5.6																	2										No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Necitumumab,Osimertinib		Completed	NCT02789345	JVDL Arm B 	PCD	2017Oct19	Yes	Yes	SAE 25%	4	NCT02789345	Previously-treated		Maximum tolerated dose/toxicity	4	4																																									No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Rezivertinib		Completed	NCT03386955		PCD	2021Dec23	Yes	Yes		1	36617560	Untreated		Maximum tolerated dose/toxicity	43	43			83.7		69.3-93.2		19.3				20.7			13.8-24.8																											No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Rezivertinib		Completed	NCT03386955		PCD	2021Dec23	Yes	Yes		2	10.1093/annonc/mdz437.002	Previously-treated		Maximum tolerated dose/toxicity	119	119			61.0								9.92										89.0																				No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Naquotinib		Completed	NCT02113813	8273-CL-0102	PCD	2017Jul28	Yes	Yes		1	28954786	Previously-treated		Maximum tolerated dose/toxicity	110	110			30.7								6.8																														No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Abivertinib		Unknown	NCT02330367		ECD	2022Dec01	Yes	Yes		1	30032814			Overall Response Rate	16	16			60.0								8.12													17.62							9	5									No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Afatinib,Cetuximab		Completed	NCT01090011		PCD	2013Jan01	Yes	Yes		1	29110849	Previously-treated		Maximum tolerated dose/toxicity	20	20											4.8																														No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 1	Olmutinib		Terminated	NCT04510415		PCD	2018Dec11	Yes	Yes	Lack of funding	4	NCT04510415	Previously-treated		Overall Response Rate	2	2																																									No	COSO29915674	2024Jan30
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Active, not recruiting	NCT02856893	A v B/C	ECD	2023Feb01	Yes	Yes	OS 18m 84.4 v 82.3, IPFS 34.3 v 22.3	3	https://www.targetedonc.com/view/first-line-osimertinib-displays-comparable-survival-outcomes-vs-sequential-gefitinib-osimertinib-in-egfr-nsclc			Progression free survival	156	103	53	Gefitinib,Osimertinib																							42.8																No	COSO29915674	2023Sep18
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	YK-029A		Recruiting	NCT05767866		ECD	2023Dec30	Yes	Yes		2	10.1158/1538-7445.AM2024-CT055	Previously-treated		Overall Response Rate	38	38			65.8								11										84.2																				No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Bafisontamab,Osimertinib		Not yet recruiting	NCT05498389	Group 2/3	ECD	2024Jul01	Yes	No		4	NCT05498389	Previously-treated		Overall Response Rate	115	115																																									No	COSO29915674	2023Sep25
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Alflutinib,Radiotherapy		Unknown	NCT04970693		ECD	2024Jan31	Yes	No		4	NCT04970693	Previously-treated		Progression free survival	64	64																																									No	COSO29915674	2024Jul11
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Almonertinib,Carboplatin,Pemetrexed		Unknown	NCT04592666	APPEAL	ECD	2021Dec31	Yes	No		4	NCT04592666			Progression free survival	226	226																																									No	COSO29915674	2024Sep02
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Anlotinib,Osimertinib		Terminated	NCT04438902	TRAIN	PCD	2022Dec08	Yes	Yes	Toxicity issues	4	NCT04438902	Previously-treated		Progression free survival	3	3																																									No	COSO29915674	2023May02
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Anlotinib,Osimertinib		Unknown	NCT04029350	ALTN-03	ECD	2020Jan31	Yes	Yes		3	https://cattendee.abstractsonline.com/meeting/10925/presentation/2326			Progression free survival	31	31			48.4		30.6-66.6						16.7			9.83-23.57							100																				No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	ZN-e4		Completed	NCT03446417		PCD	2022Jan17	Yes	No		4	NCT03446417			Maximum tolerated dose/toxicity	34	34																																									No	COSO29915674	2023Apr04
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Befotertinib		Completed	NCT03861156	Intracranial metastases 75-100 mg	PCD	2021Aug15	Yes	Yes	IORR 55.9% 95%CI 37.9-72.8	1	35724798				84	84																																									No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Befotertinib		Completed	NCT03861156	Intracranial metastases 50 mg	PCD	2021Aug15	Yes	Yes	IORR 26.7% 95%CI 7.8-55.1	1	35724798			Overall Response Rate	56	56																																									No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Befotertinib		Completed	NCT03861156	Cohort B 75-100 mg	PCD	2021Aug15	Yes	Yes		1	35724798			Overall Response Rate	290	290			67.6		61.9-72.9		18		13.8-		16.6			15.0-							94.8									0	196	79									No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Befotertinib		Completed	NCT03861156	Cohort A 50 mg	PCD	2021Aug15	Yes	Yes		1	35724798			Overall Response Rate	176	176			54.0		46.3-61.5		12.5		11.1-13.8		11			9.6-12.5							93.2										188										No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Patritumab deruxtecan		Active, not recruiting	NCT05865990	TUXEDO-3	ECD	2025Dec31	No	No		4	NCT05865990	Previously-treated		ORR, OS	63	63																																									No	COSO29915674	2024Oct17
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Avitinib maleate		Unknown	NCT03574402	CTONG1702 Arm 1	ECD	2022Dec30	Yes	No		4	NCT03574402			Overall Response Rate	400	400																																									No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Luminespib		Completed	NCT01922583		PCD	2017Feb01	Yes	No		4	NCT01922583	Previously-treated		Overall Response Rate	31	31																																									No	COSO29915674	2021Oct08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Brigatinib		Completed	NCT01449461		PCD	2015Nov16	Yes	No		4	NCT01449461	Previously-treated		Overall Response Rate	137	137																																									No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Emibetuzumab,Erlotinib		Completed	NCT01900652		PCD	2015Feb01	No	Yes	Lack of efficacy	2	10.1200/JCO.2016.34.15_suppl.9070	Previously-treated		Overall Response Rate	111			Emibetuzumab																																							No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Emibetuzumab,Erlotinib		Active, not recruiting	NCT01897480		PCD	2016Mar14	No	Yes	Primary outcome not met	2	https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9019	Untreated		Progression free survival	150			Erlotinib																																							No	COSO29915674	2021Oct28
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Itacitinib,Osimertinib		Active, not recruiting	NCT02917993		ECD	2025Dec31	Yes	No		4	NCT02917993	Previously-treated		Overall Response Rate	59	59																																									No	COSO29915674	2024Apr17
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Cabozantinib,Erlotinib		Completed	NCT01866410	NCI 9303	PCD	2018Mar30	Yes	Yes		1	30915273	Previously-treated		Overall Response Rate	37	37			10.8								3.6																				4	21									No	COSO29915674	2022May03
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Lerociclib,Osimertinib		Completed	NCT03455829		PCD	2021Dec14	Yes	Yes	SAE <= 33%	4	NCT03455829			Maximum tolerated dose/toxicity	18	18																																									No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Aspirin,Osimertinib		Unknown	NCT03532698	COAST2	ECD	2021Dec31	No	No		4	NCT03532698	Previously-treated		Overall Response Rate	100			Osimertinib																																							No	COSO29915674	2023Apr04
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Aspirin,Osimertinib		Unknown	NCT03543683	COAST1	ECD	2021Dec31	Yes	No		4	NCT03543683	Previously-treated		Progression free survival	330			Osimertinib																																							No	COSO29915674	2023Apr04
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Bevacizumab,Osimertinib		Active, not recruiting	NCT02971501		ECD	2025Jul01	Yes	No		4	NCT02971501			Progression free survival	112			Osimertinib																																							No	COSO29915674	2024Oct17
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Bevacizumab,Osimertinib		Unknown	NCT03133546	BOOSTER	ECD	2023May01	Yes	Yes		1	34839016	Previously-treated		Progression free survival	155	78	77	Osimertinib	55	55							15.4	12.3	.96	0.68-1.37	0.83									24.0	24.3	1.03	0.67-1.56	0.91													No	COSO29915674	2024Oct17
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Rezivertinib		Completed	NCT03812809		PCD	2022Jan24	Yes	Yes		1	36049654			Overall Response Rate	226	226			64.6		58.0-70.8		12.5		10.0-13.9		12.2			9.6-13.9							89.8			23.9			20.0-														No	COSO29915674	2024Jul03
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Malvertinib		Terminated	NCT02349633		PCD	2020May28	Yes	Yes	Changed business priorities	3	https://www.jto.org/article/S1556-0864(16)32909-4/pdf	Previously-treated		Overall Response Rate	65	65																																									No	COSO29915674	2022May03
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Naquotinib		Terminated	NCT02192697		PCD	2016Jan15	Yes	Yes	Serious adverse events	2	10.1111/cas.13724	Previously-treated		Overall Response Rate	45	45			49				8.4				5.6																				22	18									No	COSO29915674	2025Jan30
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Rociletinib		Terminated	NCT01526928		PCD	2018Jul03	Yes	Yes		1	25923550	Previously-treated		Overall Response Rate	46	46			59																																						No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	BMS-690514		Completed	NCT00329004		PCD	2009Jul01	Yes	Yes		1	23490650			Maximum tolerated dose/toxicity	21	21																															1	6									No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Almonertinib		Unknown	NCT02981108	APOLLO	PCD	2019Jan05	Yes	Yes	IORR 60.9%, IDOR 12.5m	1	34801749	Previously-treated		Overall Response Rate	244	244			68.9		62.6-74.6		15.1		12.5-16.6		12.4			9.7-15.0							93.4																				No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Alflutinib		Unknown	NCT03452592	Intracranial	ECD	2020Jun01	Yes	Yes	IORR 66% 95%CI 46-82	1	33780662			Overall Response Rate	29	29																																									No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Alflutinib		Unknown	NCT03502850		ECD	2021Jan01	Yes	Yes		2	10.1016/j.jtho.2022.05.011			Overall Response Rate	301	301			68.8		63.2-74.0		11.1		9.6-13.8		11			9.7-12.4							92.4						19.6-														No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Alflutinib		Unknown	NCT03452592		ECD	2020Jun01	Yes	Yes	SAE 24%	1	33780662			Overall Response Rate	220	220			74		68-80		8.3		8.3-11.1		9.6			8.2-9.7							94									0	163	43									No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Erlotinib,Ruxolitinib		Completed	NCT02155465		PCD	2017Oct01	Yes	Yes	Lack of efficacy	1	27613527	Previously-treated		Overall Response Rate	22	22																																									No	COSO29915674	2024Jan30
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Abivertinib		Unknown	NCT03300115		ECD	2019Jun17	Yes	No		4	NCT03300115			Overall Response Rate	222	222																																									No	COSO29915674	2022May03
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Poziotinib		Terminated	NCT01819428		PCD	2015Nov01	Yes	Yes	Slow accrual	4	NCT01819428	Untreated		Overall Response Rate	22	22																																									No	COSO29915674	2022Aug17
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Canertinib		Completed	NCT00050830				No	Yes	Primary outcome not met	1	17761977	Previously-treated		Clinical activity	166	166																																									No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Lazertinib		Not yet recruiting	NCT05701384		ECD	2024Jan31	Yes	No		4	NCT05701384	Previously-treated		Maximum tolerated dose/toxicity	117	117																																									No	COSO29915674	2024Dec18
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Lazertinib		Completed	NCT04075396		PCD	2021Jan08	Yes	No		4	NCT04075396			Maximum tolerated dose/toxicity	29	29																																									No	COSO29915674	2024Dec18
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Lazertinib		Unknown	NCT03046992		ECD	2022Sep01	Yes	Yes	Intracranial ORR 85.7% 95%CI 59.8-100.0%	1	34958928	Previously-treated		Overall Response Rate	76	76			55.3		44.1?66.4						11.1			 5.5?16.4																1	41										No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Olmutinib		Completed	NCT03228277		PCD	2018Jul31	Yes	No		4	NCT03228277	Untreated		Overall Response Rate	25	25																																									No	COSO29915674	2022May03
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Olmutinib		Terminated	NCT02485652	ELUXA 1	PCD	2020Dec08	Yes	Yes		1	33434335	Previously-treated		Overall Response Rate	162	162			46.3		38.4?54.3						9.4			6.9?12.3							86.4			19.7			15.1-														No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Olmutinib		Completed	NCT02444819		PCD	2017Aug01	Yes	No		4	NCT02444819	Untreated		Overall Response Rate	33	33																																									No	COSO29915674	2021May18
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Olmutinib		Completed	NCT01588145		PCD	2017Aug01	Yes	Yes		5	https://www.boehringer-ingelheim.com/press-release/new-data-olmutinib-bi-1482694-presented-asco-2016	Previously-treated		Maximum tolerated dose/toxicity	38	38			54.0				8.3																																		No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Recruiting	NCT05536505		ECD	2025Oct01	Yes	No		4	NCT05536505			Disease free survival, relapse free survival, regression free survival, recurrence free survival	180	180																																									No	COSO29915674	2022Sep27
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Unknown	NCT02736513	Arm B	ECD	2022Dec31	No	Yes		1	35156036	Previously-treated		Overall Response Rate	20	20			66.7								7.6			5.3-							94.4																				No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Unknown	NCT02824952		ECD	2022Dec01	Yes	No		4	NCT02824952	Untreated		Overall Response Rate	40	40																																									No	COSO29915674	2024Jan04
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Unknown	NCT02811354	PLASMA	ECD	2019Feb24	Yes	Yes		1	34589970	Previously-treated		Overall Response Rate	15	15			53								7.3																														No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Active, not recruiting	NCT02664935	National Lung Matrix Trial Cohort G1	ECD	2024Sep01	Yes	Yes		1	32669708			ORR, PFS, DOR	10	10											15.5			8.5-32.6																											No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Completed	NCT03394118		PCD	2021Mar11	Yes	No		4	NCT03394118			Overall Response Rate	63	63																																									No	COSO29915674	2023Sep18
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Completed	NCT02094261	AURA2	PCD	2015May01	Yes	Yes		1	27751847	Previously-treated		Overall Response Rate	199	199			70.9				7.8				8.6										91.5									6	134	42									No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Unknown	NCT02442349	AURA17	PCD	2016Mar04	Yes	Yes		2	10.1093/annonc/mdy425.022	Previously-treated		Overall Response Rate	166	166			62				9.9														88																				No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Completed	NCT02841579	AZENT	PCD	2018Dec01	Yes	Yes	SAE 45.5%	1	34763195	Untreated		Overall Response Rate	22	22			77.3		54.6-89.3		20		11.2-		23.1			14.1-							86.4			28.4			25.6-			3	14	2									No	COSO29915674	2024May16
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Active, not recruiting	NCT02504346	TREM	ECD	2023Jun01	Comparison with wt	Yes		1	32200138	Previously-treated		Overall Response Rate	167	117	50		60	28		<0.001	11.8	10.7		0.229	10.8	5.1	.62	0.43-0.88	0.007						91	64	<0.001	22.5	13.4	.55	0.37-0.81	0.002													Yes	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 2	Osimertinib		Completed	NCT01802632	AURA	PCD	2015May01	Yes	Yes		1	32861806	Previously-treated		Overall Response Rate	127	127			61.0	21							9.6	2.8																													No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Osimertinib		Completed	NCT02959749		PCD	2017Oct01	Yes	Yes		1	29858027	Previously-treated		Progression free survival	147	74	73	Bevacizumab,Docetaxel									10.2	2.95	.23	0.12-0.38	<0.001																										Yes	COSO29915674	2021May18
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Durvalumab,Osimertinib		Completed	NCT02454933	CAURAL	PCD	2017Aug21	Yes	Yes	Toxicity in other studies	1	30763730	Previously-treated		Maximum tolerated dose/toxicity	29	12	17	Osimertinib																																							No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Rociletinib		Terminated	NCT02322281	TIGER-3	PCD	2018Mar29	No	Yes	Denied regulatory approval	2	10.1093/annonc/mdw140	Previously-treated		Progression free survival	149			Chemotherapy																																							No	COSO29915674	2022May03
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Almonertinib		Unknown	NCT04870190	ATTACK	ECD	2024Jun01	Yes	Yes		4	10.1200/JCO.2022.40.16_suppl.9096	Previously-treated		Progression free survival	232			Gefitinib	82.8	75.0	0.457-5.597	0.4621																																			No	COSO29915674	2024Sep10
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Olmutinib		Terminated		ELUXA3			Yes	Yes	Changed business priorities	3	https://www.hopkinsmedicine.org/singapore/_downloads/johns-hopkins-singapore-2016-research-report.pdf	Untreated		Unknown																																											No	COSO29915674	2021May18
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Olmutinib		Terminated	2015-005079-26	ELUXA2	PCD	2016Aug01	Yes	No		5	https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-launches-ambitious-eluxa-trial-program-broadly-investigate	Previously-treated		Progression free survival	0	0		Chemotherapy																																							No	COSO29915674	2021May18
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Osimertinib		Unknown	NCT03257124	LM cohort	PCD	2019Aug31	Yes	Yes		1	32634610	Previously-treated		Overall survival	40	40											8			7.2-							92.5			13.3			9.1-			5											No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Osimertinib		Completed	NCT02474355	ASTRIS	PCD	2019Apr18	Yes	Yes		4	NCT02474355			Overall survival	3014	3014											11.1			11.0-12.0										22.8			21.6-23.8														No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Osimertinib		Unknown	NCT02972333	APOLLO	ECD	2019Sep01	Yes	Yes		1	32817079	Previously-treated		Progression free survival	38	38			39.4								8.4			5.8-10.9																											No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 3	Osimertinib		Unknown	NCT03257124	BM cohort	PCD	2019Aug31	Yes	Yes		1	32634610	Previously-treated		Overall Response Rate	40	40			55								7.6			5.0-16.6							77.5			16.9			7.9-			4	18										No	COSO29915674	2025Jan08
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Phase 4	Osimertinib		Completed	NCT03853551		PCD	2020Apr15	Yes	Yes	SAE 11.67%	4	NCT03853551			Maximum tolerated dose/toxicity	60	60																																									No	COSO29915674	2022May03
EGFR_T790M	Point	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	1	Marketed drug	Retrospective/Meta-analysis	Lazertinib		Unknown	NCT05377788		ECD	2024Jun30	Yes	No		4	NCT05377788			Progression free survival	900	900																																									No	COSO29915674	2024Dec18
EGFR_T790M and MET_unspecified	Multigene	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Gefitinib,Savolitinib		Completed	NCT02374645		PCD	2018Feb18	Comparison with wt	Yes		1	33052556	Previously-treated		Maximum tolerated dose/toxicity	46	23	23		9	52																																					No	COSO29915674	2025Jan08
EGFR_T790M and MET_unspecified	Multigene	COSV51765492		p.T790M	lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Gefitinib,Tepotinib 		Completed	NCT01982955	INSIGHT	PCD	2017Dec12	Yes	Yes		1	36971777	Previously-treated		Progression free survival	15	15			0								2.63			1.38-2.73							40			25.86			13.08-39.66														No	COSO29915674	2025Jan08
EGFR_no_C797S and EGFR_T790M	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	BLU-945		Active, not recruiting	NCT04862780	Group 2	ECD	2025Jan31	Yes	No		4	NCT04862780	Previously-treated		Overall Response Rate	190	190																																									No	COSO29915674	2024Apr17
EGFR_no_Exon19del and EGFR_no_L858R	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Almonertinib		Unknown	NCT04785742		ECD	2023Dec31	Yes	No		4	NCT04785742			Maximum tolerated dose/toxicity	40	40																																									No	COSO29915674	2024Sep02
EGFR_no_Exon19del and EGFR_no_L858R	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Anlotinib,Sintilimab		Completed	NCT04790409		PCD	2023Sep13	Yes	Yes		1	37723837			Progression free survival	9	9			33.3								7.3																														No	COSO29915674	2025Jan08
EGFR_no_Exon20ins	Exon				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Almonertinib		Recruiting	NCT04841811		ECD	2024Dec31	Yes	No		4	NCT04841811			ORR, EFS	192	192																																									No	COSO29915674	2024Sep02
EGFR_no_Exon20ins	Exon				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Bafisontamab,Osimertinib		Not yet recruiting	NCT05498389	Group 4	ECD	2024Jul01	Yes	No		4	NCT05498389	Previously-treated		Overall Response Rate	115	115																																									No	COSO29915674	2023Sep25
EGFR_no_Exon20ins	Exon				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Alflutinib,Cisplatin,Pemetrexed		Recruiting	NCT05430802	FORESEE	ECD	2023Mar01	Yes	No		4	NCT05430802	Untreated		Overall Response Rate	40	40																																									No	COSO29915674	2024Apr23
EGFR_no_Exon20ins	Exon				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	FWD1509		Recruiting	NCT05068024		ECD	2022Oct30	Yes	No		4	NCT05068024			Maximum tolerated dose/toxicity	30	30																																									No	COSO29915674	2023Sep25
EGFR_no_T790M	Gene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Neoantigen vaccine,Tyrosine kinase inhibitor		Unknown	NCT04487093		ECD	2022May17	Yes	No		4	NCT04487093			Maximum tolerated dose/toxicity	20	20																																									No	COSO29915674	2023Apr04
EGFR_no_T790M	Gene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Oleclumab,Osimertinib		Active, not recruiting	NCT03381274		PCD	2021May24	Yes	Yes		1	36641093	Previously-treated		Overall Response Rate	18	18			11.8				16.6				7.4			3.6-							82.4			24.8			12.3-			0	4	13									No	COSO29915674	2025Jan08
EGFR_no_T790M	Gene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Anlotinib,Carboplatin,Pemetrexed		Unknown	NCT03706287		ECD	2021Mar10	Yes	Yes	Slow accrual	1	36346139			Progression free survival	19	19			47.4		24.5-71.1						5.75			4.37-7.52							100										6	4									No	COSO29915674	2025Jan08
EGFR_no_T790M	Gene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Oleclumab,Osimertinib		Active, not recruiting	NCT03381274		PCD	2021May24	Yes	Yes		1	36641093	Previously-treated			4	4																															3										No	COSO29915674	2025Jan08
EGFR_no_T790M	Gene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 4	Afatinib,Osimertinib		Active, not recruiting	NCT04413201	AFAMOSI	ECD	2024Jun30	Yes	No		4	NCT04413201			Disease free survival, relapse free survival, regression free survival, recurrence free survival	34			Osimertinib																																							No	COSO29915674	2023Aug31
EGFR_no_T790M	Gene				lung / carcinoma / non small cell carcinoma	3	In trials	Unknown	Sunvozertinib		Recruiting	NCT05559645	WU-KONG15	ECD	2025Dec31	Yes	No		4	NCT05559645	Previously-treated		Progression free survival	110	110																																									No	COSO29915674	2025Jan08
EGFR_no_T790M and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Observational	LMV-12,Osimertinib		Recruiting	NCT06109558	Cohort A	ECD	2026Dec30	Expression confirmed	No		4	NCT06109558	Previously-treated		ORR, PFS, DOR	120	120																																									No	COSO29915674	2024Jul11
EGFR_no_T790M and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Osimertinib,Savolitinib		Active, not recruiting	NCT02143466	TATTON part D	PCD	2020Mar04	Yes	Yes	SAE 26%	1	32027846			Maximum tolerated dose/toxicity	42	42			64		46-79																																				No	COSO29915674	2025Jan08
EGFR_no_T790M and RET_fusions	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Observational	LMV-12,Osimertinib		Recruiting	NCT06109558	Cohort B	ECD	2026Dec30	Expression confirmed	No		4	NCT06109558	Previously-treated		ORR, PFS, DOR	120	120																																									No	COSO29915674	2024Jul11
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	Binimetinib,Dactolisib		Completed	NCT01337765		PCD	2013Mar22	No	No		4	NCT01337765			Maximum tolerated dose/toxicity	29	29																																									No	COSO31314888	2025Jan08
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	ACE2016,Cyclophosphamide,Fludarabine		Recruiting	NCT06415487		ECD	2026Dec31	Expression confirmed	No		4	NCT06415487	Previously-treated		Maximum tolerated dose/toxicity	30	30																																									No	COSO31314888	2025Jan08
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	Bendamustine,Cetuximab,Cisplatin,Cyclophosphamide,Docetaxel,FT825,Fludarabine		Recruiting	NCT06241456	Regimen B	ECD	2029May01	Expression confirmed	No		4	NCT06241456			Maximum tolerated dose/toxicity	351	351																																									No	COSO31314888	2024Jul03
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	JANX008		Recruiting	NCT05783622		ECD	2026Jan01	Expression confirmed	No		4	NCT05783622			Maximum tolerated dose/toxicity	130	130																																									No	COSO31314888	2023Jul12
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	DK210,Nivolumab or Pembrolizumab		Recruiting	NCT05704985		ECD	2024Sep01	Yes	No		4	NCT05704985	Previously-treated		Maximum tolerated dose/toxicity	60	60																																									No	COSO31314888	2025Jan08
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	DK210,Radiotherapy		Recruiting	NCT05704985		ECD	2024Sep01	Yes	No		4	NCT05704985	Previously-treated		Maximum tolerated dose/toxicity	60	60																																									No	COSO31314888	2025Jan08
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	Chemotherapy,DK210		Recruiting	NCT05704985		ECD	2024Sep01	Yes	No		4	NCT05704985	Previously-treated		Maximum tolerated dose/toxicity	60	60																																									No	COSO31314888	2025Jan08
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	DK210		Recruiting	NCT05704985		ECD	2024Sep01	Yes	Yes	Manageable toxicity	2	10.1200/JCO.2024.42.16_suppl.2584	Previously-treated		Maximum tolerated dose/toxicity	15	15																																4									No	COSO31314888	2025Jan08
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	NX-019		Recruiting	NCT05514496		ECD	2027Feb17	Yes	No		4	NCT05514496			Overall Response Rate	258	258																																									No	COSO31314888	2024Apr17
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	HLX35		Active, not recruiting	NCT05360381		ECD	2024Oct30	Expression confirmed	No		4	NCT05360381			Maximum tolerated dose/toxicity	82	82																																									No	COSO31314888	2023Sep25
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	HBI-2376		Recruiting	NCT05163028		ECD	2024Dec01	Yes	No		4	NCT05163028	Previously-treated		Maximum tolerated dose/toxicity	42	42																																									No	COSO31314888	2024Apr03
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	FOLFIRI,Varlitinib		Unknown	NCT02435927		ECD	2021Jun01	Expression confirmed	No		4	NCT02435927			Maximum tolerated dose/toxicity	60	60																																									No	COSO31314888	2025Jan08
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	Capecitabine,Oxaliplatin,Varlitinib		Unknown	NCT02435927		ECD	2021Jun01	Expression confirmed	No		4	NCT02435927			Maximum tolerated dose/toxicity	60	60																																									No	COSO31314888	2025Jan08
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	Afatinib,Docetaxel		Completed	NCT02171741		PCD	2007Dec01	No	No		4	NCT02171741			Maximum tolerated dose/toxicity	31	31																																									No	COSO31314888	2022May03
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	CUDC-101		Completed	NCT01171924		PCD	2011Oct01	No	Yes	SAE 52.17%	4	NCT01171924			Maximum tolerated dose/toxicity	23	23																																									No	COSO31314888	2025Jan08
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	HLX55		Unknown	NCT04169178		ECD	2022Dec01	Yes	No		4	NCT04169178			Overall Response Rate	98	98																																									No	COSO31314888	2023Sep25
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	BBP-398		Terminated	NCT05621525	Part A	PCD	2024Mar29	Yes	No		4	NCT05621525			ORR, DOR	7	7																																									No	COSO31314888	2024Jul11
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	ZZ06		Unknown	NCT04412616		ECD	2023Dec01	Yes	No		4	NCT04412616			Maximum tolerated dose/toxicity	60	60																																									No	COSO31314888	2024Apr17
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	WSD0922-FU		Recruiting	NCT04197934		ECD	2025Dec20	Yes	No		4	NCT04197934			Maximum tolerated dose/toxicity	55	55																																									No	COSO31314888	2025Jan08
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	Gatipotuzumab,Tomuzotuximab		Completed	NCT03360734	GATTO EP	PCD	2020May04	Yes	Yes	SAE 3.9%	1	35397434			Maximum tolerated dose/toxicity	30	30											2.8			1.8-5.5										8.0			4.8-11.6														No	COSO31314888	2025Jan08
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	Gatipotuzumab,Tomuzotuximab		Completed	NCT03360734	GATTO	PCD	2020May04	Yes	Yes	SAE 14%	1	35397434			Maximum tolerated dose/toxicity	20	20											2			1.7-3.2										11.1			4.1-18.7														No	COSO31314888	2025Jan08
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	Neratinib,Trametinib		Active, not recruiting	NCT03065387		ECD	2025Oct01	Yes	No		4	NCT03065387			Maximum tolerated dose/toxicity	93	93																																									No	COSO31314888	2023Aug31
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	Neratinib,Palbociclib		Active, not recruiting	NCT03065387		ECD	2025Oct01	Yes	No		4	NCT03065387			Maximum tolerated dose/toxicity	93	93																																									No	COSO31314888	2023Aug31
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	Everolimus,Neratinib		Active, not recruiting	NCT03065387		ECD	2025Oct01	Yes	No		4	NCT03065387			Maximum tolerated dose/toxicity	93	93																																									No	COSO31314888	2023Aug31
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	Cetuximab,FATE NK100		Completed	NCT03319459		PCD	2020May29	Expression confirmed	No		4	NCT03319459			Maximum tolerated dose/toxicity	44	44																																									No	COSO31314888	2022May03
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 1	Afatinib,Capecitabine		Completed	NCT02451553		PCD	2022Apr16	No	No		4	NCT02451553			Maximum tolerated dose/toxicity	41	41																																									No	COSO31314888	2022Nov28
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	Afatinib		Unknown	NCT03239015		ECD	2023Jun30	Yes	No		4	NCT03239015			Overall Response Rate	300	300																																									No	COSO31314888	2024Apr17
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	A2B395,Lymphodepleting chemotherapy		Not yet recruiting	NCT06682793		ECD	2029Mar31	Yes	No		4	NCT06682793			Overall Response Rate	240	240																																									No	COSO31314888	2024Dec11
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	DB-1310		Recruiting	NCT05785741		ECD	2026Aug31	No	No		4	NCT05785741			Overall Response Rate	1000	1000																																									No	COSO31314888	2024Oct17
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	DF9001,Nivolumab		Recruiting	NCT05597839		ECD	2025Aug01	Expression confirmed	No		4	NCT05597839	Previously-treated		Overall Response Rate	242	242																																									No	COSO31314888	2024Jul11
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	DF9001		Recruiting	NCT05597839		ECD	2025Aug01	Expression confirmed	No		4	NCT05597839	Previously-treated		Overall Response Rate	242	242																																									No	COSO31314888	2024Jul11
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	AFM24		Completed	NCT04259450		PCD	2023Jul12	Expression confirmed	Yes		5	https://www.affimed.com/affimed-presents-afm24-monotherapy-data-in-non-small-cell-lung-cancer-at-the-annual-meeting-of-the-american-society-of-clinical-oncology-and-provides-strategic-update-on-afm24-development-plan-2/			Overall Response Rate	15	15			13																		47										2	5									No	COSO31314888	2025Jan08
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	Amivantamab		Recruiting	NCT03767075	BoB Arm 3C	ECD	2025May01	Yes	No		4	NCT03767075			Overall Response Rate	1000	1000																																									No	COSO31314888	2023Dec15
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	AFM24,Atezolizumab		Recruiting	NCT05109442		ECD	2025Feb28	Expression confirmed	Yes	No DLTs reported 	2	10.1136/jitc-2022-SITC2022.0746	Previously-treated		Overall Response Rate	4	4																															1	1									No	COSO31314888	2025Jan08
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	TAK-186		Recruiting	NCT04844073		ECD	2025Sep27	Expression confirmed	No		4	NCT04844073			Maximum tolerated dose/toxicity	258	258																																									No	COSO31314888	2025Jan06
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	MRG003		Recruiting	NCT05688605		ECD	2025May01	Yes	No		4	NCT05688605			Overall Response Rate	18	18																																									No	COSO31314888	2024Apr25
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	Erlotinib,Temozolomide		Withdrawn	NCT02689336		ECD	2019Nov30	Yes	Yes	No patients recruited	4	NCT02689336		Pediatric	Overall Response Rate	0	0																																									No	COSO31314888	2025Jan08
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	Cetuximab,SNK01		Withdrawn	NCT04464967		ECD	2022Aug01	Yes	Yes	No patients recruited	4	NCT04464967			Overall Response Rate	0	0																																									No	COSO31314888	2024Apr24
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	SNK01,Trastuzumab		Withdrawn	NCT04464967		ECD	2022Aug01	Yes	Yes	No patients recruited	4	NCT04464967			Overall Response Rate	0	0																																									No	COSO31314888	2024Jul04
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	anti-CTLA-4/PD-1 expressing EGFR-CAR T-cells		Unknown	NCT03182816		ECD	2019Jan20	Yes	Yes		1	34032893	Previously-treated		Maximum tolerated dose/toxicity	9	9											7.13			2.71-17.1										15.63			8.82-22.03				1	6									No	COSO31314888	2025Jan08
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	Erlotinib,Tivantinib		Completed	NCT00777309		PCD	2011May01	No	Yes		1	21768463			Progression free survival	167	84	83	Erlotinib,Placebo									3.8	2.3	.81	0.57-1.16	0.24																										No	COSO31314888	2021Jun01
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	Poziotinib		Terminated	NCT04172597	Cohort 5	PCD	2022Mar29	Yes	Yes	Changed business priorities	4	NCT04172597			Overall Response Rate	1	1																																									No	COSO31314888	2025Jan08
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	Osimertinib		Not yet recruiting	NCT06692491		ECD	2027Dec31	No	No		4	NCT06692491	Previously-treated		Overall Response Rate	200	200																																									No	COSO31314888	2024Nov27
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	Gefitinib		Unknown	NCT03239015		ECD	2023Jun30	Yes	No		4	NCT03239015			Overall Response Rate	300	300																																									No	COSO31314888	2024Apr17
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	Erlotinib		Active, not recruiting	NCT04591431	ROME	ECD	2024Dec01	Yes	No		4	NCT04591431			Overall Response Rate	400	400																																									No	COSO31314888	2024Jan04
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	Erlotinib		Recruiting	NCT03297606	CAPTUR group 5	ECD	2026Jan31	Yes	No		4	NCT03297606			Overall Response Rate	720	720																																									No	COSO31314888	2023Apr04
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	Erlotinib		Unknown	NCT03239015		ECD	2023Jun30	Yes	No		4	NCT03239015			Overall Response Rate	300	300																																									No	COSO31314888	2024Apr17
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	Afatinib		Unknown					Expression confirmed	Yes		1	23775486	Previously-treated		Overall Response Rate	5	5																																2									No	COSO31314888	2021May18
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	Afatinib		Unknown	NCT03810872		ECD	2020Dec01	Yes	No		4	NCT03810872			Response rate	87	87																																									No	COSO31314888	2023Apr04
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Phase 2	Afatinib		Active, not recruiting	NCT02465060	MATCH Subprotocol A	ECD	2025Dec31	Yes	No		4	NCT06360588	Previously-treated		Overall Response Rate	6452	6452																																									No	COSO31314888	2025Jan08
EGFR_unspecified	Gene				NS / other / neoplasm	3	In trials	Unknown	Nimotuzumab		Recruiting	NCT06022276		ECD	2024Dec31	Overexpression	No		4	NCT06022276	Previously-treated		Progression free survival	46	46																																									No	COSO31314888	2023Nov09
EGFR_unspecified	Gene				biliary tract / carcinoma / adenocarcinoma	3	In trials	Phase 2	Varlitinib		Completed	NCT02609958		PCD	2017Jul07	No	No		4	NCT02609958	Previously-treated		Overall Response Rate	32	32																																									No	COSO27814826	2022May03
EGFR_unspecified	Gene				biliary tract / carcinoma / adenocarcinoma	3	In trials	Phase 2	Varlitinib		Unknown					No	Yes		3	http://cancerres.aacrjournals.org/content/69/9_Supplement/3603			Unknown	1	1																															1										No	COSO27814826	2021May18
EGFR_unspecified	Gene				biliary tract / other / neoplasm	3	In trials	Phase 1	Erlotinib,Gemcitabine,Oxaliplatin		Completed	NCT01149122		PCD	2012Jan01	No	Yes		1	22192731			Progression free survival	268	135	133	Gemcitabine,Oxaliplatin	30	16							5.8	4.2	.8	0.61-1.03	0.087									9.5	9.5	.93	0.69-1.25	0.611													No	COSO51837372	2025Jan08
EGFR_unspecified	Gene				biliary tract / other / neoplasm	3	In trials	Phase 2	Capecitabine,Varlitinib		Completed	NCT03231176		PCD	2019Jul05	No	Yes		5	http://aslanpharma.com/app/uploads/2019/09/CSCO-2019_ASLAN001-008.pdf	Previously-treated		Overall Response Rate	61	61			10.8								2.7										70.2			5.8																	No	COSO51837372	2025Jan08
EGFR_unspecified	Gene				biliary tract / other / neoplasm	3	In trials	Phase 2	MRG003		Unknown	NCT04838964		ECD	2024Oct01	Expression confirmed	No		4	NCT04838964			Overall Response Rate	80	80																																									No	COSO51837372	2025Jan08
EGFR_unspecified	Gene				biliary tract / other / neoplasm	3	In trials	Phase 2	Sunitinib		Completed	NCT01082809		PCD	2012Jan01	No	Yes		1	22176869			Time to progression, time to recurrence	56	56			8.9		3.0-19.6		2.4		2.0-2.8							1.7					50.0		36.3-63.7	4.8			3.8-4.8				5	23									No	COSO51837372	2025Jan08
EGFR_unspecified	Gene				biliary tract / other / neoplasm	3	In trials	Phase 3	Capecitabine,Varlitinib		Completed	NCT03093870	TreeTop	PCD	2019Nov12	No	Yes		1	34922298	Previously-treated		ORR, PFS, OS	127	64	63	Capecitabine	9.4	4.8		0.42					2.83	2.79	.9	0.60-1.37	0.63									7.8	7.5	1.11	0.69-1.79	0.66													No	COSO51834888	2025Jan08
EGFR_unspecified	Gene				bone / chordoma / NS	3	In trials	Phase 2	Afatinib		Unknown	NCT03083678		ECD	2023Jul01	Yes	Yes	PFS 12m 40.0%	2	10.1200/JCO.2024.42.16_suppl.11517	Untreated		Progression free survival	34	34											9.1			5.8-16.6																											No	COSO280610873	2025Jan08
EGFR_unspecified	Gene				bone / chordoma / NS	3	In trials	Phase 2	Cetuximab		Recruiting	NCT05041127		ECD	2026Sep01	No	No		4	NCT05041127			Overall Response Rate	15	15																																									No	COSO280610873	2024Oct17
EGFR_unspecified	Gene				bone / chordoma / NS	3	In trials	Phase 2	Afatinib		Unknown	NCT03083678		ECD	2023Jul01	Yes	Yes	PFS 12m 38.5%	2	10.1200/JCO.2024.42.16_suppl.11517	Previously-treated		Progression free survival	13	13											7.1			2.8-16.5																											No	COSO280610873	2025Jan08
EGFR_unspecified	Gene				breast / carcinoma / NS	3	In trials	Phase 2	Vandetanib		Active, not recruiting	NCT02299999	SAFIR02_Breast	PCD	2022Dec01	Yes	No		4	NCT02299999			Progression free survival	1460			Chemotherapy																																							No	COSO28394862	2025Jan08
EGFR_unspecified	Gene				breast / carcinoma / NS	3	In trials	Phase 2	Lapatinib,Paclitaxel		Completed	NCT00111787		PCD	2006Nov01	Overexpression	No		4	NCT00111787			Complete response, Pathological complete response	49	49																																									No	COSO28394862	2021Oct04
EGFR_unspecified	Gene				breast / carcinoma / NS	3	In trials	Phase 2	Sapitinib		Active, not recruiting	NCT02299999	SAFIR02_Breast	PCD	2022Dec01	Yes	No		4	NCT02299999			Progression free survival	1460			Chemotherapy																																							No	COSO28394862	2025Jan08
EGFR_unspecified	Gene				breast / carcinoma / NS	3	In trials	Phase 2	Lapatinib,Paclitaxel,Trastuzumab		Completed	NCT01688609		PCD	2013Dec01	No	Yes		4	NCT01688609			Complete response, Pathological complete response	18	18																														8											No	COSO28394862	2024Jul04
EGFR_unspecified	Gene				breast / carcinoma / NS	3	In trials	Phase 2	AZD4547		Active, not recruiting	NCT02299999	SAFIR02_Breast	PCD	2022Dec01	Yes	No		4	NCT02299999			Progression free survival	1460			Chemotherapy																																							No	COSO28394862	2025Jan08
EGFR_unspecified	Gene				breast / carcinoma / NS	3	In trials	Phase 2	Carboplatin,Gemcitabine,Panitumumab		Completed	NCT00894504		PCD	2014Sep01	No	Yes	Lack of efficacy, Response not correlated with mutation status	1	27340049			Progression free survival	71	71			42.0								4.4													11.6						1	29										No	COSO28394862	2024Jan30
EGFR_unspecified	Gene				breast / carcinoma / NS	3	In trials	Phase 2	Capecitabine,Pyrotinib		Completed					No	Yes		3	http://cancerres.aacrjournals.org/content/78/4_Supplement/PD3-08			Unknown	128	65	63	Capecitabine,Lapatinib	78.5	57.1		0.01					18.1	7	.363	0.228-0.579	<0.0001																										No	COSO28394862	2022May19
EGFR_unspecified	Gene				breast / carcinoma / NS	3	In trials	Phase 2	Poziotinib		Completed	NCT02544997		PCD	2020Feb01	Yes	No		4	NCT02544997	Previously-treated		Progression free survival	5	5																																									No	COSO28394862	2022May03
EGFR_unspecified	Gene				breast / carcinoma / NS	3	In trials	Phase 2	Canertinib		Completed	NCT00051051				No	Yes	Primary outcome not met	1	19294387	Previously-treated		Clinical activity	168																																										No	COSO28394862	2022May03
EGFR_unspecified	Gene				breast / carcinoma / NS	3	In trials	Phase 3	Capecitabine,Pyrotinib		Unknown	NCT03080805	PHOEBE	PCD	2019Mar31	No	Yes		2	10.1200/JCO.2020.38.15_suppl.1003	Previously-treated		Progression free survival	266	134	132	Capecitabine,Lapatinib	67.2	51.5	4.0-27.3	0.0091	11.1	7			12.5	6.8	.39	0.27-0.56	<0.0001						73.1	59.1																			Yes	COSO28394862	2025Jan08
EGFR_unspecified	Gene				central nervous system / NS / NS	3	In trials	Phase 1	EGFR806-CAR T-cells		Completed	NCT03638167		PCD	2023Dec22	Yes	No		4	NCT03638167			Maximum tolerated dose/toxicity	11	11																																									No	COSO36714954	2025Jan08
EGFR_unspecified	Gene				central nervous system / glioma / NS	3	In trials	Phase 1	AMG404,AMG596		Terminated	NCT03296696		PCD	2021Jul01	Yes	Yes		2	10.1093/neuonc/noz219.1195			Maximum tolerated dose/toxicity	8	8																															1	2									No	COSO28245257	2025Jan08
EGFR_unspecified	Gene				central nervous system / glioma / NS	3	In trials	Phase 1	BDTX-1535		Recruiting	NCT06072586		ECD	2025May01	Yes	No		4	NCT06072586			Progression free survival	34	34																																									No	COSO28245257	2024Oct17
EGFR_unspecified	Gene				central nervous system / glioma / NS	3	In trials	Phase 2	Poziotinib		Terminated	NCT04172597	Cohort 4	PCD	2022Mar29	Yes	Yes	Changed business priorities	4	NCT04172597			Overall Response Rate	0	0																																									No	COSO28245257	2025Jan08
EGFR_unspecified	Gene				central nervous system / glioma / NS	3	In trials	Phase 2	Cyclophosphamide,EGFRvIII CAR T-cells,Fludarabine,Interleukin-2		Completed	NCT01454596		PCD	2018Nov01	Expression confirmed	Yes		4	NCT01454596			Progression free survival	3	3											2.7			0.9-12.5																											No	COSO28245257	2025Jan08
EGFR_unspecified	Gene				central nervous system / glioma / NS	3	In trials	Phase 2	Irinotecan,Panitumumab		Terminated	NCT01017653		PCD	2011Oct01	No	Yes	Lack of efficacy	4	NCT01017653			Progression free survival	16	16																																									No	COSO28245257	2024Jan30
EGFR_unspecified	Gene				central nervous system / glioma / NS	3	In trials	Unknown	MAb-425		Completed					Expression confirmed	Yes	Serious adverse events	1	9191875			Overall survival	8	8																															3										No	COSO28245257	2021May18
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 1	Afatinib		Recruiting	NCT05432518		ECD	2027Jul01	Expression confirmed	No		4	NCT05432518	Previously-treated		Maximum tolerated dose/toxicity	10	10																																									No	COSO36715232	2023Aug31
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 1	Anti-EGFRvIII CAR T-cells,Pembrolizumab,Standard of care,Zanidatamab		Completed	NCT03726515		PCD	2021Feb27	Expression confirmed	Yes	Primary outcome not met	1	38216766			Maximum tolerated dose/toxicity	7	7											5.2													11.8																	No	COSO36715232	2024Nov26
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 1	BDTX-1535		Recruiting	NCT05256290		ECD	2025Jul01	Yes	No		4	NCT05256290	Previously-treated		Maximum tolerated dose/toxicity	200	200																																									No	COSO36715232	2024Jul11
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 1	ERAS-801		Active, not recruiting	NCT05222802	THUNDERBBOLT-1	ECD	2025Jan31	Yes	No		4	NCT05222802			Maximum tolerated dose/toxicity	52	52																																									No	COSO36715232	2024Apr17
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 1	RO7428731		Active, not recruiting	NCT05187624		ECD	2025Dec31	Expression confirmed	No		4	NCT05187624			Maximum tolerated dose/toxicity	36	36																																									No	COSO36715232	2025Jan08
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 1	Anti-EGFR/IL13RA2 CAR T-cells,Cyclophosphamide,Fludarabine		Recruiting	NCT05168423		ECD	2024Dec19	Overexpression	No		4	NCT05168423			Maximum tolerated dose/toxicity	18	18																																									No	COSO36715232	2024Jul31
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 1	EGFRvIII CAR T-cells		Not yet recruiting	NCT05802693		ECD	2025Nov14	Expression confirmed	No		4	NCT05802693	Previously-treated		Maximum tolerated dose/toxicity	22	22																																									No	COSO36715232	2024Jul31
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 1	CM93		Not yet recruiting	NCT04933422		ECD	2029Jul01	Yes	No		4	NCT04933422	Previously-treated		Maximum tolerated dose/toxicity	72	72																																									No	COSO36715232	2024Oct17
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 1	Anti-EGFRvIII CAR T-cells		Terminated	NCT03283631	INTERCEPT	PCD	2019Sep19	Yes	Yes	Changed business priorities	4	NCT03283631			Maximum tolerated dose/toxicity	2	2																																									No	COSO36715232	2024Aug28
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 1	Serclutamab talirine		Completed	NCT03234712		PCD	2021Apr14	Expression confirmed	Yes		1	36814898			Maximum tolerated dose/toxicity	17	17			0																												0	5									No	COSO36715232	2025Jan08
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 1	Depatuxizumab mafodotin,Temozolomide		Completed	NCT01800695		PCD	2017Jun19	Expression confirmed	Yes		1	29075855	Previously-treated		Maximum tolerated dose/toxicity	202	202			6.8																																						No	COSO36715232	2022May03
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 1	Erlotinib		Terminated	NCT00227032		PCD	2008Feb01	No	Yes	Lack of funding	4	NCT00227032			Progression free survival	10	10																																									No	COSO36715232	2022Nov18
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 2	Erlotinib		Completed	NCT00301418		PCD	2014May01	No	Yes	Manageable toxicity	1	16282176	Previously-treated		Maximum tolerated dose/toxicity	11	11																								5.49																	No	COSO36715232	2024Jan30
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 2	Atorvastatin,Temozolomide		Recruiting	NCT06327451		ECD	2026Feb28	Expression confirmed	No		4	NCT06327451			OS, PFS	50	50																																									No	COSO36715232	2024Apr30
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 2	Verteporfin		Recruiting	NCT04590664		ECD	2025Aug15	Yes	No		4	NCT04590664	Previously-treated		OS, PFS	24	24																																									No	COSO36715232	2024Apr17
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 2	GC1118		Completed	NCT03618667		PCD	2018Sep08	Expression confirmed	Yes	PFS 6m 5.6% 95%CI 0.3-25.8, Primary outcome not met	2	10.1002/cam4.6213			Progression free survival	18	18											1.7													5.7																	No	COSO36715232	2025Jan08
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 2	Afatinib,Temozolomide		Completed	NCT00727506		PCD	2011May12	Expression confirmed	Yes	Lack of efficacy	1	25140039	Previously-treated		Progression free survival	151			Afatinib																																							No	COSO36715232	2024Jan30
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 2	Depatuxizumab mafodotin,Temozolomide		Completed	NCT02343406	INTELLANCE 2	PCD	2019Jun24	Expression confirmed	Yes		2	10.1093/neuonc/noy148.072	Previously-treated		Progression free survival	255			Temozolomide																						40	28	.68	0.48-0.95	0.024													No	COSO36715232	2025Jan08
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 2	Tesevatinib		Completed	NCT02844439	Sub population A	PCD	2020Apr30	Expression confirmed	Yes	PFS 6m 25.0%	4	NCT02844439			Progression free survival	24	24			4.2								1.7			0.95-2.96										7.8			6.64-15.67														No	COSO36715232	2025Jan08
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 2	Dacomitinib		Completed	NCT01520870		PCD	2015Apr01	Expression confirmed	Yes	PFS 6m 10.6%	1	28575464	Previously-treated		Progression free survival	49	49											2.7													7.4																	No	COSO36715232	2021Aug03
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 3	Depatuxizumab mafodotin,Temozolomide		Completed	NCT02573324	Intellance1	PCD	2022Apr04	Expression confirmed	Yes	Lack of efficacy, Primary outcome not met	5	https://news.abbvie.com/news/press-releases/abbvie-provides-update-on-depatuxizumab-mafodotin-depatux-m-an-investigational-medicine-for-newly-diagnosed-glioblastoma-an-aggressive-form-brain-cancer.htm	Untreated		Overall survival	655			Temozolomide																																							No	COSO36715232	2025Jan08
EGFR_unspecified	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 3	Depatuxizumab mafodotin,Temozolomide		Terminated	NCT03419403	UNITE	PCD	2019Sep05	Expression confirmed	Yes	Lack of efficacy	4	NCT03419403	Untreated		Change in ocular side effect management	40			Temozolomide																																							No	COSO36715232	2024Jul17
EGFR_unspecified	Gene				gastrointestinal tract (site indeterminate) / carcinoma / NS	3	In trials	Phase 2	Depatuxizumab		Completed	NCT02213289	PANGEA-IMBBP	PCD	2020Feb01	Overexpression	Yes	OS 1y 75%	2	10.1200/JCO.2020.38.4_suppl.356			Overall survival	8	8																																									No	COSO36634862	2025Jan08
EGFR_unspecified	Gene				gastrointestinal tract (site indeterminate) / carcinoma / NS	3	In trials	Phase 2	Erlotinib or Gefitinib		Unknown	NCT02013089	GITIC	ECD	2017May01	Yes	No		4	NCT02013089			Overall survival	50	50																																									No	COSO36634862	2022Nov17
EGFR_unspecified	Gene				gastrointestinal tract (site indeterminate) / carcinoma / NS	3	In trials	Phase 2	Depatuxizumab		Completed	NCT02213289	PANGEA-IMBBP	PCD	2020Feb01	Expression confirmed	Yes	OS 1y 44%	2	10.1200/JCO.2020.38.4_suppl.356			Overall survival	9	9																																									No	COSO36634862	2025Jan08
EGFR_unspecified	Gene				gastrointestinal tract (site indeterminate) / carcinoma / adenocarcinoma	3	In trials	Phase 2	Capecitabine,Cetuximab,Cisplatin		Completed	NCT00477711	EXTRA	PCD	2008Dec01	No	Yes		1	25234930	Untreated		Response rate	7	7											7.1													16.6																	No	COSO36634826	2025Jan08
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Approved FDA	Cetuximab	Required	Completed	NCT00079066	CO.17	PCD	2006Nov03	Expression confirmed	Yes		4	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf	Previously-treated		Overall survival	572	287	285	Best supportive care																						6.1	4.6	.77	0.64-0.92	0.005													Yes	COSO28864826	2025Jan08
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Approved FDA	FOLFIRI,Ramucirumab	Not required	Completed	NCT01183780	RAISE	PCD	2014Jul17	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf			Progression free survival	1072	536	536	FOLFIRI,Placebo									5.7	4.5	.79	0.70-0.90	<0.01									13.1	11.7	.85	0.73-0.98	0.023													Yes	COSO28864826	2024Jul03
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Approved FDA	Cetuximab,Irinotecan	wt KRAS	Completed		BOND			Expression confirmed	Yes		1	15269313			Unknown	329	218	111	Cetuximab	22.9	10.8		0.007	5.7	4.2													55.5	32.4	<0.001																		No	COSO28864826	2023Jan17
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Approved FDA	Cetuximab,FOLFIRI	wt KRAS	Completed	NCT00154102	CRYSTAL	PCD	2006Dec01	Expression confirmed	Yes	Response not correlated with expression status PMID:23265711 	1	19339720	Untreated		Progression free survival	1198	599	599	FOLFIRI									8.9	8	.85	0.72-0.99	0.048									19.9	18.6	.93	0.81-1.07	0.31													Yes	COSO28864826	2025Jan08
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Approved FDA	Panitumumab	wt KRAS	Completed	NCT00113763	20020408	PCD	2008Oct01	Expression confirmed	Yes		1	17470858	Previously-treated		Progression free survival	463	231	232	Best supportive care	10	0		0.001					1.83	1.69																													No	COSO28864826	2025Jan08
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Approved FDA	Panitumumab	wt KRAS	Completed	NCT01001377	20080763	PCD	2013Feb05	No	Yes		1	24739896	Previously-treated		Overall survival	1010	506	504	Cetuximab																						10.4	10	.97	0.84-1.11														No	COSO28864826	2022May03
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Phase 1	Pelitinib		Unknown					Yes	Yes		1	16364494			Unknown	15	15																														2											No	COSO28864826	2021May18
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Phase 1	Batoprotafib,Nazartinib		Active, not recruiting	NCT03114319		ECD	2025May08	Yes	No		4	NCT03114319			Maximum tolerated dose/toxicity	227	227																																									No	COSO28864826	2024Oct17
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Phase 1	Gatipotuzumab,Tomuzotuximab		Completed	NCT03360734	GATTO	PCD	2020May04	Yes	Yes		1	35397434			Maximum tolerated dose/toxicity	19	19			21.1																												4										No	COSO28864826	2025Jan08
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Phase 2	Regorafenib		Active, not recruiting	NCT03992456	PULSE	PCD	2023Dec01	No	No		4	NCT03992456			Overall survival	12	12																																									No	COSO28864826	2024Jul11
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Phase 2	AFM24,SNK01		Terminated	NCT05099549		PCD	2023Sep21	Expression confirmed	Yes	Changed business priorities	4	NCT05099549			Overall Response Rate	11	11																																									No	COSO28864826	2024Nov13
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Phase 2	Trifluridine-Tipiracil hydrochloride		Active, not recruiting	NCT03992456	PULSE	PCD	2023Dec01	No	No		4	NCT03992456			Overall survival	12	12																																									No	COSO28864826	2024Jul11
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Phase 2	Erlotinib,Pemetrexed		Completed	NCT03086538		PCD	2020Jan30	Expression confirmed	Yes	Primary outcome met	1	31820199			Overall Response Rate	29	29			10.3																		62.1										3	15									Yes	COSO28864826	2022Nov29
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Phase 2	Anti-EGFR CD3-CD28-4-1BB-expressing CAR T-cells		Unknown	NCT03152435		ECD	2019Sep01	Expression confirmed	No		4	NCT03152435			Maximum tolerated dose/toxicity	20	20																																									No	COSO28864826	2024Aug01
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Phase 2	Cetuximab,FOLFOX-4		Completed	NCT00202787		PCD	2009Feb01	No	Yes		3	https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-001700-12/results			Overall Response Rate	136	68	68	FOLFOX-4	47.1	54.4			6.7	9.6			8.05	10.09				8.77	9.45				95.6	88.2		19.52	26.38			0.02													No	COSO28864826	2024Jul18
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Phase 2	Bevacizumab,Erlotinib,FOLFOX		Completed					No	Yes		1	28979818	Previously-treated		Unknown	131	66	65	Bevacizumab,FOLFOX									9.6	6.9	1.15	0.88-1.39	0.021																										No	COSO28864826	2024Jul03
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Phase 2	FOLFIRI,Imgatuzumab		Completed	NCT01326000		PCD	2013Dec01	Expression confirmed	Yes	Lack of efficacy	2	10.1200/jco.2015.33.3_suppl.669 	Previously-treated		Progression free survival				FOLFIRI																																							No	COSO28864826	2025Jan08
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Phase 2	Futuximab		Terminated	NCT03549338		PCD	2019Mar01	No	Yes	Administrative reasons	4	NCT03549338	Previously-treated		Maximum tolerated dose/toxicity	2	2																																									No	COSO28864826	2022Nov28
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Phase 2	Futuximab		Completed	NCT02083653		PCD	2016Oct24	No	Yes	Primary outcome not met	1	29423521	Previously-treated		Overall survival	254			Best supportive care																																							No	COSO28864826	2022May03
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Phase 2	Panitumumab		Active, not recruiting	NCT03992456	PULSE	PCD	2023Dec01	No	No		4	NCT03992456			Overall survival	12	12																																									No	COSO28864826	2024Jul11
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Phase 2	Panitumumab		Active, not recruiting	NCT03087071	Cohort 1	ECD	2025Jan31	Yes	Yes		2	10.1200/JCO.2022.40.16_suppl.3520	Previously-treated		Response rate	3	3			0																		67																				No	COSO28864826	2025Jan08
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Phase 2	Duligotuzumab,FOLFIRI		Completed	NCT01652482		PCD	2014Nov01	No	Yes	Lack of efficacy	1	29506988	Previously-treated		Progression free survival																																											No	COSO28864826	2025Jan08
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Phase 2	Pelitinib		Completed	NCT00072748		PCD	2004Oct01	No	Yes	Serious adverse events	1	24574860	Previously-treated		Not defined	63	63																																									No	COSO28864826	2021May18
EGFR_unspecified	Gene				large intestine / carcinoma / adenocarcinoma	2	Promising trials results	Unknown	FOLFIRI,Regorafenib		Completed	NCT03698253		PCD	2018Jun01	Expression confirmed	Yes		1	30594039			Progression free survival	28	28											2.5										46.4			9.6																	No	COSO28864826	2025Jan08
EGFR_unspecified	Gene				liver / NS / NS	3	In trials	Phase 2	Bevacizumab,Erlotinib		Completed	NCT00365391		PCD	2008Aug01	No	Yes		4	NCT00365391			Overall Response Rate	27	27			3.7																												1										No	COSO29824954	2021May18
EGFR_unspecified	Gene				liver / carcinoma / hepatocellular carcinoma	3	In trials	Phase 2	Varlitinib		Unknown	NCT03499626		ECD	2019May05	Yes	No		4	NCT03499626			Maximum tolerated dose/toxicity	22	22																																									No	COSO29825606	2022May03
EGFR_unspecified	Gene				lung / carcinoma / adenocarcinoma	3	In trials	Phase 1	Icotinib		Completed	NCT02044328	ICAPE	PCD	2018Jan01	Yes	Yes	OS 5y 61.7%	1	36355317			Disease free survival, relapse free survival, regression free survival, recurrence free survival	79	79																								67.0			21.2-						41.4			33.6-51.8					No	COSO29914826	2024Aug14
EGFR_unspecified	Gene				lung / carcinoma / adenocarcinoma	3	In trials	Phase 2	Erlotinib,Ruxolitinib		Completed	NCT02155465		PCD	2017Oct01	Yes	Yes	Lack of efficacy	1	27613527	Previously-treated		Maximum tolerated dose/toxicity	22	22																															1										No	COSO29914826	2024Jan30
EGFR_unspecified	Gene				lung / carcinoma / adenocarcinoma	3	In trials	Phase 2	Alflutinib,Bevacizumab		Recruiting	NCT05503667		ECD	2023Oct01	Yes	No		4	NCT05503667			Overall Response Rate	96			Alflutinib																																							No	COSO29914826	2024Apr23
EGFR_unspecified	Gene				lung / carcinoma / adenocarcinoma	3	In trials	Phase 2	EGFR-TKI,Nimotuzumab		Unknown	NCT04833205		ECD	2022Apr19	Expression confirmed	No		4	NCT04833205			Progression free survival	30	30																																									No	COSO29914826	2023Aug31
EGFR_unspecified	Gene				lung / carcinoma / adenocarcinoma	3	In trials	Phase 2	Cisplatin,Nimotuzumab,Pemetrexed		Unknown	NCT03574402	CTONG1702 Arm 11	ECD	2022Dec30	Expression confirmed	No		4	NCT03574402			Response rate	400	400																																									No	COSO29914826	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / bronchioloalveolar adenocarcinoma	3	In trials	Phase 2	Gefitinib		Completed	NCT00029003		PCD	2004Dec01	No	No		4	NCT00029003			Overall survival	90	90																																									No	COSO29915645	2021May18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Approved FDA	Docetaxel,Ramucirumab	Not required	Completed	NCT01168973	REVEL	PCD	2013Dec01	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125477s042lbl.pdf			Overall survival	1253	628	625	Docetaxel,Placebo									4.5	3	.76	0.68-0.86	<0.001									10.5	9.1	.86	0.75-0.98	0.024													Yes	COSO29915674	2023Apr04
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Out of trials human study	Pemetrexed		Unknown					Comparison with wt	Yes		1	21111508	Previously-treated		Unknown	156	93	63		12.9	1.59							3.9	2.3	.677	0.485-0.943	0.021						51.6	38.1		30.8	25.8			0.439													No	COSO29915674	2022May11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Afatinib		Terminated	NCT03711422		PCD	2019Dec20	Yes	Yes	Slow accrual	4	NCT03711422			OS, PFS	2	2																																									No	COSO29915674	2023Apr28
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	BG-60366		Recruiting	NCT06685718		ECD	2028Apr01	Yes	No		4	NCT06685718			Overall Response Rate	93	93																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	HS-20093,HS-20117		Not yet recruiting	NCT06621563	Cohort E1	ECD	2026Mar30	Yes	No		4	NCT06621563			PFS, ORR	780	780																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Cisplatin or Carboplatin,HS-20117,Pemetrexed		Not yet recruiting	NCT06621563	Cohort D	ECD	2026Mar30	Yes	No		4	NCT06621563			PFS, ORR	780	780																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	HS-10504		Not yet recruiting	NCT06461156	Dose escalation	ECD	2026Dec31	Yes	No		4	NCT06461156			Maximum tolerated dose/toxicity	230	230																																									No	COSO29915674	2024Oct21
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	HBI-2376,Osimertinib		Recruiting	NCT06306456		ECD	2025Dec31	Yes	No		4	NCT06306456			Progression free survival	94	94																																									No	COSO29915674	2024Apr30
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Docetaxel,SMET12,Toripalimab		Not yet recruiting	NCT06208033		ECD	2024Oct20	Expression confirmed	No		4	NCT06208033	Previously-treated		Maximum tolerated dose/toxicity	40	40																																									No	COSO29915674	2024Apr30
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Platinum-doublet chemotherapy,SMET12,Toripalimab		Not yet recruiting	NCT06208033		ECD	2024Oct20	Expression confirmed	No		4	NCT06208033	Untreated		Maximum tolerated dose/toxicity	40	40																																									No	COSO29915674	2024Apr30
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	TRX-221		Recruiting	NCT06186076		ECD	2027Jun30	Yes	No		4	NCT06186076	Previously-treated		Maximum tolerated dose/toxicity	115	115																																									No	COSO29915674	2024Jul11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	HSK40118		Recruiting	NCT06050980		ECD	2025Aug30	Yes	No		4	NCT06050980			Maximum tolerated dose/toxicity	220	220																																									No	COSO29915674	2023Nov09
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	BBP-398,Osimertinib		Terminated	NCT06032936		PCD	2024Mar29	Yes	No		4	NCT06032936			Overall Response Rate	4	4																																									No	COSO29915674	2024Jul11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Befotertinib,MCLA-129		Not yet recruiting	NCT06015568		ECD	2028Nov04	Yes	No		4	NCT06015568	Previously-treated		Overall Response Rate	172	172																																									No	COSO29915674	2023Nov08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Befotertinib,MCLA-129		Not yet recruiting	NCT06015568		ECD	2028Nov04	Yes	No		4	NCT06015568	Untreated		Overall Response Rate	172	172																																									No	COSO29915674	2023Nov08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	CPO301		Recruiting	NCT05948865	Part B Cohort 1	ECD	2025Jun13	Yes	No		4	NCT05948865			Maximum tolerated dose/toxicity	102	102																																									No	COSO29915674	2024Jan04
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	IBI363		Recruiting	NCT06081907	Promise Cohort F	ECD	2026Dec01	Expression confirmed	No		4	NCT06081907	Previously-treated		Overall Response Rate	430	430																																									No	COSO29915674	2024Jul11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	HS-20117		Not yet recruiting	NCT05940116		ECD	2025Jul30	Yes	No		4	NCT05940116			Overall Response Rate	322	322																																									No	COSO29915674	2023Sep25
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Osimertinib,Tegafur-gimeracil-oteracil potassium		Recruiting	NCT05773092	SOS-1	ECD	2026Mar31	Yes	No		4	NCT05773092	Previously-treated		Overall Response Rate	27	27																																									No	COSO29915674	2024Jan04
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Cemiplimab,Sarilumab		Recruiting	NCT05704634		ECD	2026Jan01	Yes	No		4	NCT05704634	Previously-treated		Maximum tolerated dose/toxicity	56	56																																									No	COSO29915674	2023Aug31
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Tumor treating fields		Not yet recruiting	NCT05698264		ECD	2027Dec31	Yes	No		4	NCT05698264			ctDNA mutation detection	50	50																																									No	COSO29915674	2023Mar20
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Almonertinib,Retlirafusp alfa		Not yet recruiting	NCT05503888		ECD	2027Jul30	Yes	No		4	NCT05503888			Progression free survival	160			Almonertinib,Placebo																																							No	COSO29915674	2024Sep02
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Dalpiciclib,EGFR-TKI		Unknown	NCT05497076		ECD	2024Jan01	Yes	No		4	NCT05497076	Previously-treated		Overall Response Rate	9	9																																									No	COSO29915674	2024Oct17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Carotuximab,Osimertinib		Recruiting	NCT05401110		ECD	2025Jan01	Yes	No		4	NCT05401110	Previously-treated		Maximum tolerated dose/toxicity	60	60																																									No	COSO29915674	2024Jan04
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Erlotinib,Ipilimumab		Completed	NCT01998126		PCD	2017May09	Yes	Yes	Serious adverse events	2	10.1016/j.jtho.2017.09.010			Maximum tolerated dose/toxicity	11	11											17.9																														No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	BDTX-1535		Recruiting	NCT05256290		ECD	2025Jul01	Yes	No		4	NCT05256290	Previously-treated		Maximum tolerated dose/toxicity	200	200																																									No	COSO29915674	2024Jul11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Personalized DC vaccine		Recruiting	NCT05195619		ECD	2024Sep01	Yes	No		4	NCT05195619			Maximum tolerated dose/toxicity	16	16																																									No	COSO29915674	2024Aug01
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	BAY2927088_formulation A		Recruiting	NCT05099172		ECD	2025Dec31	Yes	No		4	NCT05099172	Previously-treated		Maximum tolerated dose/toxicity	370	370																																									No	COSO29915674	2024Oct17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	BAY2927088_formulation B_1		Recruiting	NCT05099172		ECD	2025Dec31	Yes	No		4	NCT05099172	Previously-treated		Maximum tolerated dose/toxicity	370	370																																									No	COSO29915674	2024Oct17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	BAY2927088_formulation B_2		Recruiting	NCT05099172		ECD	2025Dec31	Yes	No		4	NCT05099172	Previously-treated		Maximum tolerated dose/toxicity	370	370																																									No	COSO29915674	2024Oct17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	CXCR5 modified EGFR CAR T-cells		Recruiting	NCT05060796		ECD	2029Nov01	Expression confirmed	No		4	NCT05060796			Maximum tolerated dose/toxicity	11	11																																									No	COSO29915674	2024Jul31
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	TAS2940		Active, not recruiting	NCT04982926		ECD	2025May01	Yes	No		4	NCT04982926			Overall Response Rate	29	29																																									No	COSO29915674	2024Oct17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Almonertinib,Bevacizumab		Not yet recruiting	NCT04944069	ATTRACT	ECD	2024Mar01	Yes	No		4	NCT04944069			Overall survival	69	69																																									No	COSO29915674	2024Sep02
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Osimertinib,Repotrectinib		Recruiting	NCT04772235	TOTEM	ECD	2026Apr01	Yes	No		4	NCT04772235			Maximum tolerated dose/toxicity	32	32																																									No	COSO29915674	2024Dec20
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	MRX-2843,Osimertinib		Recruiting	NCT04762199		ECD	2025Dec27	Yes	No		4	NCT04762199			Maximum tolerated dose/toxicity	69	69																																									No	COSO29915674	2024Jul11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	BBP-398		Terminated	NCT05621525	Part B	PCD	2024Mar29	Yes	No		4	NCT05621525			ORR, DOR	7	7																																									No	COSO29915674	2024Jul11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Amivantamab,Lazertinib		Active, not recruiting	NCT02609776		PCD	2024Jan31	Yes	No		4	NCT02609776			Overall Response Rate	780	780																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Amivantamab,Lazertinib		Active, not recruiting	NCT04077463		ECD	2025Feb03	Yes	Yes		2	10.1200/JCO.2022.40.16_suppl.9006			ORR, PFS, DOR	50	50			36		23-51																58									1	17										No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	BCA101		Recruiting	NCT04429542		ECD	2026Dec31	Expression confirmed	No		4	NCT04429542			Maximum tolerated dose/toxicity	292	292																																									No	COSO29915674	2024Jul11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	BCA101,Pembrolizumab		Recruiting	NCT04429542		ECD	2026Dec31	Expression confirmed	No		4	NCT04429542			Maximum tolerated dose/toxicity	292	292																																									No	COSO29915674	2024Jul11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Individualized neoantigen peptides vaccine		Unknown	NCT04397926		ECD	2022May30	Yes	No		4	NCT04397926			Maximum tolerated dose/toxicity	20	20																																									No	COSO29915674	2023Apr04
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Alisertib,Osimertinib		Recruiting	NCT04085315		ECD	2026Dec31	Yes	No		4	NCT04085315			Maximum tolerated dose/toxicity	38	38																																									No	COSO29915674	2024Jul11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	TY-9591		Completed	NCT04204473	P1.12A.07	PCD	2023Mar03	Yes	Yes	IORR 90.9%	2	10.1016/j.jtho.2024.09.353	Untreated		Overall Response Rate	11	11																														4	6	1									No	COSO29915674	2025Jan07
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	TY-9591		Completed	NCT04204473	P1.12A.07	PCD	2023Mar03	Yes	Yes	SAE 7.6%	2	10.1016/j.jtho.2024.09.353	Untreated		Overall Response Rate	78	78			85.8		76.2-92.7		20.2		15.9-		21.5			17.3-27.3							94.9																				No	COSO29915674	2024Nov20
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Afatinib,Talcum powder		Active, not recruiting	NCT03827070	DPTA	PCD	2023Feb21	Yes	No		4	NCT03827070			Clinical activity	12	12																																									No	COSO29915674	2023Sep27
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Carboplatin,Pemetrexed,Zimberelimab		Completed	NCT03846310		PCD	2024Nov18	Yes	No		4	NCT03846310			Maximum tolerated dose/toxicity	77	77																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Carboplatin,Etrumadenant,Pemetrexed,Zimberelimab		Completed	NCT03846310		PCD	2024Nov18	Yes	No		4	NCT03846310			Maximum tolerated dose/toxicity	77	77																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Osimertinib,Pelcitoclax		Recruiting	NCT04001777		ECD	2024Dec01	Yes	Yes	Manageable toxicity, Promising efficacy	2	10.1200/JCO.2022.40.16_suppl.9116			Maximum tolerated dose/toxicity	20	20			80																																						No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Niraparib,Osimertinib		Unknown	NCT03891615		ECD	2022Apr30	Yes	No		4	NCT03891615			Maximum tolerated dose/toxicity	30	30																																									No	COSO29915674	2024Jul11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Ipilimumab,Osimertinib		Active, not recruiting	NCT04141644	Osi+Ipi	PCD	2024Jan29	Yes	Yes	Manageable toxicity	2	10.1016/j.annonc.2023.09.2368			Maximum tolerated dose/toxicity	10	10																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Pembrolizumab,Stereotactic body radiation therapy		Terminated	NCT03436056	PRIMING	PCD	2019Jul08	Yes	Yes	Lack of funding	4	NCT03436056			Maximum tolerated dose/toxicity	2	2																																									No	COSO29915674	2024Jul31
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Osimertinib,Stereotactic radiotherapy		Completed	NCT03535363		PCD	2022Apr01	Yes	No		4	NCT03535363			Maximum tolerated dose/toxicity	6	6																																									No	COSO29915674	2024Apr17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Gatipotuzumab,Tomuzotuximab		Completed	NCT03360734	GATTO	PCD	2020May04	Yes	Yes		1	35397434			Maximum tolerated dose/toxicity	5	5			0								5.3			1.9-10.6										10.5			4.7-														No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Abemaciclib,Necitumumab		Completed	NCT02411591		PCD	2017Jun23	No	Yes		2	10.1016/S1556-0864(18)30406-4	Previously-treated		Maximum tolerated dose/toxicity	57	57			5.3		1.1-14.6																47.7			6.93							3	24									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Cucurmin,EGFR-TKI		Unknown	NCT02321293	CURCUMIN	ECD	2016Aug01	No	Yes	Manageable toxicity	2	10.1200/JCO.2019.37.15_suppl.e20611			Maximum tolerated dose/toxicity	41	41																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Buparlisib,Gefitinib		Completed	NCT01570296		PCD	2016Feb22	Expression confirmed	Yes		2	10.1200/jco.2013.31.15_suppl.8107			Maximum tolerated dose/toxicity	10	10											2.8			2.3-8.1																											No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Dasatinib,Erlotinib		Completed	NCT00903734		PCD	2015Jul01	Yes	No		4	NCT00903734			Maximum tolerated dose/toxicity	16	16																																									No	COSO29915674	2021May18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Bortezomib,Erlotinib		Completed	NCT00903734		PCD	2015Jul01	Yes	No		4	NCT00903734			Maximum tolerated dose/toxicity	16	16																																									No	COSO29915674	2021May18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Cetuximab,Erlotinib		Completed	NCT00903734		PCD	2015Jul01	Yes	No		4	NCT00903734			Maximum tolerated dose/toxicity	16	16																																									No	COSO29915674	2021May18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Durvalumab,Gefitinib		Completed	NCT02088112	Arm 2	PCD	2021Mar09	Yes	Yes		1	33012782	Untreated		Maximum tolerated dose/toxicity	10	10			70.0		34.8-93.3		12.6		5.5-20.4		12			2.7-15.6							90.0									0	7										No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Durvalumab,Gefitinib		Completed	NCT02088112	Arms 1 + 1a	PCD	2021Mar09	Yes	Yes		1	33012782	Untreated		Maximum tolerated dose/toxicity	30	30			63.3		43.9-80.1		9.2		3.7-14.0		10.1			5.5-15.2							100									0	19										No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Erlotinib,Momelotinib		Terminated	NCT02206763		PCD	2017Jan12	Yes	Yes	Serious adverse events, Lack of efficacy	1	34773474	Previously-treated		Maximum tolerated dose/toxicity	11	11			54.5				7.1				9.2			6.2?12.4																	11										No	COSO29915674	2024May13
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Pacritinib		Terminated	NCT02342353		PCD	2018Feb06	Yes	Yes	Drug unavailable	4	NCT02342353			Maximum tolerated dose/toxicity	8	8																																									No	COSO29915674	2022May03
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Crizotinib,Ipilimumab		Completed	NCT01998126		PCD	2017May09	Yes	No		4	NCT01998126			Maximum tolerated dose/toxicity	14	14																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Futuximab,Nivolumab		Withdrawn	NCT02924233		PCD	2017Feb01	Expression confirmed	Yes	Changed business priorities	4	NCT02924233			Maximum tolerated dose/toxicity	0	0																																									No	COSO29915674	2022Nov28
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Matuzumab,Pemetrexed		Completed					Expression confirmed	Yes		1	16533873			Unknown	18																															1	3										No	COSO29915674	2021May18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Binimetinib,Erlotinib		Completed	NCT01859026		PCD	2019Aug22	Yes	Yes		1	37499521	Previously-treated		Maximum tolerated dose/toxicity	8	8			0																													1									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Binimetinib,Erlotinib		Completed	NCT01859026		PCD	2019Aug22	Yes	Yes		1	37499521	Untreated		Maximum tolerated dose/toxicity	9	9			89																																						No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Afatinib,Necitumumab		Terminated	NCT03054038		PCD	2022Mar23	Yes	Yes	Slow accrual	4	NCT03054038	Previously-treated		Maximum tolerated dose/toxicity	22	22																																									No	COSO29915674	2022Jun20
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Dacomitinib,Osimertinib		Completed	NCT03755102		PCD	2023Jul07	Yes	Yes		1	36729110			Overall Response Rate	5	5																															3										No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Dacomitinib,Osimertinib		Active, not recruiting	NCT03810807		ECD	2025Jan01	Yes	Yes	Primary outcome met	1	34140482	Untreated		Maximum tolerated dose/toxicity	22	22			73%																																						Yes	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Afatinib,Dasatinib		Completed	NCT01999985		PCD	2017Mar21	No	Yes	Lack of efficacy	1	30880334	Previously-treated		Maximum tolerated dose/toxicity	25	25			0								3.7													14.7								6									No	COSO29915674	2024Jan30
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Naquotinib		Terminated	NCT03082300		PCD	2017May12	Yes	Yes	IDMC recommendation	4	NCT03082300			Maximum tolerated dose/toxicity	3	3																																									No	COSO29915674	2024Jan30
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Almonertinib		Not yet recruiting	NCT04455594	ANSWER	ECD	2023Jan01	Yes	No		4	NCT04455594			Overall Response Rate	168	168																																									No	COSO29915674	2024Sep02
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Gefitinib,Savolitinib		Completed	NCT02374645		PCD	2018Feb18	Yes	No		4	NCT02374645	Previously-treated		Maximum tolerated dose/toxicity	64	64																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	DS-1205c,Osimertinib		Terminated	NCT03255083		PCD	2020Sep04	Yes	Yes	Changed business priorities	4	NCT03255083	Previously-treated		Maximum tolerated dose/toxicity	13	13																																									No	COSO29915674	2023Sep22
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Pelitinib		Unknown					Yes	Yes		1	16364494			Unknown																																	2										No	COSO29915674	2021May18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 1	Dacomitinib		Completed	NCT03755102		PCD	2023Jul07	Yes	Yes		1	36729110			Overall Response Rate	2	2																															1										No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Ipilimumab,Nivolumab		Terminated	NCT03091491		PCD	2019Nov18	Yes	Yes	Lack of efficacy	1	36426287			Overall Response Rate	31	31			3.2								1.22			1.15-1.35																											No	COSO29915674	2022Dec12
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Afatinib,Carboplatin,Pemetrexed or nab-paclitaxel		Not yet recruiting	NCT06709859		ECD	2026May31	Yes	No		4	NCT06709859	Untreated		Resection rate, surgery rate	30	30																																									No	COSO29915674	2024Dec11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Cisplatin or Carboplatin,Pemetrexed,TY-9591		Not yet recruiting	NCT06672068		ECD	2027Dec01	Yes	No		4	NCT06672068	Untreated		Overall Response Rate	60	60																																									No	COSO29915674	2024Dec11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Alflutinib,Cisplatin or Carboplatin,Pemetrexed		Not yet recruiting	NCT06652048		ECD	2026Dec01	Yes	No		4	NCT06652048	Previously-treated		Progression free survival	60	60																																									No	COSO29915674	2024Dec11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	PH009-1		Not yet recruiting	NCT06590194		ECD	2026Jun30	Yes	No		4	NCT06590194			MTD, ORR, Toxicity	96	96																																									No	COSO29915674	2024Oct21
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Alflutinib,Anlotinib,Chemotherapy		Not yet recruiting	NCT06585644		ECD	2025Nov01	Yes	No		4	NCT06585644	Previously-treated		Overall Response Rate	44	44																																									No	COSO29915674	2024Oct21
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Alflutinib,Bevacizumab,Pemetrexed		Not yet recruiting	NCT06537297	Patients with Leptomeningeal Metastases	ECD	2025Aug31	No	No		4	NCT06537297	Previously-treated		Overall survival	30	30																																									No	COSO29915674	2024Oct21
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	FHND-9041		Completed	NCT06521034	Arm 2	PCD	2021May17	Yes	No		4	NCT06521034	Previously-treated		Absorption rate	124	124																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Almonertinib,Etoposide		Not yet recruiting	NCT06463171		ECD	2026Jun01	Yes	No		4	NCT06463171			Progression free survival	60	60																																									No	COSO29915674	2024Oct21
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Dalpiciclib,Osimertinib		Recruiting	NCT06363734		ECD	2025Dec15	Yes	No		4	NCT06363734	Previously-treated		Overall Response Rate	32	32																																									No	COSO29915674	2024Jun12
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Bevacizumab,Carboplatin,Pemetrexed,Serplulimab		Recruiting	NCT06334757		ECD	2024Aug31	Yes	No		4	NCT06334757	Previously-treated		Overall Response Rate	46	46																																									No	COSO29915674	2024Jun12
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Adebrelimab,Chemotherapy,Famitinib		Withdrawn	NCT06332300		ECD	2025Feb01	Yes	Yes	Drug unavailable, No patients recruited	4	NCT06332300	Previously-treated		Overall Response Rate	0	0																																									No	COSO29915674	2024Oct23
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Alflutinib,Pemetrexed		Recruiting	NCT06315686		ECD	2024Jul31	Yes	No		4	NCT06315686			Progression free survival	20	20																																									No	COSO29915674	2024Apr30
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Golidocitinib,Sunvozertinib		Recruiting	NCT06295432	WU-KONG21	ECD	2025Jun01	Yes	No		4	NCT06295432			Maximum tolerated dose/toxicity	90	90																																									No	COSO29915674	2024Apr30
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Anlotinib,Cadonilimab,Pemetrexed		Recruiting	NCT06277674		ECD	2024Dec01	Yes	No		4	NCT06277674	Previously-treated	Geriatric	Overall Response Rate	20	20																																									No	COSO29915674	2024Apr30
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Bevacizumab,SY-3505		Recruiting	NCT06276283	WU-KONG29 - Part A	ECD	2025May31	Yes	No		4	NCT06276283	Previously-treated		Maximum tolerated dose/toxicity	60	60																																									No	COSO29915674	2024Apr30
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Ivonescimab,Platinum-based chemotherapy		Not yet recruiting	NCT06196814	Cohort A	ECD	2026Mar01	Yes	No		4	NCT06196814	Previously-treated		PFS, ORR	150	150																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Afatinib or Erlotinib or Gefitinib,Nintedanib		Not yet recruiting	NCT06071013		ECD	2026Aug27	Yes	No		4	NCT06071013			Overall Response Rate	20	20																																									No	COSO29915674	2023Nov09
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Alflutinib,Ifebemtinib		Recruiting	NCT05994131	Cohort 2	ECD	2026Jul31	Yes	No		4	NCT05994131	Previously-treated		Overall Response Rate	110	110																																									No	COSO29915674	2024Apr23
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Alflutinib,Ifebemtinib		Recruiting	NCT05994131	Cohort 1	ECD	2026Jul31	Yes	No		4	NCT05994131	Previously-treated		Overall Response Rate	110	110																																									No	COSO29915674	2024Apr23
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Alflutinib,Ifebemtinib		Recruiting	NCT05994131	Cohort 3	ECD	2026Jul31	Yes	No		4	NCT05994131	Untreated		Overall Response Rate	110			Alflutinib																																							No	COSO29915674	2024Apr23
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Alflutinib,RC108		Recruiting	NCT05821933		ECD	2025Sep01	Yes	No		4	NCT05821933			Overall Response Rate	106	106																																									No	COSO29915674	2024Apr23
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Alflutinib,RC108,Toripalimab		Recruiting	NCT05821933		ECD	2025Sep01	Yes	No		4	NCT05821933			Overall Response Rate	106	106																																									No	COSO29915674	2024Apr25
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Carboplatin,SKB264		Recruiting	NCT05816252	Cohort 5	ECD	2025Dec01	Yes	No		4	NCT05816252			Overall Response Rate	498	498																																									No	COSO29915674	2024Oct17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Carboplatin,Dresbuxelimab,Ivonescimab,Pemetrexed		Recruiting	NCT05636267		ECD	2024Dec01	Yes	No		4	NCT05636267	Previously-treated		Overall Response Rate	114	114																																									No	COSO29915674	2023Sep22
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Dresbuxelimab,Ivonescimab		Recruiting	NCT05636267		ECD	2024Dec01	Yes	No		4	NCT05636267	Previously-treated		Overall Response Rate	114	114																																									No	COSO29915674	2023Sep22
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	H002		Recruiting	NCT05552781		ECD	2025Feb28	Yes	No		4	NCT05552781			Overall Response Rate	76	76																																									No	COSO29915674	2022Sep27
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	H002		Recruiting	NCT05519293		ECD	2025Feb28	Yes	No		4	NCT05519293			Overall Response Rate	76	76																																									No	COSO29915674	2023Apr04
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Erlotinib,OBI-821,OBI-833		Recruiting	NCT05442060		ECD	2024Dec31	Yes	No		4	NCT05442060			Progression free survival	60			Erlotinib																																							No	COSO29915674	2022Sep27
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	BPI-361175		Not yet recruiting	NCT05393466		ECD	2026Jan30	Yes	No		4	NCT05393466			Overall Response Rate	30	30																																									No	COSO29915674	2023Sep22
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Carboplatin,Etoposide,Serplulimab		Recruiting	NCT05957510		ECD	2025Jun30	Yes	No		4	NCT05957510				36	36																																									No	COSO29915674	2023Nov08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Platinum-based chemotherapy,SKB264,Tagitanlimab		Recruiting	NCT05351788	OptiTROP-Lung01 Cohort 3	ECD	2024Aug01	Yes	No		4	NCT05351788	Previously-treated		Overall Response Rate	110	110																																									No	COSO29915674	2024Nov13
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Afatinib,Carboplatin,Osimertinib,Pemetrexed		Unknown	NCT05298176	COMBINATION	ECD	2024Jan01	Yes	No		4	NCT05298176	Previously-treated		Disease control rate, Clinical benefit rate	21	21																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Osimertinib,TQB3525		Unknown	NCT05284994		ECD	2024Apr01	Yes	No		4	NCT05284994	Previously-treated		Overall Response Rate	160	160																																									No	COSO29915674	2024Jul11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	NRC-2694-A,Paclitaxel		Recruiting	NCT05283226		ECD	2024Dec31	No	No		4	NCT05283226	Previously-treated		Overall Response Rate	46	46																																									No	COSO29915674	2024Apr17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Carboplatin,Nab-paclitaxel,Sintilimab		Active, not recruiting	NCT05244213	NEOTIDE	PCD	2024Jun05	Yes	Yes	MPaR 30%, Primary outcome met	2	10.1016/j.jtho.2023.09.486			Major pathologic response	10	10			70.0																																						Yes	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Afatinib,Thoracic surgery		Recruiting	NCT05215548		ECD	2024Jul01	Yes	No		4	NCT05215548			Progression free survival	100			Afatinib																																							No	COSO29915674	2022Apr29
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Carboplatin,Pemetrexed,Pimurutamab		Unknown	NCT05215925	Expt. A	ECD	2023Jul15	Overexpression	No		4	NCT05215925			Overall Response Rate	60	60																																									No	COSO29915674	2024Oct17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Docetaxel,Pimurutamab		Unknown	NCT05215925	Expt. B	ECD	2023Jul15	Overexpression	No		4	NCT05215925			Overall Response Rate	60	60																																									No	COSO29915674	2024Oct17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Pimurutamab		Unknown	NCT05215925	Expt. C	ECD	2023Jul15	Overexpression	No		4	NCT05215925			Overall Response Rate	60	60																																									No	COSO29915674	2024Oct17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Alflutinib,Chemotherapy		Unknown	NCT05209256		ECD	2024Jan01	Yes	No		4	NCT05209256			Maximum tolerated dose/toxicity	90			Alflutinib																																							No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Sutetinib		Recruiting	NCT06014827		ECD	2026Jul11	Yes	No		4	NCT06014827			Disease control rate, Clinical benefit rate	32	32																																									No	COSO29915674	2024Apr17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Sutetinib		Recruiting	NCT06010329		ECD	2025Sep01	Yes	No		4	NCT06010329			Overall Response Rate	66	66																																									No	COSO29915674	2024Apr17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Becotatug,Osimertinib		Active, not recruiting	NCT06391944		PCD	2023May17	Yes	No		4	NCT06391944	Previously-treated		Overall Response Rate	161	161																																									No	COSO29915674	2024Nov13
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	AFM24,SNK01		Terminated	NCT05099549		PCD	2023Sep21	Expression confirmed	Yes	Changed business priorities	4	NCT05099549			Overall Response Rate	11	11																																									No	COSO29915674	2024Nov13
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Osimertinib,Radiotherapy		Recruiting	NCT05089916	ROSE	ECD	2025Dec01	Yes	No		4	NCT05089916			Maximum tolerated dose/toxicity	40	40																																									No	COSO29915674	2024Oct17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Izalontamab		Recruiting	NCT05044897		ECD	2025Jun01	No	No		4	NCT05044897			Maximum tolerated dose/toxicity	30	30																																									No	COSO29915674	2024Oct17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	ERAS-007,Osimertinib		Completed	NCT04959981		PCD	2023Apr27	Yes	No		4	NCT04959981			Maximum tolerated dose/toxicity	24	24																																									No	COSO29915674	2023Aug31
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Almonertinib,Anlotinib		Unknown	NCT04978753		ECD	2022May30	Yes	Yes	IORR 74.4% 95%CI 57.9-87.0	3	https://www.onclive.com/view/frontline-aumolertinib-plus-anlotinib-elicits-responses-in-egfr-mutant-nsclc-with-brain-metastases	Untreated		Progression free survival	39	39			62.5		45.8-77..3																97.5																				No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	MCLA-129		Recruiting	NCT04930432	Cohort C - 1500mg - Prior 3rd EGFR TKI	ECD	2028Apr30	Yes	Yes		2	10.1200/JCO.2024.42.16_suppl.8604	Previously-treated		Overall Response Rate	49	49			20.4		10.2-34.3		8.3														69.4																				No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	MCLA-129		Recruiting	NCT04930432	Cohort C - 1500mg	ECD	2028Apr30	Yes	Yes		2	10.1200/JCO.2024.42.16_suppl.8604			Overall Response Rate	55	55			21.8		11.8-35.0		9.8														69.1																				No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Alflutinib,Anlotinib		Not yet recruiting	NCT06483672	LungBrain001 - patients with brain metastases	ECD	2025Dec31	Yes	No		4	NCT06483672	Untreated 		Intracranial ORR, CNS ORR	27	27																																									No	COSO29915674	2024Oct21
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Buparlisib,Erlotinib		Completed	NCT01487265		PCD	2016May31	No	Yes	PFS 3m 50.4%	4	NCT01487265			Progression free survival	37	37			5.4																																						No	COSO29915674	2023Sep28
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Erlotinib,Gemcitabine,Platinum-based chemotherapy		Recruiting	NCT02098954		ECD	2024Dec01	Yes	No		4	NCT02098954	Previously-treated		Progression free survival	40	40																																									No	COSO29915674	2024Jan04
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Ivonescimab		Recruiting	NCT05636267		ECD	2024Dec01	Yes	No		4	NCT05636267	Previously-treated		Overall Response Rate	114	114																																									No	COSO29915674	2023Sep22
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	BBT-176,Cetuximab		Terminated	NCT04820023		PCD	2023Nov29	Yes	No		4	NCT04820023	Previously-treated		Overall Response Rate	45	45																																									No	COSO29915674	2024Jan04
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	BBT-176		Terminated	NCT04820023		PCD	2023Nov29	Yes	No		4	NCT04820023	Previously-treated		Overall Response Rate	45	45																																									No	COSO29915674	2024Jan04
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	MRG003		Unknown	NCT04838548		ECD	2022Dec01	Expression confirmed	No		4	NCT04838548			Overall Response Rate	90	90																																									No	COSO29915674	2024Apr25
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Bozitinib,Osimertinib		Recruiting	NCT04743505		ECD	2027Jun30	Yes	No		4	NCT04743505			Progression free survival	25	25																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Carboplatin,Nivolumab,Pemetrexed		Completed	NCT03256136		PCD	2019Aug19	Yes	Yes		4	NCT03256136			Overall Response Rate	4	4			25								4.65										75																				No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Abemaciclib,Osimertinib		Active, not recruiting	NCT04545710		ECD	2025Dec01	Yes	No		4	NCT04545710	Previously-treated		Progression free survival	18	18																																									No	COSO29915674	2024Oct17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Carboplatin,Osimertinib,Pemetrexed		Recruiting	NCT04335292	OCELOT	ECD	2026Jun01	Yes	No		4	NCT04335292	Previously-treated		Overall Response Rate	200	200																																									No	COSO29915674	2024Oct17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Bevacizumab,Cisplatin,Durvalumab,Stereotactic body radiation therapy		Unknown	NCT04517526		ECD	2022Nov01	Yes	No		4	NCT04517526			OS, PFS	60	60																																									No	COSO29915674	2024Jul31
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Necitumumab,Osimertinib,Trastuzumab		Active, not recruiting	NCT04285671		ECD	2025Dec02	Yes	Yes	Promising activity 	2	10.1200/JCO.2023.41.16_suppl.e21165			Overall Response Rate	12	2																					58.3																				No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Afatinib,Cisplatin,Pemetrexed		Unknown	NCT04470076	Neoafa	ECD	2021Dec30	Yes	No		4	NCT04470076			Overall Response Rate	30	30																																									No	COSO29915674	2023Aug31
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Osimertinib,Quaratusugene ozeplasmid		Recruiting	NCT04486833	GEN-104	ECD	2028Mar01	Yes	No		4	NCT04486833	Previously-treated		Progression free survival	158	158																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Amivantamab,Lazertinib		Active, not recruiting	NCT04965090		ECD	2025Jul01	Yes	No		4	NCT04965090			Overall Response Rate	43	43																																									No	COSO29915674	2024Dec18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Carboplatin,Osimertinib,Paclitaxel		Recruiting	NCT04410796		ECD	2025May01	Yes	No		4	NCT04410796			Progression free survival	571	571																																									No	COSO29915674	2024Apr17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Carboplatin,Pemetrexed,Tislelizumab		Recruiting	NCT04405674		ECD	2022Apr01	Yes	Yes	PFS 1y 23.8%, Primary outcome met, OS 1y 74.5% 95%CI 56.5-86.0	1	37597849			Progression free survival	62	62			56.5		43.3-69.0						7.6			6.4-9.8							87.1																				Yes	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Almonertinib,Famitinib		Unknown	NCT03904823		ECD	2022Dec01	Yes	No		4	NCT03904823			Overall Response Rate	58	58																																									No	COSO29915674	2024Sep02
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	TY-9591		Completed	NCT05146219		PCD	2024Mar21	Yes	No		4	NCT05146219			Intracranial Response Rate	29	29																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	TY-9591		Recruiting	NCT05948813		ECD	2025Jun30	Yes	No		4	NCT05948813			IRR, IPFS	420			Osimertinib																																							No	COSO29915674	2024Jan04
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	TY-9591		Recruiting	NCT05948813		ECD	2025Jun30	Yes	No		4	NCT05948813			IPFS, IORR	420			Osimertinib																																							No	COSO29915674	2024Jan24
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Apatinib,Tyrosine kinase inhibitor		Unknown	NCT03811054		ECD	2020Dec01	Yes	No		4	NCT03811054			Overall Response Rate	60	60																																									No	COSO29915674	2022Jan25
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Bafisontamab		Recruiting	NCT03797391		ECD	2025Mar14	Yes	No		4	NCT03797391			OS, PFS	186	186																																									No	COSO29915674	2023Sep25
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Anlotinib,Osimertinib		Completed	NCT04770688	AUTOMAN	PCD	2024Jun20	Yes	Yes		2	10.1200/JCO.2022.40.16_suppl.e21140	Untreated		Overall Response Rate	23	23			65.2		42.7-83.6																95.7																				No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Zipalertinib		Active, not recruiting	NCT05967689	REZILIENT2 Cohort D	ECD	2025Jun30	Yes	No		4	NCT05967689	Previously-treated		Overall Response Rate	160	160																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Zipalertinib		Active, not recruiting	NCT05967689	REZILIENT2 Cohort C	ECD	2025Jun30	Yes	No		4	NCT05967689			Overall Response Rate	160	160																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Osimertinib,Vociprotafib		Completed	NCT03989115		PCD	2022Feb08	Yes	Yes	SAE 25%	4	NCT03989115			Maximum tolerated dose/toxicity	6	6			0																																						No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Sunvozertinib		Unknown		WU-KONG1+2+15			Yes	Yes	BOR 21.9%, Manageable toxicity	2	10.1200/JCO.2023.41.16_suppl.9103	Previously-treated		Best overall response	32	32							4				5.9																														No	COSO29915674	2024Apr25
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Mobocertinib		Unknown	NCT03574402	CTONG1702 Arm 12	ECD	2022Dec30	Yes	No		4	NCT03574402			Response rate	400	400																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Pembrolizumab,Ramucirumab		Active, not recruiting	NCT04120454		PCD	2023Aug19	Yes	No		4	NCT04120454			Overall Response Rate	6	6																																									No	COSO29915674	2024Jan04
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Osimertinib,Stereotactic body radiation therapy		Terminated	NCT04908956	STEREO	PCD	2023Oct31	Yes	Yes	Slow accrual	4	NCT04908956	Untreated		Progression free survival	6	6																																									No	COSO29915674	2024Oct23
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Osimertinib,Stereotactic body radiation therapy		Active, not recruiting	NCT03667820		ECD	2025Mar30	Yes	Yes		3	https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.8518			Progression free survival	43	43											32.6													45.7																	No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Anlotinib,Sintilimab		Unknown	NCT03765775		ECD	2019Dec31	Yes	No		4	NCT03765775			Progression free survival	20	20																																									No	COSO29915674	2022Sep27
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	FCN-411		Unknown	NCT03420079		ECD	2020Dec31	Yes	Yes		1	35248866			Maximum tolerated dose/toxicity	67	67			14.9		8.3-24.0						4.1			2.9-5.3							73.1										10	39									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Dihydroartemisinin,Icotinib		Unknown	NCT03402464		ECD	2019Jun01	Yes	No		4	NCT03402464			OS, PFS	30	30																																									No	COSO29915674	2021May18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Afatinib,Tucidinostat		Unknown	NCT03574402	CTONG1702 Arm 2	ECD	2022Dec30	Yes	No		4	NCT03574402			Overall Response Rate	400	400																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Rilertinib		Unknown	NCT03823807	Part A	ECD	2020Dec01	Yes	Yes		2	10.1016/j.jtho.2022.06.013	Previously-treated		Overall Response Rate	59	59			55.9		42.4-68.6		15.2		8.3-		12.4			8.3-20.8							98.3				26		23.3-			1	32	24									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Rilertinib		Unknown	NCT03823807	Part B	ECD	2020Dec01	Yes	Yes		2	10.1016/j.jtho.2022.06.013	Previously-treated		Overall Response Rate	227	227			60.4		53.7-66.8		12.5		11.2-		12.6			9.7-15.3							92.5																				No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Golidocitinib,Osimertinib		Completed	NCT03450330	JACKPOT1	PCD	2019Sep03	Yes	No		4	NCT03450330			Maximum tolerated dose/toxicity	10	10																																									No	COSO29915674	2023Sep26
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Osimertinib,Stereotactic radiotherapy		Recruiting	NCT04519983		ECD	2023Dec01	Yes	Yes	IORR 100%, Promising efficacy	2	10.1016/S1556-0864(23)00272-1	Previously-treated		Intracranial ORR, CNS ORR	32	32																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Osimertinib,Stereotactic radiotherapy		Completed	NCT03497767	OUTRUN	PCD	2024Apr30	Yes	No		4	NCT03497767			Progression free survival	40	40																																									No	COSO29915674	2024Jul11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Stereotactic body radiation therapy,Tyrosine kinase inhibitor		Completed	NCT03595644		PCD	2019Jun10	Yes	Yes		2	10.1016/j.jtho.2019.08.499			Progression free survival	61	30	31	EGFR-TKI									17.4	8.9			0.042																										Yes	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Gefitinib,Ningetinib		Unknown	NCT03758287		ECD	2023Jul17	Yes	Yes	Promising activity 	2	10.1200/JCO.2020.38.15_suppl.9583	Previously-treated		Overall Response Rate	84	84			19.1								4.4			3.7-4.6							91.7										16	61									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Apatinib,Chemotherapy		Unknown	NCT03758677		ECD	2020Nov20	Yes	No		4	NCT03758677			Progression free survival	30	30																																									No	COSO29915674	2022Aug04
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Avitinib maleate		Unknown	NCT03574402	CTONG1702 Arm 13	ECD	2022Dec30	Expression confirmed	No		4	NCT03574402			Response rate	400	400																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	AVID100		Terminated	NCT03094169		PCD	2020Nov28	Yes	Yes	Lack of efficacy	4	NCT03094169			Clinical activity	49	49																																									No	COSO29915674	2024Jan30
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Icotinib,Stereotactic body radiation therapy		Unknown	NCT03754530		ECD	2020Jun01	Yes	No		4	NCT03754530			Progression free survival	162	162																																									No	COSO29915674	2024Jul31
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Atezolizumab,Cabozantinib		Active, not recruiting	NCT03170960	Expansion Cohort 9	ECD	2023Jul01	Yes	No		4	NCT03170960			Overall Response Rate	1732	1732																																									No	COSO29915674	2023Aug31
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Pemetrexed		Not yet recruiting	NCT05805631		ECD	2026Jun01	Yes	No		4	NCT05805631	Previously-treated		Disease control rate, Clinical benefit rate	23	23																																									No	COSO29915674	2024Jul11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Erlotinib,Sunitinib		Completed	NCT00265317	SUN1058	PCD	2010Jan01	Expression confirmed	Yes		4	NCT00265317			Progression free survival	65	29	36	Erlotinib,Placebo									3.69	2.4	.86		0.32																										No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Anlotinib,Docetaxel		Unknown	NCT04619563		ECD	2021Oct01	Yes	No		4	NCT04619563			Progression free survival	42	42																																									No	COSO29915674	2022Nov28
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Carboplatin,Durvalumab,Pemetrexed		Active, not recruiting	NCT03944772	ORCHARD	ECD	2025May06	Yes	No		4	NCT03944772	Previously-treated		Overall Response Rate	248	248																																									No	COSO29915674	2024Apr17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Osimertinib,Savolitinib		Active, not recruiting	NCT03944772	ORCHARD	ECD	2025May06	Yes	No		4	NCT03944772	Previously-treated		Overall Response Rate	248	248																																									No	COSO29915674	2024Apr17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Cetuximab,Cilengitide,Cisplatin,Vinorelbine		Completed	NCT00842712	CERTO	PCD	2013Jul01	No	Yes		4	NCT00842712	Untreated		Progression free survival	169	85	84	Cetuximab,Cisplatin,Vinorelbine									6.2	5	.72		0.0845																										No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Carboplatin,Cetuximab,Pemetrexed,Radiotherapy		Completed	NCT00117962		PCD	2009Mar01	No	Yes		4	NCT00117962			Overall survival	101	53	48	Carboplatin,Pemetrexed																						54	48																No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Erlotinib,Foretinib		Completed	NCT01068587		PCD	2014Mar21	No	Yes		1	29050231	Previously-treated		Overall Response Rate	3	3																															2										No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Cetuximab,Natural killer cell immunotherapy		Completed	NCT02845856		PCD	2017Jul01	Yes	Yes		1	29888109			Maximum tolerated dose/toxicity	54	27	27										6	4.5												9.5	7.5			<0.05													No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Bevacizumab,Carboplatin,Pemetrexed		Completed	NCT01344824		PCD	2016May24	Yes	Yes		1	26774201			Progression free survival	6	6											7.1													31.3																	No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Rociletinib,Trametinib		Terminated	NCT02580708		PCD	2016May05	Yes	Yes	Development discontinued	4	NCT02580708			Unknown	7	7																																									No	COSO29915674	2022May03
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	MP0250,Osimertinib		Terminated	NCT03418532		PCD	2019Aug30	Yes	Yes	Changed business priorities	4	NCT03418532	Previously-treated		Overall Response Rate	8	8																																									No	COSO29915674	2023Sep25
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Cetuximab,Chemotherapy,Radiotherapy		Completed	NCT00492206		PCD	2012Feb01	No	Yes		4	NCT00492206			Overall survival	38	38											9.3			8.5-17.2										19.4			15.4-26														No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Erlotinib,MK2206		Completed	NCT01294306		PCD	2015Aug01	Yes	Yes		4	NCT01294306	Previously-treated		DCR, ORR	45	45			9								4.4										40																				No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Apatinib,Erlotinib		Unknown	NCT02704767		ECD	2019Jun01	Yes	No		4	NCT02704767	Untreated		Progression free survival	60	60																																									No	COSO29915674	2021May18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Capecitabine,Cetuximab,Oxaliplatin		Completed	NCT00444678		PCD	2012Aug01	Expression confirmed	Yes		4	NCT00444678			Response rate	36	36			58.3													9.04			1.41-136.96																						No	COSO29915674	2021May18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Atezolizumab,Bevacizumab,Carboplatin,Pemetrexed		Unknown	NCT03647956		ECD	2019Dec31	Yes	Yes	Promising activity 	2	10.1016/j.annonc.2020.10.374	Previously-treated		Overall Response Rate	40	40			62.5								9.43			7.62-12.1																											No	COSO29915674	2024Oct23
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Atezolizumab,Bevacizumab,Carboplatin,Paclitaxel		Completed	NCT04245085	ABC-lung	PCD	2024Jul22	Yes	Yes	PFS 1y 25 v 25%, Primary outcome not met	2	10.1016/j.esmoop.2024.102591			Progression free survival	88	45	43	Atezolizumab,Bevacizumab,Pemetrexed	32	47							7.6	6.4												15.6	15.4																No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Durvalumab,Olaparib		Completed	NCT04538378		PCD	2023Mar22	Yes	No		4	NCT04538378			Best overall response	4	4																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Erlotinib,Tivantinib		Completed	NCT01580735		PCD	2015Apr01	Yes	Yes	Primary outcome not met	1	27843623			Overall Response Rate	45	45			6.7		1.4-18.3						2.7			1.4-4.2							48.9			18.0			13.4-22.2			0	3	19									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Gemcitabine,Vandetanib		Completed	NCT00753714	ZELIG	PCD	2011Apr01	No	Yes	Lack of efficacy	2	10.1200/jco.2012.30.15_suppl.7550 		Geriatric	Progression free survival	124	61	63	Gemcitabine																																							No	COSO29915674	2024Jan30
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Fruquintinib		Unknown					No	Yes		5	https://www.chi-med.com/wp-content/uploads/2017/10/pre171031.pdf			Unknown													3.8	1.1	.34	0.2-0.57	0.001									8.1	5.5	.62	0.3-1.27	0.18													No	COSO29915674	2021May18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Fruquintinib		Completed	NCT02590965		PCD	2015Aug07	Yes	Yes		1	29528793	Previously-treated		Progression free survival	91			Placebo																						8.4	5.5	.58	0.30-1.14	0.11													No	COSO29915674	2022May03
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Cisplatin,Panitumumab,Pemetrexed		Completed	NCT01042288		PCD	2014Dec01	No	Yes	OS 1y 65.5% 95%CI 44.8-80	2	10.1200/jco.2013.31.15_suppl.8062	Untreated		Time to progression, time to recurrence	60	60											6.2			3.0-9.0		6.2			3.7-9.5		68										23	18									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Cisplatin,Panitumumab,Pemetrexed		Terminated	NCT01038037	Lung-TRIO	PCD	2013Jun01	No	Yes	Slow accrual	4	NCT01038037	Untreated		Overall Response Rate	23	23																																									No	COSO29915674	2021May18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Cisplatin,Panitumumab,Pemetrexed		Completed	NCT00979212		PCD	2015Dec01	No	Yes	Serious adverse events	4	NCT00979212			Clinical activity	61	39	22	Carboplatin,Panitumumab									89.1	94.4																													No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Cisplatin,Panitumumab,Pemetrexed		Suspended	NCT01088620	CHAMP	PCD	2013Jan01	No	Yes	Serious adverse events	1	26094080	Untreated		Progression free survival	134			Cisplatin,Pemetrexed																																							No	COSO29915674	2022May03
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Matuzumab,Pemetrexed		Completed	NCT00111839		PCD	2007Jul31	Expression confirmed	Yes		1	20978446	Previously-treated		Overall Response Rate	150			Gefitinib,Tremelimumab	11.0	5		0.332																																			No	COSO29915674	2022May03
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Cisplatin,Gemcitabine,Imgatuzumab,Pemetrexed		Completed	NCT01185847	GAIN-(L)	PCD	2012Sep01	No	Yes		2	10.1200/jco.2012.30.15_suppl.7544			Progression free survival	14	14		Cisplatin,Pemetrexed																													6	7									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Carboplatin,Erlotinib,Paclitaxel		Completed	NCT00126581		PCD	2010Jun30	Yes	Yes		4	NCT00126581			Progression free survival	164	87	77	Carboplatin,Paclitaxel	73	70							17.2	14.1																													No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Nimotuzumab,Nivolumab		Completed	NCT02947386		PCD	2021Apr15	No	No		4	NCT02947386			Overall Response Rate	7	7																																									No	COSO29915674	2024Jan04
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Gefitinib,Metformin		Completed	NCT01864681		PCD	2017Dec01	No	Yes		2	10.1200/JCO.2019.37.15_suppl.9035	Untreated		Progression free survival	224			Placebo	66	67							10.3	11.4												22	27.5																No	COSO29915674	2024Jul17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Celecoxib,Erlotinib		Completed	NCT00499655		PCD	2016Dec01	Yes	Yes	Response not correlated with mutation status	1	26033830	Previously-treated		Progression free survival	26	12	14	Erlotinib,Placebo									9.2	9.2	.98		0.97																										No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Erlotinib,Trametinib		Completed	NCT03076164		PCD	2020Dec18	Yes	Yes		2	10.1200/PO.20.00315	Previously-treated		Overall Response Rate	23	23											1.8													21							1										No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Fulvestrant,Gefitinib		Completed	NCT01556191	LADIE	PCD	2018May15	Yes	Yes	Lack of efficacy	2	10.1200/JCO.2018.36.15_suppl.9097			Progression free survival	204	100	104										9.9	10.1												22.1	29.9																No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Dacomitinib,Osimertinib		Recruiting	NCT04811001	CAPLAND	ECD	2023Dec31	Yes	No		4	NCT04811001	Untreated		Overall survival	170	170																																									No	COSO29915674	2024Feb08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Necitumumab,Osimertinib		Active, not recruiting	NCT03944772	ORCHARD	ECD	2025May06	Yes	No		4	NCT03944772	Previously-treated		Overall Response Rate	248	248																																									No	COSO29915674	2024Apr17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Bevacizumab,Osimertinib		Completed	NCT02803203		PCD	2022Mar01	Yes	Yes	PFS 12m 76%, Primary outcome met	1	32463456			Progression free survival	49	49			80								19			15-24																	34										Yes	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	BMS-690514		Completed					Yes	No		4	NCT01167244	Previously-treated		Overall Response Rate	11	11																																									No	COSO29915674	2023Sep22
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Almonertinib		Recruiting	NCT05662813		ECD	2023Dec30	Yes	No		4	NCT05662813	Untreated		Overall Response Rate	55	55																																									No	COSO29915674	2024Sep02
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Almonertinib		Unknown	NCT04882345	ACTIVE	ECD	2024Jan15	Yes	No		4	NCT04882345	Previously-treated		Maximum tolerated dose/toxicity	40	40																																									No	COSO29915674	2024Sep02
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Almonertinib		Unknown	NCT04423185		ECD	2022Jul01	Yes	No		4	NCT04423185			Overall Response Rate	770	770																																									No	COSO29915674	2024Sep02
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Almonertinib		Active, not recruiting	NCT04685070		PCD	2022Dec31	Yes	No		4	NCT04685070	Untreated		Overall Response Rate	56	56																																									No	COSO29915674	2024Sep02
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Almonertinib		Active, not recruiting	NCT04808752	ACHIEVE	ECD	2024Jun15	Yes	Yes	IORR 86.3 95%CI 65.1-97.1	2	10.1016/j.annonc.2022.10.405	Untreated		Progression free survival	22	22			90.9		70.8-98.9																100																				No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Almonertinib		Unknown	NCT04553887	AUTUMN	ECD	2023May01	Yes	No		4	NCT04553887	Untreated		Overall Response Rate	53	53																																									No	COSO29915674	2024Sep02
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Alflutinib		Not yet recruiting	NCT06652048		ECD	2026Dec01	Yes	No		4	NCT06652048	Previously-treated		Progression free survival	60	60																																									No	COSO29915674	2024Dec11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Alflutinib		Not yet recruiting	NCT05987826		ECD	2024Aug01	Yes	No		4	NCT05987826	Untreated		Overall Response Rate	40	40																																									No	COSO29915674	2024Apr23
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Alflutinib		Recruiting	NCT05469022		ECD	2024May19	Yes	No		4	NCT05469022			Overall Response Rate	40	40																																									No	COSO29915674	2024Apr23
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Alflutinib		Unknown	NCT05465343	iFORCE	ECD	2023Jun30	Yes	No		4	NCT05465343			PFS, ORR	36	36																																									No	COSO29915674	2024Jul11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Alflutinib		Not yet recruiting	NCT06319950		ECD	2026Dec30	Yes	No		4	NCT06319950			Progression free survival	255	255		Osimertinib																																							No	COSO29915674	2024Apr30
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	AZD4635,Oleclumab		Active, not recruiting	NCT03381274		PCD	2021May24	Yes	No		1	36641093	Previously-treated		Overall Response Rate	43	43																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Gefitinib,Osimertinib		Active, not recruiting	NCT03944772	ORCHARD	ECD	2025May06	Yes	No		4	NCT03944772	Previously-treated		Overall Response Rate	248	248																																									No	COSO29915674	2024Apr17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Zorifertinib		Unknown	NCT03574402	CTONG1702 Arm 8	ECD	2022Dec30	Yes	Yes	IORR 73% 95%CI 54-88, Primary outcome met	1	37781161			Overall Response Rate	30	30			70		51-85		12		8.3-14.9		12.9			9.2-16.6							83			33.7			18.4-46.4														Yes	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Afatinib,Cetuximab		Completed	NCT02716311	ACE-LUNG	PCD	2019Feb01	Yes	Yes	Lack of efficacy	2	10.1200/JCO.2019.37.15_suppl.9079	Untreated		Time to progression, time to recurrence	118			Afatinib																																							No	COSO29915674	2024Jan30
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Erlotinib,Hydroxychloroquine		Unknown	NCT00977470		PCD	2015May01	Yes	Yes	Lack of efficacy	2	10.1200/jco.2014.32.15_suppl.8088 	Untreated		Progression free survival	76	76																																									No	COSO29915674	2024Jan30
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Ficlatuzumab,Gefitinib		Completed	NCT01039948		PCD	2013Aug01	No	Yes	Lack of efficacy	1	27448761			Overall Response Rate	203	203																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Canertinib		Completed	NCT00050830				No	Yes	Primary outcome not met	1	17761977	Previously-treated		Clinical activity	166																																										No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Lazertinib		Recruiting	NCT05338619	PLATINUM	ECD	2026Mar02	Yes	No		4	NCT05338619			Progression free survival	77	77																																									No	COSO29915674	2024Dec18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Lazertinib		Unknown	NCT05277701	LU21-16	ECD	2024Dec01	Yes	No		4	NCT05277701			Overall Response Rate	36	36																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Pelitinib		Completed	NCT00067548		PCD	2005Jan01	No	Yes	Serious adverse events	4	NCT00067548			Not defined	44	44																																									No	COSO29915674	2024Jul17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Vandetanib		Completed	NCT00777179		PCD	2010Jan01	No	Yes		1	24075125	Previously-treated		Progression free survival	117	75	42	Placebo	18.7	2.4							2.7	1.7		0.9-2.6																											No	COSO29915674	2021May18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Docetaxel,Vandetanib		Completed	NCT00687297	PrE0501	PCD	2011Jan01	No	Yes	Lack of efficacy	1	23689430	Untreated		Progression free survival	162	80	82										4.5	4.2												9.8	9.4			0.68													No	COSO29915674	2024Jan30
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Osimertinib		Not yet recruiting	NCT06530719		ECD	2026May01	Yes	No		4	NCT06530719	Previously-treated		Overall Response Rate	54	54																																									No	COSO29915674	2024Oct21
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Osimertinib		Recruiting	NCT05686434	OSTAR	ECD	2024Oct14	Yes	No		4	NCT05686434			Disease free survival, relapse free survival, regression free survival, recurrence free survival	65	65																																									No	COSO29915674	2023Mar20
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Osimertinib		Active, not recruiting	NCT05526755	TARGET	ECD	2029Apr05	Yes	No		4	NCT05526755			Disease free survival, relapse free survival, regression free survival, recurrence free survival	188	188																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Osimertinib		Active, not recruiting	NCT03804580		ECD	2025Jun01	No	No		4	NCT03804580	Untreated		Overall Response Rate	100	100																																									No	COSO29915674	2024Jul11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Osimertinib		Active, not recruiting	NCT03865511	MELROSE	ECD	2025Jan01	Yes	Yes	PFD 12m 69.8%	2	10.1016/j.annonc.2022.07.1176			Biomarker discovery	138	138											19.6																														No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Osimertinib		Unknown	NCT03460275		ECD	2020Dec01	Yes	No		4	NCT03460275			Clinical activity	100	100																																									No	COSO29915674	2021May18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Osimertinib		Unknown	NCT02736513	Arm A	ECD	2022Dec31	No	Yes		1	35156036	Untreated		Overall Response Rate	20	20			84.2								11.8			7.7-							94.7																				No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Osimertinib		Completed	NCT03239340	ELIOS	PCD	2023Sep19	Yes	Yes	SAE 31%	2	10.1016/j.annonc.2022.08.055	Untreated		Unknown	154	154											16.4			12.7-20.3																											No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Dacomitinib		Completed	NCT00818441		PCD	2012Apr27	Yes	Yes		4	NCT00818441			Progression free survival	89	89							12.9		9.6-18.4		11.5			9.0-12.9										29.5			22.8-35.6														No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Dacomitinib		Unknown	NCT04423185		ECD	2022Jul01	Yes	No		4	NCT04423185			Overall Response Rate	770	770																																									No	COSO29915674	2023Aug31
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Dacomitinib		Unknown	NCT04339829	CTONG2001	ECD	2022Jul01	Yes	Yes	IORR 96.7%, IPFS 18m 70.4%	2	10.1016/j.esmoop.2023.102068			Progression free survival	50	50			96.7								17.5																														No	COSO29915674	2024Jan15
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Dacomitinib		Unknown	NCT04504071		ECD	2022Oct31	Yes	No		4	NCT04504071			Overall Response Rate	30	30																																									No	COSO29915674	2024Jul11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Gefitinib		Completed	NCT00344773		PCD	2007Dec01	Yes	Yes		4	NCT00344773			Overall Response Rate	46	46			0																																						No	COSO29915674	2021Jun17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Gefitinib		Completed	NCT00411047		PCD	2007Jan01	Yes	No		4	NCT00411047	Untreated		Overall Response Rate	34	34																																									No	COSO29915674	2021May18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Gefitinib		Completed	NCT02804776	ECRU-LUNG	PCD	2018Feb21	Yes	Yes		2	10.1016/j.jtho.2024.09.556			Tumour volume	13	13			62																		100																				No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Erlotinib		Completed	NCT01306045	Arm 1	PCD	2014Feb12	Yes	Yes		1	25667274			Response rate	15	15			60		32.3-83.7						11.3													25.7							9	5									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Erlotinib		Completed	NCT00087412		PCD	2007Jul01	No	No		4	NCT00087412			Overall survival	65	65																																									No	COSO29915674	2021May18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Afatinib		Completed	NCT02183883	DARWIN1	PCD	2023Mar22	Yes	No		4	NCT02183883			Progression free survival	12	12																																									No	COSO29915674	2024Jan04
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Afatinib		Completed	NCT04201756		PCD	2022Feb28	Yes	Yes	Primary outcome met, pCR 3.0%	1	37537219			Overall Response Rate	47	47			70.2		56.5-84.0																																				Yes	COSO29915674	2023Sep14
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Ipilimumab,Nivolumab		Completed	NCT03256136		PCD	2019Aug19	Yes	Yes		4	NCT03256136			Overall Response Rate	3	3			0								1.3										0																				No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Erlotinib		Active, not recruiting	NCT02193282		ECD	2026Oct10	No	No		4	NCT02193282			Overall survival	450			Placebo																																							No	COSO29915674	2021Oct28
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	SHR-A2009		Recruiting	NCT06671379		ECD	2026Dec01	Yes	No		4	NCT06671379			Progression free survival	500			Platinum-based chemotherapy																																							No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Osimertinib,Sacituzumab tirumotecan		Not yet recruiting	NCT06670196		ECD	2027May01	Yes	No		4	NCT06670196	Untreated		Progression free survival	420			Osimertinib																																							No	COSO29915674	2024Dec11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Afatinib,Dacomitinib		Recruiting	NCT06486142	ERIS	ECD	2028Sep01	Yes	No		4	NCT06486142			Progression free survival	200	200		Osimertinib																																							No	COSO29915674	2024Oct21
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Carboplatin,Ivonescimab,Pemetrexed		Active, not recruiting	NCT06396065		ECD	2025Dec31	Yes	No		4	NCT06396065	Previously-treated		OS, PFS	420			Carboplatin,Pemetrexed,Placebo																																							No	COSO29915674	2024Oct17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Carboplatin,Ivonescimab,Pemetrexed		Active, not recruiting	NCT05184712		ECD	2024Jun28	Yes	Yes		2	10.1001/jama.2024.10613	Previously-treated		Progression free survival	322	161	161	Chemotherapy,Placebo	50.6	35.4		0.006					7.06	4.8	.46	0.34-0.62	<0.001																										Yes	COSO29915674	2024Sep10
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	BL-B01D1		Recruiting	NCT06382116		ECD	2026May01	Yes	No		4	NCT06382116	Previously-treated		Progression free survival	428			Carboplatin or Cisplatin,Pemetrexed																																							No	COSO29915674	2024Jun12
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Sacituzumab tirumotecan		Recruiting	NCT06305754		ECD	2028Sep12	No	No		4	NCT06305754	Previously-treated		OS, PFS	520	520		Carboplatin,Pemetrexed																																							No	COSO29915674	2024Jul11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Anlotinib,Penpulimab		Not yet recruiting	NCT06048315		ECD	2026Jun01	Yes	No		4	NCT06048315			Progression free survival	52	52																																									No	COSO29915674	2023Nov09
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	SKB264		Recruiting	NCT05870319		ECD	2025May20	Yes	No		4	NCT05870319	Previously-treated		Progression free survival	356			Carboplatin,Pemetrexed																																							No	COSO29915674	2023Dec11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Almonertinib,Radiotherapy		Not yet recruiting	NCT05994339		ECD	2025Aug08	Yes	No		4	NCT05994339	Untreated		Overall survival	40			Chemotherapy,Radiotherapy																																							No	COSO29915674	2024Sep02
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Carboplatin,PM8002,Pemetrexed		Active, not recruiting	NCT05756972		ECD	2025Mar01	Yes	No		4	NCT05756972			Progression free survival	374			Carboplatin,Pemetrexed,Placebo																																							No	COSO29915674	2024Oct17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	EGFR-TKI,Metformin		Recruiting	NCT05445791	METLUNG	ECD	2024Jul14	Yes	No		4	NCT05445791			Progression free survival	312			EGFR-TKI,Placebo																																							No	COSO29915674	2022Sep27
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Osimertinib,TY-9591		Recruiting	NCT05382728	FLETEO	ECD	2025May01	Yes	No		4	NCT05382728			Progression free survival	680			Placebo,TY-9591																																							No	COSO29915674	2023Apr04
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Pemetrexed,Placebo,Platinum-based chemotherapy,Retlirafusp alfa		Unknown	NCT05132413		ECD	2024Dec30	Yes	No		4	NCT05132413			Progression free survival	561			Pemetrexed,Platinum-based chemotherapy																																							No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Bevacizumab,Pemetrexed,Platinum-based chemotherapy,Retlirafusp alfa		Unknown	NCT05132413		ECD	2024Dec30	Yes	No		4	NCT05132413			Progression free survival	561			Pemetrexed,Platinum-based chemotherapy																																							No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Almonertinib,Chemotherapy		Terminated	NCT05493501		PCD	2023Aug31	Yes	Yes	Changed business priorities	4	NCT05493501			Progression free survival	8			Osimertinib																																							No	COSO29915674	2024Sep02
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Almonertinib,Cisplatin,Pemetrexed		Recruiting	NCT04762459	APEX	ECD	2026May01	Yes	No		4	NCT04762459	Previously-treated		Disease free survival, relapse free survival, regression free survival, recurrence free survival	606			Cisplatin,Pemetrexed																																							No	COSO29915674	2024Sep02
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Osimertinib,Pemetrexed,Platinum-based chemotherapy		Active, not recruiting	NCT04765059	COMPEL	PCD	2024Oct28	Yes	No		4	NCT04765059	Previously-treated		Progression free survival	98			Pemetrexed,Platinum-based chemotherapy																																							No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Osimertinib,Pemetrexed,Platinum-based chemotherapy		Active, not recruiting	NCT04351555	NeoADAURA	PCD	2024Oct15	Yes	No		4	NCT04351555			Major pathologic response	358			Pemetrexed,Platinum-based chemotherapy																																							No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Carboplatin,Pemetrexed,Toripalimab		Unknown	NCT03924050		ECD	2023Jul17	Yes	Yes	Promising activity 	2	10.1038/s41392-021-00751-9	Previously-treated		Overall Response Rate	40	40			50.0								7										87.5			23.5																	No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Bevacizumab,Carboplatin,Paclitaxel		Completed	NCT01364012	BEYOND	PCD	2013Jan27	No	Yes		1	26014294	Untreated		Progression free survival	40	23	17										12.4	7.9	.27	0.12-0.63										24.3	27.5	.9	0.40-2.02														No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Cisplatin,Pemetrexed,Placebo,Sintilimab		Completed	NCT03802240		PCD	2021Jul31	Yes	Yes		2	10.1016/S2213-2600(23)00135-2	Previously-treated		Progression free survival	318	158	160	Cisplatin,Pemetrexed									5.5	4.3	.72	0.55-0.94	0.016									20.5	19.2																Yes	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Cisplatin,IBI305,Pemetrexed,Sintilimab		Completed	NCT03802240		PCD	2021Jul31	Yes	Yes		2	10.1016/S2213-2600(23)00135-2	Previously-treated		Progression free survival	318	158	160	Cisplatin,Pemetrexed									7.2	4.3	.51	0.39-0.67	<0.0001									21.1	19.2																Yes	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Rilertinib		Recruiting	NCT06080776		ECD	2028Feb01	Yes	No		4	NCT06080776			Disease free survival, relapse free survival, regression free survival, recurrence free survival	242			Placebo																																							No	COSO29915674	2024Nov26
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Rilertinib		Unknown	NCT04239833		ECD	2022Jan31	Yes	Yes	SAE 6.2 v 9.6%	2	10.1016/j.jtho.2024.09.027			Progression free survival	245	162	83	Gefitinib	72.8	78.3			20.7	11.1			19.3	9.8	.46	0.33-0.65	<0.0001						93.8	97.6																			Yes	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Befotertinib		Active, not recruiting	NCT04206072		PCD	2022Jul30	Yes	Yes		2	10.1016/j.annonc.2022.10.333			Progression free survival	362	182	180	Icotinib	75.8	78.3							22.1	13.8	.49	0.36-0.68	<0.0001						94.5	98.3																			Yes	COSO29915674	2024Jan04
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Carboplatin,Pembrolizumab,Pemetrexed		Completed	NCT03515837	KEYNOTE-789	PCD	2023Jan17	Yes	Yes	Primary outcome not met	2	10.1200/JCO.2023.41.17_suppl.LBA900			OS, PFS	492	245	247	Carboplatin,Pemetrexed					6.3	5.6			5.6	5.5	.8	0.65-0.97	0.0122									15.9	14.7	.84	0.69-1.02	0.0362													No	COSO29915674	2024Jan22
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Stereotactic body radiation therapy,Tyrosine kinase inhibitor		Unknown	NCT03727867		ECD	2021Jun01	Yes	No		4	NCT03727867			Progression free survival	300			Stereotactic body radiation therapy																																							No	COSO29915674	2024Jul31
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Anlotinib,Icotinib		Unknown	NCT04797806	SAINT	ECD	2022Apr30	Yes	No		4	NCT04797806			Progression free survival	206			Icotinib																																							No	COSO29915674	2023Aug31
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Endostatin,Tyrosine kinase inhibitor		Unknown	NCT03008109		ECD	2017Nov01	Yes	No		4	NCT03008109			Progression free survival	80	80																																									No	COSO29915674	2021Aug20
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Carboplatin,Vinorelbine		Not yet recruiting	NCT03203590		ECD	2026Jan01	Yes	No		4	NCT03203590			Disease free survival, relapse free survival, regression free survival, recurrence free survival	590			Gefitinib																																							No	COSO29915674	2021May18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Erlotinib,Sunitinib		Completed	NCT00558103		PCD	2011May01	Overexpression	Yes		4	NCT00558103			Overall Response Rate	74	38	36	Lapatinib,Placebo	57.9	47.2							3.7	2.63																													No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Erlotinib,Sunitinib		Completed	NCT00558103		PCD	2011May01	Overexpression	Yes		4	NCT00558103			Overall Response Rate	76	38	38	Lapatinib,Placebo	44.7	29.0							3.3	3.7																													No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Erlotinib or Gefitinib or Icotinib,Whole brain radio therapy		Unknown	NCT02882984		ECD	2020Mar01	Yes	Yes	iPFS 21.4 v 22.3m	1	38801945			Intracranial progression free survival	85	41	44	Erlotinib or Gefitinib or Icotinib,Stereotactic radiotherapy																																							No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Gefitinib,Thalidomide		Unknown	NCT02387086	GELI	ECD	2017May01	Yes	No		4	NCT02387086	Untreated		Progression free survival	380			Placebo																																							No	COSO29915674	2021May18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Chemotherapy,Gefitinib		Completed	NCT01544179		PCD	2014May05	Yes	Yes		1	26159065	Previously-treated		Progression free survival	265	133	132	Placebo	31.6	34.1		0.76					5.4	5.4												14.8	17.2	1.62	1.05-2.52	0.029													No	COSO29915674	2022May03
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Fruquintinib		Completed	NCT02691299	FALUCA	PCD	2018Sep21	No	Yes		2	10.1016/j.lungcan.2020.06.016	Previously-treated		Overall survival	527	354	173	Placebo	13.8	0.6							3.7	1	.34	0.28?0.43	<0.001						66.7	24.9		8.9	10.4	1.2	0.82?1.28	0.841													No	COSO29915674	2022May03
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Erlotinib,Onartuzumab		Completed	NCT02031744		PCD	2016Jan06	No	No		4	NCT02031744	Previously-treated		Overall survival	530			Erlotinib																																							No	COSO29915674	2022May03
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Carboplatin,Erlotinib,Paclitaxel		Completed		TRIBUTE			No	Yes	Lack of efficacy	1	16043829			Unknown	1059	526	533	Carboplatin,Paclitaxel																																							No	COSO29915674	2024Jan30
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Rezivertinib		Active, not recruiting	NCT03866499		PCD	2023Nov30	Yes	No		4	NCT03866499			Progression free survival	369			Gefitinib																																							No	COSO29915674	2024Oct17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Rociletinib		Terminated	NCT02186301	TIGER 1	PCD	2017Jun28	Yes	Yes	Development discontinued	4	NCT02186301			Progression free survival	80	30	50	Erlotinib	40	78																																					No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Almonertinib		Recruiting	NCT04762459	APEX	ECD	2026May01	Yes	No		4	NCT04762459	Previously-treated		Disease free survival, relapse free survival, regression free survival, recurrence free survival	606			Cisplatin,Pemetrexed																																							No	COSO29915674	2024Sep02
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Almonertinib		Terminated	NCT05493501		PCD	2023Aug31	Yes	Yes	Changed business priorities	4	NCT05493501			Progression free survival	8			Osimertinib																																							No	COSO29915674	2024Sep02
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Alflutinib		Unknown	NCT04853342	FORWARD	ECD	2023Dec01	Yes	No		4	NCT04853342	Untreated		Disease free survival, relapse free survival, regression free survival, recurrence free survival	318			Placebo																																							No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Bevacizumab,Erlotinib		Active, not recruiting	UMIN000017069	NEJ026			Yes	Yes		1	30975627			Progression free survival	224	112	112	Erlotinib									16.9	13.3	.61	0.42-0.88	0.016																										Yes	COSO29915674	2024Apr23
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Lazertinib		Active, not recruiting	NCT04248829	LASER301	PCD	2022Jul29	Yes	Yes		2	10.1016/j.annonc.2022.10.349			Progression free survival	393	196	197	Gefitinib	76	76			19.4	8.3			20.6	9.7	.45	0.34-0.58	<0.001																										Yes	COSO29915674	2024Dec18
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Docetaxel,Vandetanib		Completed	NCT00312377	ZODIAC	PCD	2008Aug01	Yes	Yes	Regulatory submissions withdrawn 6/2009	1	25057173	Previously-treated		Progression free survival	50	32	18	Docetaxel	56.3	27.8	0.8-13.89	0.058					7.6	5.9	.51	0.25-1.06	p=0.038										18.6	.46	0.14-1.57	p=0.155													Yes	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Gefitinib		Unknown	NCT03656393	RCTACSCNSCLC	ECD	2020Jul31	Yes	No		4	NCT03656393			Disease free survival, relapse free survival, regression free survival, recurrence free survival	48			Carboplatin,Vinorelbine																																							No	COSO29915674	2022May03
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Gefitinib		Unknown	NCT01066195		ECD	2010Oct01	Yes	Yes		1	22674612	Previously-treated		Progression free survival	33	16	17	Pemetrexed									15.7	2.9	.3	0.13-0.72	0.005																										Yes	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Gefitinib		Completed	NCT00252707				No	Yes		1	18779611	Previously-treated		Overall survival	484			Docetaxel									2	2	.81	0.65-1.02	0.077									11.5	14	1.12															No	COSO29915674	2022May03
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 3	Gefitinib		Unknown	NCT01405079	ADJUVANT/CTONG1104	PCD	2017Mar01	Yes	Yes		1	33332190			Progression free survival	222	111	111	Cisplatin,Vinorelbine																						75.5	62.8	.92	0.62-1.36	0.674					28.7	18	.6	0.42-0.87	0.0054				No	COSO29915674	2022May03
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 4	Beta-elemene,Tyrosine kinase inhibitor		Recruiting	NCT04401059	SELECT-2	ECD	2025Sep30	Yes	No		4	NCT04401059			Progression free survival	744			EGFR-TKI																																							No	COSO29915674	2023Nov20
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 4	Cobicistat,Osimertinib		Recruiting	NCT05748093	OSIBOOST-2	ECD	2026Jun01	Yes	No		4	NCT05748093			Disease control rate, Clinical benefit rate	60	60																																									No	COSO29915674	2024Apr17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Unknown	Osimertinib		Active, not recruiting	NCT03969823		ECD	2025Sep30	Yes	No		4	NCT03969823			Progression free survival	148	148																																									No	COSO29915674	2024Jul11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Unknown	Alflutinib,Bevacizumab,Pemetrexed		Not yet recruiting	NCT06643000		ECD	2025Jan01	Yes	No		4	NCT06643000			Overall survival	60	60																																									No	COSO29915674	2024Dec11
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Unknown	Carboplatin,Pemetrexed,Tyrosine kinase inhibitor		Completed	NCT04552613		PCD	2023Sep24	Yes	No		4	NCT04552613	Previously-treated		OS, PFS	114	114																																									No	COSO29915674	2024Apr17
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Unknown	Sunvozertinib		Recruiting	NCT05559645	WU-KONG15	ECD	2025Dec31	Yes	No		4	NCT05559645	Previously-treated		Progression free survival	110	110																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Unknown	Chemotherapy,Icotinib		Not yet recruiting	NCT03983811		ECD	2021Oct31	Yes	No		4	NCT03983811			Disease free survival, relapse free survival, regression free survival, recurrence free survival	174			Chemotherapy,Placebo																																							No	COSO29915674	2022May03
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Unknown	Anlotinib,Tyrosine kinase inhibitor		Unknown	NCT04007835		ECD	2021Jul01	Yes	Yes	SAE 7.8%	2	10.1016/S1556-0864(23)00276-9			Progression free survival	105	105			5.7								9.2			6.6-11.6							92.4																				No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Unknown	Radiotherapy,Tyrosine kinase inhibitor		Unknown	NCT03916913		ECD	2022Jan01	Yes	No		4	NCT03916913	Previously-treated		Progression free survival	85	85																																									No	COSO29915674	2023Apr04
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Unknown	Metformin,Tyrosine kinase inhibitor		Unknown	NCT03071705		ECD	2017Apr01	Yes	Yes		1	31486833			Progression free survival	139	69	70	Tyrosine kinase inhibitor	71	54.3		0.04					13.1	9.9	.6	0.4-0.94	0.03									31.7	17.5	.5	0.28-0.90	0.02													Yes	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Unknown	Almonertinib		Unknown	NCT04778800	ARTISTRY	ECD	2023Feb20	Yes	Yes	IORR 66.7% 95%CI 34.9-90.1	2	10.1016/j.jtho.2022.07.686	Untreated		Progression free survival	12	12																																									No	COSO29915674	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / small cell carcinoma	3	In trials	Phase 2	Erlotinib		Completed	NCT01306045	Arm 2	PCD	2014Feb12	Yes	Yes	No patients recruited	1	25667274			Response rate	0	0																																									No	COSO29915333	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / squamous cell carcinoma	3	In trials	Approved FDA	Cisplatin,Gemcitabine,Necitumumab	Not required	Completed	NCT00981058	SQUIRE	PCD	2013Jun17	No	Yes		1	27668058	Untreated		Overall survival	1093	545	548	Cisplatin,Gemcitabine									5.7	5.5	.85	0.74-0.98	0.02									11.5	9.9	.84	0.74-0.96	0.01													Yes	COSO29914830	2024Oct17
EGFR_unspecified	Gene				lung / carcinoma / squamous cell carcinoma	3	In trials	Phase 1	Afatinib		Unknown	NCT04132102		ECD	2021Apr30	Yes	No		4	NCT04132102			Progression free survival	20	20																																									No	COSO29914830	2022May03
EGFR_unspecified	Gene				lung / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	Osimertinib		Recruiting	NCT06383728	GALAXY-02	ECD	2025Oct31	Yes	No		4	NCT06383728			Overall Response Rate	51	51																																									No	COSO29914830	2024Jun12
EGFR_unspecified	Gene				lung / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	Carboplatin,Gemcitabine,Nimotuzumab		Unknown	NCT03574402	CTONG1702 Arm 10	ECD	2022Dec30	Expression confirmed	No		4	NCT03574402			Response rate	400	400																																									No	COSO29914830	2025Jan08
EGFR_unspecified	Gene				lung / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	Afatinib,Cisplatin,Gemcitabine		Unknown	NCT04470076	Neoafa	ECD	2021Dec30	Yes	No		4	NCT04470076			Overall Response Rate	30	30																																									No	COSO29914830	2023Aug31
EGFR_unspecified	Gene				oesophagus / carcinoma / NS	2	Promising trials results	Phase 1	Afatinib,Becotatug		Unknown	NCT05164848		ECD	2023Oct01	No	No		4	NCT05164848	Previously-treated		Maximum tolerated dose/toxicity	50	50																																									No	COSO31394862	2024Nov13
EGFR_unspecified	Gene				oesophagus / carcinoma / NS	2	Promising trials results	Phase 2	Afatinib		Unknown	NCT03940976	ESCC-A01	ECD	2020Jan01	Overexpression	Yes	Primary outcome met 	2	10.1038/s41392-024-01875-4			Overall Response Rate	38	38			39								3.7			3-4.9										7.8			5.6-9.3														Yes	COSO31394862	2025Jan08
EGFR_unspecified	Gene				oesophagus / carcinoma / NS	2	Promising trials results	Phase 2	Amivantamab		Recruiting	NCT05117931		ECD	2025Nov01	Expression confirmed	No		4	NCT05117931			Overall Response Rate	25	25																																									No	COSO31394862	2024Jan04
EGFR_unspecified	Gene				oesophagus / carcinoma / NS	2	Promising trials results	Phase 2	Larotinib		Completed	NCT03888092	350mg	PCD	2022Dec13	Expression confirmed	Yes	Response not correlated with expression status	1	34688250			Maximum tolerated dose/toxicity	50	50			16.3								3.4			2.4-3.7										8.0			4.9-10.2														No	COSO31394862	2025Jan08
EGFR_unspecified	Gene				oesophagus / carcinoma / NS	2	Promising trials results	Phase 2	Irinotecan,Panitumumab		Completed	NCT00836277		PCD	2015Aug01	No	Yes		1	29769385	Previously-treated		Response rate	24	24											2.9													7.2							1										No	COSO31394862	2021May18
EGFR_unspecified	Gene				oesophagus / carcinoma / NS	2	Promising trials results	Phase 2	Erlotinib,Radiotherapy		Completed	NCT00524121		PCD	2010May01	No	Yes		4	NCT00524121	Untreated		Overall survival	17	17																								7.3																	No	COSO31394862	2025Jan08
EGFR_unspecified	Gene				oesophagus / carcinoma / NS	2	Promising trials results	Phase 2	Nimotuzumab		Completed	NCT02591784	BT-IST-ESO-002	PCD	2011Dec01	No	Yes		1	22555809			Maximum tolerated dose/toxicity	63	33	30		47.8	15.4		0.014															60.9	26.9		0.017																	No	COSO31394862	2025Jan08
EGFR_unspecified	Gene				oesophagus / carcinoma / squamous cell carcinoma	3	In trials	Phase 1	Nimotuzumab,Radiotherapy,Tigio		Recruiting	NCT06048913		ECD	2025Jul01	Expression confirmed	No		4	NCT06048913			Overall survival	45	45																																									No	COSO31394830	2024Jan04
EGFR_unspecified	Gene				oesophagus / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	Afatinib,Toripalimab		Unknown	NCT04880811		ECD	2022Oct01	Expression confirmed	No		4	NCT04880811	Previously-treated		Overall Response Rate	43	43																																									No	COSO31394830	2024Apr25
EGFR_unspecified	Gene				oesophagus / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	BNT323/DB-1303,Cisplatin,Fluorouracil,Pimurutamab,Serplulimab		Recruiting	NCT05221658	Group A	ECD	2024Jun30	Expression confirmed	Yes		2	10.1200/JCO.2023.41.16_suppl.402	Untreated		Overall Response Rate	29	29			55.2		35.7-73.6																																				No	COSO31394830	2025Jan08
EGFR_unspecified	Gene				oesophagus / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	Pimurutamab		Recruiting	NCT05221658	Group B	ECD	2024Jun30	Expression confirmed	Yes		2	10.1200/JCO.2023.41.16_suppl.402	Previously-treated		Overall Response Rate	13	13			23.1		5.0-53.8						1.5			1.2-																											No	COSO31394830	2025Jan08
EGFR_unspecified	Gene				ovary / carcinoma / NS	3	In trials	Phase 2	Gefitinib		Completed	NCT00023699				Yes	Yes		1	16061871	Previously-treated		Not defined	11	11			9.0																																						No	COSO30134862	2025Jan08
EGFR_unspecified	Gene				ovary / carcinoma / NS	3	In trials	Phase 2	Matuzumab		Completed	NCT00073541		PCD	2004Mar01	Expression confirmed	Yes	Lack of efficacy	1	17126894	Previously-treated		Not defined	32	32																																									No	COSO30134862	2025Jan08
EGFR_unspecified	Gene				ovary / carcinoma / mixed carcinoma	3	In trials	Phase 3	Erlotinib		Completed	NCT00263822		PCD	2008Feb01	No	Yes	Response not correlated with mutation or expression status	1	24366937	Previously-treated		Progression free survival	835	420	415	Observation									12.7	12.4	1.05	0.90-1.2	0.525									50.8	59.1	.99	0.81-1.20	0.903													No	COSO30135797	2021May18
EGFR_unspecified	Gene				pancreas / carcinoma / NS	3	In trials	Approved FDA	Erlotinib,Gemcitabine	Not required	Completed	NCT00040183	PA.3	PCD	2004Jan15	No	Yes		7	https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021743s025lbl.pdf			Overall survival	521	261	260	Gemcitabine	8.6	7.9							3.8	3.6	.76	0.64-0.92										6.5	6	.81	0.68-0.97	0.028													Yes	COSO29004862	2025Jan08
EGFR_unspecified	Gene				pancreas / carcinoma / NS	3	In trials	Phase 1	PKI-166		Completed					No	Yes		1	16203782			Unknown	54																																	11									No	COSO29004862	2023Sep25
EGFR_unspecified	Gene				pancreas / carcinoma / NS	3	In trials	Phase 2	Erlotinib		Terminated	NCT00470535		PCD	2009Jan01	Yes	Yes	Lack of efficacy	4	NCT00470535			Progression free survival	18	18																																									No	COSO29004862	2024Jan30
EGFR_unspecified	Gene				pancreas / carcinoma / NS	3	In trials	Phase 2	Fluorouracil,Irinotecan hydrochloride liposome,Leucovorin calcium,Nimotuzumab,Oxaliplatin		Active, not recruiting	NCT06429904	IST-Nim-PC-29	ECD	2027May01	No	No		4	NCT06429904	Untreated 		Overall survival	31	31																																									No	COSO29004862	2024Jun13
EGFR_unspecified	Gene				pancreas / carcinoma / NS	3	In trials	Phase 2	Gemcitabine,Nab-paclitaxel,Nimotuzumab		Recruiting	NCT06405685		ECD	2025Oct30	No	No		4	NCT06405685			Resection rate, surgery rate	30	30																																									No	COSO29004862	2024Jun12
EGFR_unspecified	Gene				pancreas / carcinoma / NS	3	In trials	Phase 2	Fluorouracil,Irinotecan,Leucovorin calcium,Nimotuzumab,Oxaliplatin		Recruiting	NCT06389760		ECD	2026Sep30	No	No		4	NCT06389760			Disease free survival, relapse free survival, regression free survival, recurrence free survival	57	57																																									No	COSO29004862	2025Jan08
EGFR_unspecified	Gene				pancreas / carcinoma / NS	3	In trials	Phase 2	Erlotinib,Gemcitabine,Trastuzumab		Completed	NCT01204372	GATE 1	PCD	2012Feb01	Expression confirmed	Yes	Response correlated with expression status	1	33405269			Disease control rate, Clinical benefit rate	63	63											3.5			2.4-3.8							74.6			7.9			5.1-10.2				11	33									No	COSO29004862	2024Oct23
EGFR_unspecified	Gene				pancreas / carcinoma / NS	3	In trials	Phase 2	Nimotuzumab		Not yet recruiting	NCT05316480		ECD	2025Apr30	Overexpression	No		4	NCT05316480			Overall Response Rate	42	42																																									No	COSO29004862	2022May17
EGFR_unspecified	Gene				pancreas / carcinoma / NS	3	In trials	Phase 3	Capecitabine,Gemcitabine,Nimotuzumab		Not yet recruiting	NCT06409429		ECD	2027May30	No	No		4	NCT06409429			Disease free survival, relapse free survival, regression free survival, recurrence free survival	146			Capecitabine,Gemcitabine,Placebo																																							No	COSO29004862	2024Jun18
EGFR_unspecified	Gene				pleura / mesothelioma / NS	3	In trials	Phase 2	Cetuximab,Chemotherapy		Completed	NCT00996567	MesoMab	PCD	2015Sep01	Yes	Yes		2	10.1200/JCO.2017.35.15_suppl.e20030			Progression free survival	18	18											5.54													11.31							8										No	COSO30105680	2025Jan08
EGFR_unspecified	Gene				prostate / carcinoma / NS	3	In trials	Unknown	Gefitinib		Unknown	NCT02208583		ECD	2016Dec01	Yes	No		4	NCT02208583	Previously-treated		Progression free survival	150	150																																									No	COSO32054862	2021May18
EGFR_unspecified	Gene				salivary gland / carcinoma / NS	3	In trials	Phase 2	Lapatinib		Completed	NCT00095563		PCD	2009Feb01	Expression confirmed	Yes		4	NCT00095563			Overall Response Rate	40	40			0																																						No	COSO32204862	2021Sep30
EGFR_unspecified	Gene				skin / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	Cemiplimab,Cetuximab sarotalocan		Active, not recruiting	NCT04305795		ECD	2024Jun01	Expression confirmed	No		4	NCT04305795			Overall Response Rate	74	74																																									No	COSO32664830	2025Jan08
EGFR_unspecified	Gene				soft tissue / sarcoma / NS	3	In trials	Phase 3	Lapatinib		Active, not recruiting	NCT03784014	MULTISARC	PCD	2023Dec01	Yes	No		4	NCT03784014			Unknown	603	603																																									No	COSO31375226	2024Apr17
EGFR_unspecified	Gene				soft tissue / synovial sarcoma / NS	3	In trials	Phase 2	Gefitinib		Unknown					Expression confirmed	Yes	Primary outcome not met	1	18448563	Previously-treated		Disease control rate, Clinical benefit rate	46	46																																5									No	COSO31356219	2021May18
EGFR_unspecified	Gene				stomach / carcinoma / NS	3	In trials	Phase 2	GC1118,Paclitaxel		Recruiting	NCT04077255		ECD	2023Dec31	Yes	Yes		2	10.1158/1538-7445.AM2024-CT216			Overall Response Rate	19	19			31.6								4.7			1.8-5.1										7.6 			4.2-11.1														No	COSO36004862	2024Apr22
EGFR_unspecified	Gene				stomach / carcinoma / NS	3	In trials	Phase 2	MRG003		Unknown	NCT05188209		ECD	2023Mar21	Yes	No		4	NCT05188209			Overall Response Rate	60	60																																									No	COSO36004862	2024Apr25
EGFR_unspecified	Gene				stomach / carcinoma / NS	3	In trials	Phase 3	FOLFOX-6,Varlitinib		Completed	NCT03130790		PCD	2018Dec20	Expression confirmed	Yes	Primary outcome not met	6	https://ir.aslanpharma.com/news-releases/news-release-details/aslan-pharmaceuticals-announces-study-results-phase-2-study	Untreated		Overall survival	400			FOLFOX-6,Placebo																																							No	COSO36004862	2025Jan08
EGFR_unspecified	Gene				thymus / thymic carcinoma / NS	3	In trials	Phase 2	Erlotinib		Completed	NCT01306045	Arm 3	PCD	2014Feb12	Yes	Yes		1	25667274			Response rate	1	1			0																												0	0									No	COSO38307384	2025Jan08
EGFR_unspecified	Gene				upper aerodigestive tract / carcinoma / nasopharyngeal carcinoma	3	In trials	Phase 2	Cetuximab,Chemotherapy,Intensity modulated radiation therapy		Completed	NCT01271439	REPLACE	PCD	2012Jun01	No	No		4	NCT01271439 			Overall Response Rate	60	60																																									No	COSO319110600	2022Nov09
EGFR_unspecified	Gene				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Approved FDA	Carboplatin,Cetuximab,Cisplatin,Fluorouracil	Not required	Completed	NCT00122460	EXTREME	PCD	2007Mar01	No	Yes	Response not correlated with expression status PMID:23265711 	4	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf	Untreated		Overall survival	442	222	220	Cisplatin,Fluorouracil	35.6	19.5	1.5-3.6	0.0001					5.5	3.3	.57	0.46-0.72	<0.0001									10.1	7.4	.8	0.64-0.89	0.034													Yes	COSO29324830	2024Oct23
EGFR_unspecified	Gene				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Approved FDA	Cetuximab,Radiotherapy	Not required	Terminated	NCT00004227	BONNER	PCD	2007Mar01	Expression confirmed	Yes	Primary outcome met LRC 24.4 vs 14.9 HR 0.68 p=0.005	1	16467544			Locoregional control	424	213	211	Radiotherapy					24.4	14.9	0.52-0.89	0.005			.7	0.54-0.90	0.0006									49.0	29.3	.74	0.57-0.97	0.03													Yes	COSO29324830	2025Jan08
EGFR_unspecified	Gene				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Phase 1	Erlotinib		Completed	NCT00079053		PCD	2008Dec09	No	No		4	NCT00079053			Maximum tolerated dose/toxicity	19	19																																									No	COSO29324830	2022May03
EGFR_unspecified	Gene				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Phase 1	Nitozumab,Radiotherapy,Sinilimab		Recruiting	NCT05831930		ECD	2026Jan01	Expression confirmed	No		4	NCT05831930			Complete remission	62	62																																									No	COSO29324830	2023Jul13
EGFR_unspecified	Gene				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Phase 1	Bortezomib,Cetuximab,Cisplatin		Completed	NCT00629226		PCD	2010Dec01	No	No		4	NCT00629226	Untreated		Maximum tolerated dose/toxicity	46	46																																									No	COSO29324830	2021May18
EGFR_unspecified	Gene				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Phase 1	Imgatuzumab		Completed	NCT01046266		PCD	2012Jun01	No	Yes		1	28950289			Immune cell infiltration	21	21																														1											No	COSO29324830	2025Jan08
EGFR_unspecified	Gene				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	Cetuximab,Ficlatuzumab		Completed	NCT03422536		PCD	2022Mar29	No	Yes		4	NCT03422536			Progression free survival	32	32			19								3.6																														No	COSO29324830	2025Jan08
EGFR_unspecified	Gene				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	Cisplatin,MRG003,Pucotenlimab,Surgery		Not yet recruiting	NCT06530914		ECD	2026Dec31	Expression confirmed	No		4	NCT06530914	Untreated 		Complete response, Pathological complete response	30	30																																									No	COSO29324830	2024Oct21
EGFR_unspecified	Gene				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	MRG003,Pucotenlimab,Surgery		Not yet recruiting	NCT06530914		ECD	2026Dec31	Expression confirmed	No		4	NCT06530914	Untreated 		Complete response, Pathological complete response	30	30																																									No	COSO29324830	2024Oct21
EGFR_unspecified	Gene				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	Nab-paclitaxel,Nedaplatin,Nimotuzumab		Unknown	NCT05351762		ECD	2024May30	No	No		4	NCT05351762			Overall Response Rate	55	55																																									No	COSO29324830	2024Oct17
EGFR_unspecified	Gene				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	AFM24,SNK01		Terminated	NCT05099549		PCD	2023Sep21	Expression confirmed	Yes	Changed business priorities	4	NCT05099549			Overall Response Rate	11	11																																									No	COSO29324830	2024Nov13
EGFR_unspecified	Gene				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	Nimotuzumab,Radiotherapy		Not yet recruiting	NCT05024019		ECD	2025Aug21	No	No		4	NCT05024019			Disease free survival, relapse free survival, regression free survival, recurrence free survival	95	95																																									No	COSO29324830	2021Nov15
EGFR_unspecified	Gene				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	Nimotuzumab,Sintilimab		Unknown	NCT04882462	Carpp-1	ECD	2021Nov30	Expression confirmed	No		4	NCT04882462	Untreated		Progression free survival	100	100																																									No	COSO29324830	2023Aug31
EGFR_unspecified	Gene				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	Nimotuzumab		Completed		h-R3/SCCHN/001/IND			No	Yes		1	24613543	Untreated		Unknown	92			Radiotherapy	100	70		0.02																																			No	COSO29324830	2024Feb07
EGFR_unspecified	Gene				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	Panitumumab		Completed	NCT02643056	S10PANI01	PCD	2015Dec01	No	Yes		1	28592616	Previously-treated		Overall Response Rate	33	33			6								2.6										51			9.7							2	15									No	COSO29324830	2025Jan08
EGFR_unspecified	Gene				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Phase 3	Best supportive care,Zalutumumab		Completed	NCT00382031	ZALUTE	PCD	2009Dec01	No	Yes	Primary outcome not met	1	21377930	Previously-treated		Overall survival	286			Best supportive care									9.9	8.4	.63	0.47-0.84	0.0012									6.7	5.2			0.065													No	COSO29324830	2021May18
EGFR_unspecified	Gene				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Phase 3	Radiotherapy,Zalutumumab		Completed	NCT00496652	DAHANCA-19	PCD	2012Jul01	No	Yes	Lack of efficacy	3	https://www.medscape.com/viewarticle/823574#vp_1	Untreated		Locoregional control	619			Radiotherapy																																							No	COSO29324830	2024Jan30
EGFR_unspecified	Gene				urinary tract / papilloma / typical	3	In trials	Phase 2	Afatinib		Completed	NCT02780687	LUX-Bladder 1 Cohort B	PCD	2018Sep24	Expression confirmed	Yes	SAE 75%	1	38102226			Progression free survival	8	8											1.8			1.52-3.81										6.83			1.71-10.85														No	COSO27964893	2025Jan08
EGFR_unspecified and ERBB2_absent and ESR1_absent and PGR_absent	Multigene				breast / carcinoma / basal (triple-negative) carcinoma	3	In trials	Phase 2	Erlotinib		Terminated	NCT00597597		PCD	2011Apr01	Expression confirmed	Yes	Slow accrual	4	NCT00597597			Progression free survival	11	11																																									No	COSO283911696	2023Jul27
EGFR_unspecified and ERBB2_absent and ESR1_absent and PGR_absent	Multigene				breast / carcinoma / basal (triple-negative) carcinoma	3	In trials	Phase 2	Doxorubicin-loaded anti-EGFR immunoliposomes		Terminated	NCT02833766		PCD	2020Oct31	Expression confirmed	Yes	PFS 12m 13%, Primary outcome not met	1	36879012			Progression free survival	48	48											3.5			1.9-54																1	1	10									No	COSO283911696	2024Oct23
EGFR_unspecified and ERBB2_absent and ESR1_absent and PGR_absent	Multigene				breast / carcinoma / basal (triple-negative) carcinoma	3	In trials	Phase 2	Gefitinib		Unknown	NCT01732276		ECD	2015Apr01	Expression confirmed	No		4	NCT01732276			Disease control rate, Clinical benefit rate	50	50																																									No	COSO283911696	2022Nov28
EGFR_unspecified and ERBB2_unspecified	Multigene				NS / other / neoplasm	3	In trials	Phase 1	Afatinib		Completed	NCT02171728		PCD	2006Sep01	No	No		4	NCT02171728			Maximum tolerated dose/toxicity	30	30																																									No	COSO31314888	2021Dec14
EGFR_unspecified and ERBB2_unspecified	Multigene				NS / other / neoplasm	3	In trials	Phase 1	ORIC-114		Recruiting	NCT05315700		ECD	2025Mar01	Yes	No		4	NCT05315700			Maximum tolerated dose/toxicity	350	350																																									No	COSO31314888	2024Jul11
EGFR_unspecified and ERBB2_unspecified	Multigene				NS / other / neoplasm	3	In trials	Phase 1	Afatinib,Vinorelbine		Completed	NCT00906698		PCD	2013Jan01	No	Yes		4	NCT00906698			Maximum tolerated dose/toxicity	18	18			16.7								3.67			1.71-5.47							50																				No	COSO31314888	2025Jan08
EGFR_unspecified and ERBB2_unspecified	Multigene				NS / other / neoplasm	3	In trials	Phase 2	Afatinib		Terminated	NCT00748709		PCD	2010Nov01	Overexpression	Yes	Slow accrual	4	NCT00748709			Overall Response Rate	20	20																																									No	COSO31314888	2021Oct15
EGFR_unspecified and ERBB2_unspecified	Multigene				breast / carcinoma / NS	2	Promising trials results	Phase 2	Paclitaxel,Trastuzumab		Unknown	NCT02226757		ECD	2016Aug01	Expression confirmed	Yes	Primary outcome met	2	10.1200/JCO.2017.35.15_suppl.9042	Previously-treated		Overall Response Rate	17	17																															7	2									Yes	COSO28394862	2025Jan08
EGFR_unspecified and ERBB2_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Erlotinib,Gemcitabine,Platinum-based chemotherapy		Recruiting	NCT02098954		ECD	2024Dec01	Yes	No		4	NCT02098954	Previously-treated		Progression free survival	40	40																																									No	COSO29915674	2024Jan04
EGFR_unspecified and ERBB2_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Almonertinib or Furmonertinib or Osimertinib,Disitamab vedotin		Not yet recruiting	NCT06185400	Arm 1	ECD	2025Jul01	Expression confirmed	No		4	NCT06185400	Untreated		Overall Response Rate	108	108																																									No	COSO29915674	2024Apr02
EGFR_unspecified and ERBB2_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Alflutinib,Disitamab vedotin		Not yet recruiting	NCT05847764	Arm 2	ECD	2024Oct01	Expression confirmed	No		4	NCT05847764			Overall Response Rate	95	95																																									No	COSO29915674	2024Apr23
EGFR_unspecified and ERBB2_unspecified	Multigene				stomach / carcinoma / NS	3	In trials	Phase 2	Varlitinib		Completed	NCT01614522		PCD	2013Mar01	Yes	No		4	NCT01614522	Previously-treated		Clinical activity	24	24																																									No	COSO36004862	2021Dec03
EGFR_unspecified and ERBB2_unspecified	Multigene				stomach / carcinoma / NS	3	In trials	Phase 2	Paclitaxel,Varlitinib		Completed	NCT05400915	K-MASTER-13	PCD	2021Dec13	Expression confirmed	Yes		2	10.4143/crt.2023.1324	Previously-treated		Progression free survival	27	27											3.3			1.7-4.9										7.9			5.0-10.8														No	COSO36004862	2024Nov13
EGFR_unspecified and ERBB2_unspecified	Multigene				stomach / carcinoma / NS	3	In trials	Phase 2	Varlitinib,mFOLFOX6		Completed	NCT03130790		PCD	2018Dec20	Expression confirmed	Yes	TV -22 v -12.5%, Primary outcome not met 	6	https://ir.aslanpharma.com/news-releases/news-release-details/aslan-pharmaceuticals-announces-study-results-phase-2-study			Tumour volume	50			Placebo,mFOLFOX6																																							No	COSO36004862	2025Jan08
EGFR_unspecified and HHLA2_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	NPX267		Recruiting	NCT05958199		ECD	2026Jan01	Yes	No		4	NCT05958199			Disease control rate, Clinical benefit rate	131	131																																									No	COSO29915674	2023Nov08
EGFR_unspecified and KRAS_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Erlotinib,Gemcitabine,Platinum-based chemotherapy		Recruiting	NCT02098954		ECD	2024Dec01	Yes	No		4	NCT02098954	Previously-treated		Progression free survival	40	40																																									No	COSO29915674	2024Jan04
EGFR_unspecified and MET_unspecified	Multigene				NS / other / neoplasm	3	In trials	Phase 1	ALK202		Not yet recruiting	NCT06707610		ECD	2027Dec01	No	No		4	NCT06707610			Maximum tolerated dose/toxicity	234	234																																									No	COSO31314888	2024Dec04
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Capmatinib,Erlotinib		Completed	NCT01911507		PCD	2020Aug26	Yes	Yes		2	10.1200/jco.2015.33.15_suppl.2587	Previously-treated		Maximum tolerated dose/toxicity	8	8			50																		50																				No	COSO29915674	2025Jan08
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Osimertinib,Tepotinib 		Withdrawn	NCT05120960		PCD	2024Apr12	Yes	Yes	No patients recruited	4	NCT05120960			Maximum tolerated dose/toxicity	0	0																																									No	COSO29915674	2025Jan30
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Osimertinib,Savolitinib		Active, not recruiting	NCT05163249	FLOWERS	ECD	2024Apr01	Yes	Yes		2	10.1016/j.jtho.2024.09.020	Untreated		Overall Response Rate	44	21	23	Osimertinib	90.5	60.9			18.6	8.4			19.6	9.3									95.2	87.0																			No	COSO29915674	2024Nov13
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Andamertinib,Bozitinib		Recruiting	NCT06343064	Cohort 3 - EGFR-mutated and MET overexpression (Failed 1st/2nd gen EGFRi)	ECD	2024Dec31	Overexpression	No		4	NCT06343064	Previously-treated		MTD, ORR, Toxicity	156	156																																									No	COSO29915674	2024Sep25
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Andamertinib,Bozitinib		Recruiting	NCT06343064	Cohort 2 - EGFR-mutated and MET amplification (Failed 3rd gen EGFRi)	ECD	2024Dec31	Overexpression	No		4	NCT06343064	Previously-treated		MTD, ORR, Toxicity	156	156																																									No	COSO29915674	2024Sep25
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Andamertinib,Bozitinib		Recruiting	NCT06343064	Cohort 1 - EGFR-mutated and MET amplification (Failed 1st/2nd gen EGFRi)	ECD	2024Dec31	Overexpression	No		4	NCT06343064	Previously-treated		MTD, ORR, Toxicity	156	156																																									No	COSO29915674	2024Sep25
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Andamertinib,Bozitinib		Recruiting	NCT06574347		ECD	2026Oct31	Expression confirmed	No		4	NCT06574347			Overall Response Rate	120			Osimertinib																																							No	COSO29915674	2024Sep25
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Capmatinib,Osimertinib,Ramucirumab		Recruiting	NCT05642572	Arm A	ECD	2026May31	Expression confirmed	No		4	NCT05642572			Progression free survival	66	66																																									No	COSO29915674	2023Aug31
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Tepotinib 		Active, not recruiting	NCT03940703	INSIGHT 2	PCD	2023May11	Yes	Yes		4	NCT03940703	Previously-treated		Overall Response Rate	12	12			8.3																																						No	COSO29915674	2025Jan08
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Capmatinib,Gefitinib		Completed	NCT01610336		PCD	2016Jun10	Expression confirmed	Yes		1	30156984				78	78			32																												25	33									No	COSO29915674	2025Jan08
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Capmatinib,Osimertinib		Recruiting	NCT05642572	Arm B	ECD	2026May31	Expression confirmed	No		4	NCT05642572			Progression free survival	66	66																																									No	COSO29915674	2023Aug31
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Osimertinib,Tepotinib 		Active, not recruiting	NCT03940703	INSIGHT 2	PCD	2023May11	Expression confirmed	Yes		2	10.1200/JCO.2023.41.16_suppl.9021	Previously-treated		Overall Response Rate	98	98			43.9		33.9-54.3		9.7		5.6-		5.4																														No	COSO29915674	2025Jan08
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Osimertinib,Savolitinib		Active, not recruiting	NCT03778229	SAVANNAH not IHC90+/FISH10+	ECD	2024Aug23	Yes	Yes		2	10.1016/j.jtho.2022.07.823	Previously-treated		Overall Response Rate	63	63			10		4-20		7.3		4.1-		2.8			1.8-4.2																											No	COSO29915674	2025Jan08
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Osimertinib,Savolitinib		Active, not recruiting	NCT03778229	SAVANNAH not IHC90+/FISH10+	ECD	2024Aug23	Yes	Yes		2	10.1016/j.jtho.2022.07.823			Overall Response Rate	77	77			9		4-18		6.9		4.1-16.9		2.8			2.6-4.3																											No	COSO29915674	2025Jan08
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Osimertinib,Savolitinib		Active, not recruiting	NCT03778229	SAVANNAH IHC90+/FISH10+	ECD	2024Aug23	Yes	Yes		2	10.1016/j.jtho.2022.07.823	Previously-treated		Overall Response Rate	87	87			52		41-63		9.6		7.6-14.9		7.2			4.7-9.2																											No	COSO29915674	2025Jan08
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Osimertinib,Savolitinib		Active, not recruiting	NCT03778229	SAVANNAH IHC90+/FISH10+	ECD	2024Aug23	Yes	Yes		2	10.1016/j.jtho.2022.07.823			Overall Response Rate	108	108			49		39-59		9.3		7.6-10.6		7.1			5.3-8.0																											No	COSO29915674	2025Jan08
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Osimertinib,Savolitinib		Active, not recruiting	NCT03778229	SAVANNAH IHC50+/FISH5+	ECD	2024Aug23	Yes	Yes		2	10.1016/j.jtho.2022.07.823	Previously-treated		Overall Response Rate	157	157			33		26-41		9.6		7.6-15.3		4.5			4.0-5.8																											No	COSO29915674	2025Jan08
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Osimertinib,Savolitinib		Active, not recruiting	NCT03778229	SAVANNAH IHC50+/FISH5+	ECD	2024Aug23	Yes	Yes	Promising activity 	2	10.1016/j.jtho.2022.07.823			Overall Response Rate	193	193			32		26-39		8.3		6.9-9.7		5.3			4.2-5.8																											No	COSO29915674	2025Jan08
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Osimertinib,Savolitinib		Active, not recruiting	NCT04606771	CoC MET IHC90+/FISH10+	PCD	2022Dec21	Yes	Yes		2	10.1158/1538-7445.AM2024-CT251	Previously-treated		Overall Response Rate	15	8	7	Placebo,Savolitinib	63	29			7.06				8.2	4																													No	COSO29915674	2025Jan08
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Osimertinib,Savolitinib		Active, not recruiting	NCT04606771	CoC	PCD	2022Dec21	Yes	Yes	SAE 29 v 19	2	10.1158/1538-7445.AM2024-CT251	Previously-treated		Overall Response Rate	30	14	16	Placebo,Savolitinib	57	13			7.06				7.4	1.6																													No	COSO29915674	2025Jan08
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Erlotinib,Onartuzumab		Completed	NCT01456325	METLung	PCD	2016Jan01	No	Yes	Response not correlated with mutation or expression status	1	27937096	Previously-treated		Overall survival	499	249	250	Erlotinib	8.4	9.6							2.7	2.6	.99	0.81-1.2	0.92									6.8	9.1	1.27	0.98-1.65	0.067													No	COSO29915674	2025Jan08
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Osimertinib,Savolitinib		Recruiting	NCT05015608	SACHI	ECD	2024Sep15	Yes	No		4	NCT05015608			Progression free survival	250			Cisplatin,Pemetrexed																																							No	COSO29915674	2022Jan24
EGFR_unspecified and MET_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Erlotinib,Onartuzumab		Completed	NCT01887886		PCD	2015Feb01	Yes	Yes	Lack of funding	8	https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000868-29/results	Untreated		Progression free survival	10	5	5	Erlotinib,Placebo																																							No	COSO29915674	2024Jan30
EGFR_unspecified and MET_unspecified	Multigene				pancreas / carcinoma / NS	3	In trials	Phase 2	Cabozantinib,Erlotinib		Terminated	NCT03213626		PCD	2019Apr15	Expression confirmed	Yes	Lack of efficacy	4	NCT03213626			Overall Response Rate	7	7																																									No	COSO29004862	2024Jan30
EGFR_unspecified and MUC1_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	M1231		Completed	NCT04695847		PCD	2023Jun23	Expression confirmed	No		4	NCT04695847	Previously-treated		ORR, DOR	23	23																																									No	COSO29915674	2023Aug31
EGFR_unspecified and PIK3CA_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Erlotinib,Gemcitabine,Platinum-based chemotherapy		Recruiting	NCT02098954		ECD	2024Dec01	Yes	No		4	NCT02098954	Previously-treated		Progression free survival	40	40																																									No	COSO29915674	2024Jan04
EGFR_unspecified and TP53_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Bevacizumab,Carboplatin,Osimertinib,Pemetrexed		Unknown	NCT05507606		ECD	2023Aug01	Yes	No		4	NCT05507606			Overall Response Rate	50	50																																									No	COSO29915674	2024Oct17
EGFR_unspecified and TP53_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Almonertinib,Anlotinib		Recruiting	NCT06043973		ECD	2026Sep01	Yes	No		4	NCT06043973	Untreated		Progression free survival	98	98																																									No	COSO29915674	2024Sep02
EGFR_unspecified and TP53_unspecified and RB1_unspecified	Multigene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Cisplatin,Etoposide,Osimertinib		Active, not recruiting	NCT03567642		ECD	2025Jun01	Yes	No		4	NCT03567642			Maximum tolerated dose/toxicity	11	11																																									No	COSO29915674	2024Jul11
EGFR_unspecified or EPHA2_unspecified or ERBB2_unspecified or IL13RA2_unspecified or PROM1_unspecified	Set				central nervous system / glioma / NS	3	In trials	Phase 1	Anti-HER2 CAR T-cells		Unknown	NCT03423992		ECD	2023Jan30	Expression confirmed	No		4	NCT03423992			Maximum tolerated dose/toxicity	100	100																																									No	COSO28245257	2025Jan08
EGFR_unspecified or ERBB2_unspecified	Set				breast / carcinoma / NS	3	In trials	Phase 1	Neratinib		Completed	NCT00146172		PCD	2007Jan01	Expression confirmed	Yes		1	19318484			Maximum tolerated dose/toxicity	25	25			32																												3	1									No	COSO28394862	2025Jan08
EGFR_unspecified or ERBB2_unspecified	Set				breast / carcinoma / NS	3	In trials	Phase 1	MVF-HER-2 (266-296) HER2 B-cell epitope vaccine,MVF-HER-2 (597-626) HER2 B-cell epitope vaccine		Recruiting	NCT06414733		ECD	2026Dec01	Expression confirmed	No		4	NCT06414733			MTD, ORR, Toxicity	42	42																																									No	COSO28394862	2025Jan08
EGFR_unspecified or ERBB2_unspecified	Set				gastrointestinal tract (site indeterminate) / carcinoma / NS	3	In trials	Phase 1	MVF-HER-2 (266-296) HER2 B-cell epitope vaccine,MVF-HER-2 (597-626) HER2 B-cell epitope vaccine		Recruiting	NCT06414733		ECD	2026Dec01	Expression confirmed	No		4	NCT06414733			MTD, ORR, Toxicity	42	42																																									No	COSO36634862	2025Jan08
EGFR_unspecified or ERBB2_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Neratinib		Completed	NCT00146172		PCD	2007Jan01	Expression confirmed	Yes		1	19318484			Maximum tolerated dose/toxicity	14	14																																6									No	COSO29915674	2025Jan08
EGFR_unspecified or ERBB2_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Rosuvastatin calcium,Sunvozertinib		Completed	NCT05926180		PCD	2024May16	Yes	No		4	NCT05926180			Maximum tolerated dose/toxicity	25	25																																									No	COSO29915674	2025Jan08
EGFR_unspecified or ERBB2_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Digoxin,Sunvozertinib		Completed	NCT05926180	WU-KONG19	PCD	2024May16	Yes	No		4	NCT05926180			Maximum tolerated dose/toxicity	25	25																																									No	COSO29915674	2025Jan08
EGFR_unspecified or ERBB2_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Midazolam,Sunvozertinib		Completed	NCT05926180	WU-KONG19	PCD	2024May16	Yes	No		4	NCT05926180			Maximum tolerated dose/toxicity	25	25																																									No	COSO29915674	2025Jan08
EGFR_unspecified or ERBB2_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Andamertinib		Active, not recruiting	NCT05347628		PCD	2023Apr04	Yes	Yes	Manageable toxicity	2	10.1158/1538-7445.AM2023-CT102			Maximum tolerated dose/toxicity	65	65																																									No	COSO29915674	2025Jan08
EGFR_unspecified or ERBB2_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Sunvozertinib		Completed	NCT05926180	WU-KONG19	PCD	2024May16	Yes	No		4	NCT05926180			Maximum tolerated dose/toxicity	25	25																																									No	COSO29915674	2025Jan08
EGFR_unspecified or ERBB2_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Mobocertinib		Active, not recruiting	NCT03807778		PCD	2021Nov08	Yes	Yes	Manageable toxicity	2	10.1016/j.annonc.2021.08.1851			Overall Response Rate	20	20																																									No	COSO29915674	2025Jan08
EGFR_unspecified or ERBB2_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 1	Alflutinib		Active, not recruiting	NCT05364073		ECD	2025Sep01	Yes	No		4	NCT05364073			Maximum tolerated dose/toxicity	170	170																																									No	COSO29915674	2024Oct17
EGFR_unspecified or ERBB2_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Sunvozertinib		Active, not recruiting	NCT03974022	WU-KONG1	PCD	2024Jul29	Yes	No		4	NCT03974022			Overall Response Rate	336	336																																									No	COSO29915674	2025Jan08
EGFR_unspecified or ERBB2_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	BH-30643		Recruiting	NCT06706076	SOLARA	ECD	2029Jan31	Yes	No		4	NCT06706076	Previously-treated		Overall Response Rate	266	266																																									No	COSO29915674	2024Dec11
EGFR_unspecified or ERBB2_unspecified or ERBB3_unspecified	Set				NS / other / neoplasm	3	In trials	Phase 2	Tuxobertinib		Terminated	NCT04209465	MasterKey-01	PCD	2022Sep02	Yes	Yes	Development discontinued, Manageable toxicity	2	10.1200/JCO.2021.39.15_suppl.3086			Overall Response Rate	27	27																															1	3									No	COSO31314888	2025Jan08
EGFR_unspecified or ERBB2_unspecified or ERBB3_unspecified	Set				urinary tract / papilloma / typical	3	In trials	Phase 2	Afatinib		Terminated	NCT02122172		PCD	2024Apr04	No	Yes	PFS 3m 71.4%	2	10.1200/jco.2016.34.2_suppl.459			Progression free survival	7	7																																									No	COSO27964893	2025Jan08
EGFR_unspecified or ERBB2_unspecified or ERBB3_unspecified or ERBB4_unspecified	Set				stomach / carcinoma / NS	3	In trials	Phase 2	Neratinib,Paclitaxel,Pembrolizumab		Withdrawn	NCT05512182		ECD	2023Oct30	Expression confirmed	Yes	No patients recruited 	4	NCT05512182			Overall Response Rate	0	0																																									No	COSO36004862	2024Jun21
EGFR_unspecified or ERBB2_unspecified or ERBB3_unspecified or PIK3CA_unspecified	Set				gastrointestinal tract (site indeterminate) / carcinoma / adenocarcinoma	3	In trials	Phase 2	Atezolizumab,Ipatasertib		Unknown	NCT04739202	IMMUNOGAST group 1	ECD	2023Oct26	No	No		4	NCT04739202	Previously-treated		Overall Response Rate	60	60																																									No	COSO36634826	2024Jan04
EGFR_unspecified or ERBB2_unspecified or ESR1_unspecified or PGR_unspecified	Set				NS / other / neoplasm	3	In trials	Phase 1	Afatinib		Completed	NCT02171663		PCD	2006Feb01	No	No		4	NCT02171663			Maximum tolerated dose/toxicity	43	43																																									No	COSO31314888	2023Mar06
EGFR_unspecified or ERBB2_unspecified or ESR1_unspecified or PGR_unspecified	Set				NS / other / neoplasm	3	In trials	Phase 1	Afatinib,Docetaxel		Completed	NCT02171676		PCD	2008Mar01	No	No		4	NCT02213289			Maximum tolerated dose/toxicity	40	40																																									No	COSO31314888	2023Mar06
EGFR_unspecified or ERBB2_unspecified or ESR1_unspecified or PGR_unspecified	Set				NS / other / neoplasm	3	In trials	Phase 1	Afatinib		Completed	NCT02171702		PCD	2007Mar01	No	No		4	NCT02171702			Maximum tolerated dose/toxicity	53	53																																									No	COSO31314888	2023Mar06
EGFR_unspecified or ERBB2_unspecified or ESR1_unspecified or PGR_unspecified	Set				NS / other / neoplasm	3	In trials	Phase 1	Afatinib		Completed	NCT02171728		PCD	2006Sep01	No	No		4	NCT02171728			Maximum tolerated dose/toxicity	30	30																																									No	COSO31314888	2023May03
EGFR_unspecified or ERBB2_unspecified or ESR1_unspecified or PGR_unspecified	Set				NS / other / neoplasm	3	In trials	Phase 1	Afatinib		Completed	NCT02171637		PCD	2006Feb01	No	No		4	NCT02171637			Maximum tolerated dose/toxicity	38	38																																									No	COSO31314888	2023Mar06
EGFR_unspecified or ERBB2_unspecified or MET_unspecified	Set				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Carboplatin,Pemetrexed,Sulfatinib,Toripalimab		Recruiting	NCT05003037		ECD	2023Apr30	Yes	Yes		3	https://oncologypro.esmo.org/meeting-resources/esmo-immuno-oncology-congress/a-single-center-phase-ii-study-of-surufatinib-combined-with-toripalimab-pemetrexed-a-and-platinum-p-in-patients-with-advanced-non-squamous-no			Progression free survival	24	24			54.2																		95.8																				No	COSO29915674	2025Jan08
EGFR_unspecified or ERBB2_unspecified or PTEN_unspecified	Set				upper aerodigestive tract / carcinoma / squamous cell carcinoma	3	In trials	Phase 2	Afatinib		Active, not recruiting	NCT03088059	UPSTREAM Cohort B1	ECD	2025Jun01	No	No		4	NCT03088059			Overall Response Rate	340	340																																									No	COSO29324830	2024Jan10
EGFR_unspecified or IGF1R_unspecified 	Set				lung / carcinoma / non small cell carcinoma	2	Promising trials results	Phase 2	Afatinib,Simvastatin		Completed	NCT01156545		PCD	2016Dec31	Comparison with wt	Yes		4	NCT01156545			Overall Response Rate	64	4	60		50.0	5.0		0.028					2.9	1.9	.42	0.13-1.36	0.122																										Yes	COSO29915674	2025Jan08
EGFR_unspecified or KRAS_G12C	Multigene				NS / other / neoplasm	3	In trials	Phase 1	BBP-398		Terminated	NCT04528836		PCD	2024Mar22	Yes	No		4	NCT04528836			Maximum tolerated dose/toxicity	72	72																																									No	COSO31314888	2025Jan08
EGFR_unspecified or KRAS_unspecified or NF1_unspecified or PTPN11_unspecfied or SOS1_unspecified	Set				NS / other / neoplasm	3	In trials	Phase 2	MRTX0902		Recruiting	NCT05578092		ECD	2026Jun30	Yes	No		4	NCT05578092			PFS, ORR	228	228																																									No	COSO31314888	2024Jul03
EGFR_unspecified or MET_unspecified	Set				NS / other / neoplasm	3	In trials	Phase 1	Amivantamab,Cyclophosphamide,FT536,Fludarabine,Interleukin-2		Terminated	NCT05395052	Cohort F/FF	PCD	2023Aug11	Expression confirmed	Yes	Slow accrual	4	NCT05395052			Maximum tolerated dose/toxicity	5	5																																									No	COSO31314888	2024Oct23
EGFR_unspecified or MET_unspecified	Set				NS / other / neoplasm	3	In trials	Phase 2	Bafisontamab		Recruiting	NCT05176665		ECD	2025Dec31	Expression confirmed	No		4	NCT05176665			ORR, PFS, DOR	152	152																																									No	COSO31314888	2024Oct17
EGFR_unspecified or MET_unspecified	Set				gastrointestinal tract (site indeterminate) / carcinoma / NS	3	In trials	Phase 2	CKD-702,Irinotecan		Recruiting	NCT05750290		ECD	2024Dec31	Expression confirmed	No		4	NCT05750290			Overall Response Rate	40	40																																									No	COSO36634862	2023Sep22
EGFR_unspecified or PIK3CA_unspecified	Set				large intestine / carcinoma / adenocarcinoma	3	In trials	Phase 2	Folfirinox,Panitumumab		Completed	NCT01328171	VOLFI	PCD	2017Jun01	No	Yes		1	31609637	Untreated		Overall Response Rate	96	63	33	Folfirinox	87.3	60.6		0.004																																			Yes	COSO28864826	2025Jan08
EGFR_unspecified or TP53_unspecified	Set				large intestine / carcinoma / adenocarcinoma	3	In trials	Phase 3	Nimotuzumab,Trifluridine-Tipiracil hydrochloride		Not yet recruiting	NCT06343116		ECD	2027Apr01	No	No		4	NCT06343116	Previously-treated		Overall survival	420			Placebo,Trifluridine-Tipiracil hydrochloride																																							No	COSO28864826	2024Jul04
ERBB2_unspecified or EML4-ALK_fusion or EGFR_unspecified or MET_unspecified	Set				NS / neoplasm / NS	3	In trials	Phase 1	Lapatinib,Pazopanib		Completed	NCT01454804		PCD	2015Mar01	Expression confirmed	No		4	NCT01454804			Response rate	43	43																																									No	COSO31315444	2024Dec20
ERBB2_unspecified or EML4-ALK_fusion or EGFR_unspecified or MET_unspecified	Set				NS / neoplasm / NS	3	In trials	Phase 1	Pazopanib,Trastuzumab		Completed	NCT01454804		PCD	2015Mar01	Expression confirmed	No		4	NCT01454804			Response rate	43	43																																									No	COSO31315444	2024Dec20
FLT1_unspecified (VEGFR1_unspecified)	Gene				NS / other / neoplasm	3	In trials	Phase 2	Dovitinib		Completed	NCT01831726	SIGNATURE	PCD	2015Dec01	Yes	No		1	32292573			Disease control rate, Clinical benefit rate	0	0																																									No	COSO31314888	2025Jan08
FLT1_unspecified (VEGFR1_unspecified)	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 2	Anlotinib		Unknown	NCT04004975		ECD	2020Jul25	Yes	No		4	NCT04004975			Progression free survival	50	50																																									No	COSO36715232	2025Jan08
FLT1_unspecified (VEGFR1_unspecified)	Gene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Sunitinib		Completed	NCT00372775		PCD	2009Dec01	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																														No	COSO29915674	2021May18
FLT1_unspecified (VEGFR1_unspecified)	Gene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Bevacizumab,Chemotherapy		Completed	NCT00700180	Bevacizumab 7.5 mg	PCD	2012Sep01	Expressed/not	Yes		4	NCT00700180			Overall Response Rate	140	70	70		37.14	60.0		0.3193																																			No	COSO29915674	2025Jan08
FLT1_unspecified (VEGFR1_unspecified)	Gene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Bevacizumab,Chemotherapy		Completed	NCT00700180	Bevacizumab 15 mg	PCD	2012Sep01	Expressed/not	Yes		4	NCT00700180			Overall Response Rate	143	71	72		40.85	37.50																																					No	COSO29915674	2025Jan08
FLT1_unspecified (VEGFR1_unspecified)	Gene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Erlotinib,Sunitinib		Completed	NCT00265317	SUN1058	PCD	2010Jan01	Expression confirmed	Yes		4	NCT00265317			Progression free survival	53	23	30	Erlotinib,Placebo									2.89	2.59	1.1		0.56																										No	COSO29915674	2025Jan08
FLT1_unspecified (VEGFR1_unspecified)	Gene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Nintedanib		Active, not recruiting	NCT02299141		PCD	2020Jan09	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11.0							3	12									No	COSO29915674	2025Jan08
FLT1_unspecified (VEGFR1_unspecified) or FLT4_unspecified (VEGFR3_unspecified) or KDR_unspecfied (VEGFR2_unspecfied)	Set				NS / other / neoplasm	3	In trials	Phase 2	Axitinib		Recruiting	NCT03297606	CAPTUR group 1	ECD	2026Jan31	Yes	No		4	NCT03297606			Overall Response Rate	720	720																																									No	COSO31314888	2023Apr04
FLT1_unspecified (VEGFR1_unspecified) or FLT4_unspecified (VEGFR3_unspecified) or KDR_unspecfied (VEGFR2_unspecfied) or VEGFA_unspecicied or VEGFC_unspecified or VEGFD_unspecified	Set				large intestine / carcinoma / adenocarcinoma	3	In trials	Phase 2	Bevacizumab,Capecitabine,Fluorouracil,Leucovorin calcium,Oxaliplatin		Unknown	NCT01679327		ECD	2014Jun01	Expression confirmed	No		4	NCT01679327			Overall Response Rate	100	100																																									No	COSO28864826	2023Jun29
FLT1_unspecified (VEGFR1_unspecified) or HGF_unspecified or KDR_unspecfied (VEGFR2_unspecfied) or PGF_unspecified or VEGFA_unspecified or VEGFB_unspecified	Set				large intestine / carcinoma / adenocarcinoma	3	In trials	Phase 2	Aflibercept,Fluorouracil,Irinotecan,Leucovorin calcium		Completed	NCT02129257	AMALTHEA	PCD	2017Jan01	Expression confirmed	Yes		1	29980490			Progression free survival	73	73			46.6								8.4			7.44-9.44										24.7			17.3-30.5														No	COSO28864826	2023Jun29
FLT4_unspecified (VEGFR3_unspecified)	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 2	Anlotinib		Unknown	NCT04004975		ECD	2020Jul25	Yes	No		4	NCT04004975			Progression free survival	50	50																																									No	COSO36715232	2025Jan08
FLT4_unspecified (VEGFR3_unspecified)	Gene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Sunitinib		Completed	NCT00372775		PCD	2009Dec01	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																														No	COSO29915674	2021May18
FLT4_unspecified (VEGFR3_unspecified)	Gene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Nintedanib		Active, not recruiting	NCT02299141		PCD	2020Jan09	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11.0							3	12									No	COSO29915674	2025Jan08
KDR_unspecified (VEGFR2_unspecified)	Gene				NS / other / neoplasm	3	In trials	Phase 1	Human IL-21 oncolytic vaccinia virus		Recruiting	NCT05914376		ECD	2025Mar01	No	No		4	NCT05914376			Maximum tolerated dose/toxicity	24	24																																									No	COSO31314888	2023Aug22
KDR_unspecified (VEGFR2_unspecified)	Gene				NS / other / neoplasm	3	In trials	Phase 2	Dovitinib		Completed	NCT01831726	SIGNATURE	PCD	2015Dec01	Yes	Yes		1	32292573			Disease control rate, Clinical benefit rate	8	8																																2									No	COSO31314888	2025Jan08
KDR_unspecified (VEGFR2_unspecified)	Gene				breast / carcinoma / NS	3	In trials	Phase 2	Bevacizumab,Chemotherapy		Completed	NCT00559754		PCD	2010Sep01	Overexpression	Yes	pCR 0	4	NCT00559754			Complete response, Pathological complete response	4	4																																									No	COSO28394862	2025Jan08
KDR_unspecified (VEGFR2_unspecified)	Gene				breast / carcinoma / NS	3	In trials	Phase 2	Bevacizumab,Chemotherapy		Completed	NCT00559754		PCD	2010Sep01	Expressed/not	Yes	pCR p=0.8311	4	NCT00559754			Complete response, Pathological complete response	17	10	7																																								No	COSO28394862	2025Jan08
KDR_unspecified (VEGFR2_unspecified)	Gene				central nervous system / glioma / NS	3	In trials	Phase 2	Bevacizumab,Erlotinib		Completed	NCT00671970		PCD	2008Nov01	Expression confirmed	Yes	OS 1y correlated with expression status p=0.008	4	NCT00671970			Progression free survival	22	22																																									No	COSO28245257	2025Jan08
KDR_unspecified (VEGFR2_unspecified)	Gene				central nervous system / glioma / NS	3	In trials	Phase 2	Bevacizumab		Completed	NCT00381797		PCD	2015Oct01	Expression confirmed	Yes		4	NCT00381797		Pediatric	Overall Response Rate	18	18													.632	0.161-2.482																											No	COSO28245257	2025Jan08
KDR_unspecified (VEGFR2_unspecified)	Gene				central nervous system / glioma / astrocytoma Grade IV	3	In trials	Phase 2	Anlotinib		Unknown	NCT04004975		ECD	2020Jul25	Yes	No		4	NCT04004975			Progression free survival	50	50																																									No	COSO36715232	2025Jan08
KDR_unspecified (VEGFR2_unspecified)	Gene				gastrointestinal tract (site indeterminate) / carcinoid-endocrine tumour / NS	3	In trials	Phase 2	Cabozantinib,Lanreotide acetate		Unknown	NCT04427787	LOLA	ECD	2023Nov01	Expression confirmed	No		4	NCT04427787			Overall Response Rate	69	69																																									No	COSO36634841	2024Jan04
KDR_unspecified (VEGFR2_unspecified)	Gene				kidney / carcinoma / renal cell carcinoma unclassified	3	In trials	Phase 2	Pazopanib		Completed	NCT01538238		PCD	2015Feb28	No	Yes	Promising activity	1	28546525			Overall Response Rate	28	28			28								16.5			10.9-22.1																											No	COSO296410604	2025Jan08
KDR_unspecified (VEGFR2_unspecified)	Gene				large intestine / carcinoma / adenocarcinoma	3	In trials	Phase 2	Aflibercept,Fluorouracil,Irinotecan,Leucovorin calcium		Unknown	NCT04252456	DISTINCTIVE VEGFR2<=/> 4ng/ml	ECD	2020Apr01	Expressed/not	Yes		2	10.1200/JCO.2022.40.16_suppl.e15571			Progression free survival	44																									14.2	9.1		6.367-10.067	0.0001													No	COSO28864826	2025Jan08
KDR_unspecified (VEGFR2_unspecified)	Gene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Sunitinib		Completed	NCT00372775		PCD	2009Dec01	No	Yes		4	NCT00372775			Progression free survival	66	66											2.17																														No	COSO29915674	2021May18
KDR_unspecified (VEGFR2_unspecified)	Gene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Bevacizumab,Chemotherapy		Completed	NCT00700180	Bevacizumab 15 mg	PCD	2012Sep01	Expressed/not	Yes		4	NCT00700180			Overall Response Rate	140	71	69		50.70	46.38																																					No	COSO29915674	2025Jan08
KDR_unspecified (VEGFR2_unspecified)	Gene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Bevacizumab,Chemotherapy		Completed	NCT00700180	Bevacizumab 7.5 mg	PCD	2012Sep01	Expressed/not	Yes		4	NCT00700180			Overall Response Rate	143	69	74		46.38	32.43		0.1758																																			No	COSO29915674	2025Jan08
KDR_unspecified (VEGFR2_unspecified)	Gene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 2	Erlotinib,Sunitinib		Completed	NCT00265317	SUN1058	PCD	2010Jan01	Expression confirmed	Yes		4	NCT00265317			Progression free survival	62	30	32	Erlotinib,Placebo									3.92	2.84	.92		0.44																										No	COSO29915674	2025Jan08
KDR_unspecified (VEGFR2_unspecified)	Gene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Nintedanib		Active, not recruiting	NCT02299141		PCD	2020Jan09	No	Yes	Primary outcome not met	1	26074395			Overall Response Rate	20	20			15								4.2										60			11.0							3	12									No	COSO29915674	2025Jan08
KDR_unspecified (VEGFR2_unspecified)	Gene				lung / carcinoma / non small cell carcinoma	3	In trials	Phase 3	Bevacizumab,Carboplatin,Paclitaxel		Completed	NCT01364012	BEYOND	PCD	2013Jan27	No	Yes		1	26014294	Untreated		Progression free survival	276	138	138	Carboplatin,Paclitaxel,Placebo	54	26							9.2	6.5	.4	0.29-0.54	<0.001									24.3	17.7	.68	0.50-0.93	0.0154													Yes	COSO29915674	2025Jan08
KDR_unspecified (VEGFR2_unspecified)	Gene				meninges / meningioma / NS	3	In trials	Phase 2	Bevacizumab		Completed	NCT01125046		PCD	2014Mar10	No	Yes	PFS 6m 42%, Primary outcome met	2	10.1200/jco.2015.33.15_suppl.2055	Previously-treated		Progression free survival	36	36											5.2			2.8-8.3										24.6			16.5-38.4														Yes	COSO28365270	2025Jan08
KDR_unspecified (VEGFR2_unspecified)	Gene				stomach / carcinoma / NS	3	In trials	Phase 2	Apatinib		Completed	NCT03104283		PCD	2019Dec01	Expression confirmed	Yes		1	34434051	Previously-treated	Geriatric	Progression free survival	48	48			16.7								3			2.17-3.84							72.9			8.10			4.35-11.85			0	8	27									No	COSO36004862	2024Jul18
KDR_unspecified (VEGFR2_unspecified) or PDGFRB_unspecified	Set				soft tissue / solitary fibrous tumour / NS	3	In trials	Phase 2	Axitinib		Completed	NCT02261207		PCD	2017Oct01	No	Yes		1	30528807			Response rate	17	17			41.2																												7	6									No	COSO313510797	2023Sep08
KDR_unspecified (VEGFR2_unspecified) or PIGF_unspecified	Set				soft tissue / sarcoma / NS	3	In trials	Phase 2	Pazopanib,Topotecan		Completed	NCT02357810		PCD	2018Apr27	No	Yes	PFS 1y 57.5%	4	NCT02357810			Progression free survival	104	104			6.7																		63.5			10.94			9.30-18.73														No	COSO31375226	2025Jan08
